BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Douillard J, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-morawiec M, Šmakal M, Canon JL, Rother M, Williams R, Rong A, Wiezorek J, Sidhu R, Patterson SD. Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer. N Engl J Med 2013;369:1023-34. [DOI: 10.1056/nejmoa1305275] [Cited by in Crossref: 1412] [Cited by in F6Publishing: 744] [Article Influence: 156.9] [Reference Citation Analysis]
Number Citing Articles
1 Chen KH, Lin YL, Liau JY, Tsai JH, Tseng LH, Lin LI, Liang JT, Lin BR, Hung JS, Chang YL, Yeh KH, Cheng AL. BRAF mutation may have different prognostic implications in early- and late-stage colorectal cancer. Med Oncol. 2016;33:39. [PMID: 27034263 DOI: 10.1007/s12032-016-0756-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
2 Kocarnik JM, Shiovitz S, Phipps AI. Molecular phenotypes of colorectal cancer and potential clinical applications. Gastroenterol Rep (Oxf) 2015;3:269-76. [PMID: 26337942 DOI: 10.1093/gastro/gov046] [Cited by in Crossref: 19] [Cited by in F6Publishing: 58] [Article Influence: 2.7] [Reference Citation Analysis]
3 Goel S, Ocean AJ, Parakrama RY, Ghalib MH, Chaudhary I, Shah U, Viswanathan S, Kharkwal H, Coffey M, Maitra R. Elucidation of Pelareorep Pharmacodynamics in A Phase I Trial in Patients with KRAS-Mutated Colorectal Cancer. Mol Cancer Ther 2020;19:1148-56. [PMID: 32156785 DOI: 10.1158/1535-7163.MCT-19-1117] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
4 Cho H, Kim JE, Kim KP, Yu CS, Kim JC, Kim JH, Lee MA, Jang HS, Oh ST, Kim SY, Oh JH, Kim DY, Hong YS, Kim TW. Phase II Study of Preoperative Capecitabine and Oxaliplatin-based Intensified Chemoradiotherapy With or Without Induction Chemotherapy in Patients With Locally Advanced Rectal Cancer and Synchronous Liver-limited Resectable Metastases. Am J Clin Oncol 2016;39:623-9. [PMID: 27322695 DOI: 10.1097/COC.0000000000000315] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]
5 Di Nicolantonio F, Vitiello PP, Marsoni S, Siena S, Tabernero J, Trusolino L, Bernards R, Bardelli A. Precision oncology in metastatic colorectal cancer - from biology to medicine. Nat Rev Clin Oncol 2021;18:506-25. [PMID: 33864051 DOI: 10.1038/s41571-021-00495-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
6 Möhrmann L, Huang HJ, Hong DS, Tsimberidou AM, Fu S, Piha-Paul SA, Subbiah V, Karp DD, Naing A, Krug A, Enderle D, Priewasser T, Noerholm M, Eitan E, Coticchia C, Stoll G, Jordan LM, Eng C, Kopetz ES, Skog J, Meric-Bernstam F, Janku F. Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers. Clin Cancer Res 2018;24:181-8. [PMID: 29051321 DOI: 10.1158/1078-0432.CCR-17-2007] [Cited by in Crossref: 61] [Cited by in F6Publishing: 50] [Article Influence: 12.2] [Reference Citation Analysis]
7 Niogret J, Limagne E, Thibaudin M, Blanc J, Bertaut A, Le Malicot K, Rinaldi Y, Caroli-Bosc FX, Audemar F, Nguyen S, Sarda C, Lombard-Bohas C, Locher C, Carreiro M, Legoux JL, Etienne PL, Baconnier M, Porneuf M, Aparicio T, Ghiringhelli F. Baseline Splenic Volume as a Prognostic Biomarker of FOLFIRI Efficacy and a Surrogate Marker of MDSC Accumulation in Metastatic Colorectal Carcinoma. Cancers (Basel) 2020;12:E1429. [PMID: 32486421 DOI: 10.3390/cancers12061429] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Grenader T, Nash S, Adams R, Kaplan R, Fisher D, Maughan T, Bridgewater J. Derived neutrophil lymphocyte ratio is predictive of survival from intermittent therapy in advanced colorectal cancer: a post hoc analysis of the MRC COIN study. Br J Cancer 2016;114:612-5. [PMID: 26889974 DOI: 10.1038/bjc.2016.23] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
9 Bronte G, Silvestris N, Castiglia M, Galvano A, Passiglia F, Sortino G, Cicero G, Rolfo C, Peeters M, Bazan V, Fanale D, Giordano A, Russo A. New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS? Oncotarget 2015;6:24780-96. [PMID: 26318427 DOI: 10.18632/oncotarget.4959] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 9.2] [Reference Citation Analysis]
10 Cheng WL, Feng PH, Lee KY, Chen KY, Sun WL, Van Hiep N, Luo CS, Wu SM. The Role of EREG/EGFR Pathway in Tumor Progression. Int J Mol Sci 2021;22:12828. [PMID: 34884633 DOI: 10.3390/ijms222312828] [Reference Citation Analysis]
11 Fakih MG, Kopetz S, Kuboki Y, Kim TW, Munster PN, Krauss JC, Falchook GS, Han SW, Heinemann V, Muro K, Strickler JH, Hong DS, Denlinger CS, Girotto G, Lee MA, Henary H, Tran Q, Park JK, Ngarmchamnanrith G, Prenen H, Price TJ. Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial. Lancet Oncol 2022;23:115-24. [PMID: 34919824 DOI: 10.1016/S1470-2045(21)00605-7] [Reference Citation Analysis]
12 Gordan L, Grogg A, Blazer M, Fortner B. Unintended Consequences in Cancer Care Delivery Created by the Medicare Part B Proposal: Is the Clinical Rationale for the Experiment Flawed? J Oncol Pract 2017;13:e139-51. [PMID: 28029298 DOI: 10.1200/JOP.2016.016550] [Reference Citation Analysis]
13 Pellino G, Gallo G, Pallante P, Capasso R, De Stefano A, Maretto I, Malapelle U, Qiu S, Nikolaou S, Barina A, Clerico G, Reginelli A, Giuliani A, Sciaudone G, Kontovounisios C, Brunese L, Trompetto M, Selvaggi F. Noninvasive Biomarkers of Colorectal Cancer: Role in Diagnosis and Personalised Treatment Perspectives. Gastroenterol Res Pract. 2018;2018:2397863. [PMID: 30008744 DOI: 10.1155/2018/2397863] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 8.3] [Reference Citation Analysis]
14 Goel G. Molecular characterization and biomarker identification in colorectal cancer: Toward realization of the precision medicine dream. Cancer Manag Res 2018;10:5895-908. [PMID: 30510457 DOI: 10.2147/CMAR.S162967] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
15 Elez E, Pericay C, Valladares-Ayerbes M, Bando I, Safont MJ, Gallego J, Grávalos C, Arrivi A, Carrato A, Conde V, Ortiz MJ, López C, Alonso B, Ruiz de Mena I, Díaz-Rubio E, Tabernero J, Aranda E. A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients. Br J Cancer 2019;121:378-83. [PMID: 31363167 DOI: 10.1038/s41416-019-0537-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
16 Taniguchi H, Uehara K, Nakayama G, Nakayama H, Aiba T, Hattori N, Kataoka M, Nakano Y, Kawase Y, Okochi O, Matsuoka H, Utsunomiya S, Sakamoto E, Mori Y, Umeda S, Shikano T, Komori K, Tajika M, Kadowaki S, Muro K, Yatabe Y. Tumor Location Is Associated With the Prevalence of Braf And Pik3ca Mutations in Patients with Wild-Type Ras Colorectal Cancer: A Prospective Multi-Center Cohort Study in Japan. Transl Oncol 2020;13:100786. [PMID: 32428838 DOI: 10.1016/j.tranon.2020.100786] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Kubo A, Hashimoto H, Takahashi N, Yamada Y. Biomarkers of skin toxicity induced by anti-epidermal growth factor receptor antibody treatment in colorectal cancer. World J Gastroenterol 2016; 22(2): 887-894 [PMID: 26811634 DOI: 10.3748/wjg.v22.i2.887] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
18 Vera R, Salgado M, Safont MJ, Gallego J, González E, Élez E, Aranda E. Controversies in the treatment of RAS wild-type metastatic colorectal cancer. Clin Transl Oncol 2021;23:827-39. [PMID: 32789773 DOI: 10.1007/s12094-020-02475-8] [Reference Citation Analysis]
19 Polivka J, Windrichova J, Pesta M, Houfkova K, Rezackova H, Macanova T, Vycital O, Kucera R, Slouka D, Topolcan O. The Level of Preoperative Plasma KRAS Mutations and CEA Predict Survival of Patients Undergoing Surgery for Colorectal Cancer Liver Metastases. Cancers (Basel) 2020;12:E2434. [PMID: 32867151 DOI: 10.3390/cancers12092434] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
20 Kratz JD, Deming DA. The evolving treatment paradigm for BRAF V600 mutant colorectal cancer. Ann Transl Med 2019;7:S257. [PMID: 32015976 DOI: 10.21037/atm.2019.12.61] [Reference Citation Analysis]
21 Richman SD, Fairley J, Butler R, Deans ZC. RAS screening in colorectal cancer: a comprehensive analysis of the results from the UK NEQAS colorectal cancer external quality assurance schemes (2009-2016). Virchows Arch 2017;471:721-9. [PMID: 28653203 DOI: 10.1007/s00428-017-2162-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
22 Stanley A, Ashrafi GH, Seddon AM, Modjtahedi H. Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines. Sci Rep 2017;7:3964. [PMID: 28638122 DOI: 10.1038/s41598-017-04301-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
23 Carrasco J, Gizzi M, Pairet G, Lannoy V, Lefesvre P, Gigot JF, Hubert C, Jouret-Mourin A, Humblet Y, Canon JL, Sempoux C, Chapaux X, Danse E, Tinton N, Navez B, Van den Eynde M. Pathological responses after angiogenesis or EGFR inhibitors in metastatic colorectal cancer depend on the chemotherapy backbone. Br J Cancer 2015;113:1298-304. [PMID: 26461062 DOI: 10.1038/bjc.2015.321] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
24 Moriarity A, O'Sullivan J, Kennedy J, Mehigan B, McCormick P. Current targeted therapies in the treatment of advanced colorectal cancer: a review. Ther Adv Med Oncol. 2016;8:276-293. [PMID: 27482287 DOI: 10.1177/1758834016646734] [Cited by in Crossref: 54] [Cited by in F6Publishing: 54] [Article Influence: 9.0] [Reference Citation Analysis]
25 Pereira AA, Rego JF, Morris V, Overman MJ, Eng C, Garrett CR, Boutin AT, Ferrarotto R, Lee M, Jiang ZQ. Association between KRAS mutation and lung metastasis in advanced colorectal cancer. Br J Cancer. 2015;112:424-428. [PMID: 25535726 DOI: 10.1038/bjc.2014.619] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 6.5] [Reference Citation Analysis]
26 Lee MS, McGuffey EJ, Morris JS, Manyam G, Baladandayuthapani V, Wei W, Morris VK, Overman MJ, Maru DM, Jiang ZQ. Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer. Br J Cancer. 2016;114:1352-1361. [PMID: 27272216 DOI: 10.1038/bjc.2016.87] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 8.2] [Reference Citation Analysis]
27 Bonadio RC, Amor Divino PH, Obando JSM, Lima KCA, Recchimuzzi DZ, Kruger JAP, Saragiotto DF, Capareli FC, Hoff PM. Conversion Chemotherapy With a Modified FLOX Regimen for Borderline or Unresectable Liver Metastases From Colorectal Cancer: An Alternative for Limited-Resources Settings. J Glob Oncol. 2019;5:1-6. [PMID: 31479339 DOI: 10.1200/jgo.19.00180] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Yan M, Song M, Bai R, Cheng S, Yan W. Identification of potential therapeutic targets for colorectal cancer by bioinformatics analysis. Oncol Lett 2016;12:5092-8. [PMID: 28105216 DOI: 10.3892/ol.2016.5328] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
29 Zhang B, Fang C, Deng D, Xia L. Research progress on common adverse events caused by targeted therapy for colorectal cancer. Oncol Lett 2018;16:27-33. [PMID: 29928383 DOI: 10.3892/ol.2018.8651] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
30 Derangère V, Fumet JD, Boidot R, Bengrine L, Limagne E, Chevriaux A, Vincent J, Ladoire S, Apetoh L, Rébé C, Ghiringhelli F. Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer? Oncotarget 2016;7:9309-21. [PMID: 26824184 DOI: 10.18632/oncotarget.7008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
31 Elez E, Argilés G, Tabernero J. First-Line Treatment of Metastatic Colorectal Cancer: Interpreting FIRE-3, PEAK, and CALGB/SWOG 80405. Curr Treat Options Oncol. 2015;16:52. [PMID: 26374340 DOI: 10.1007/s11864-015-0369-x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 55] [Article Influence: 8.0] [Reference Citation Analysis]
32 Schumacher D, Andrieux G, Boehnke K, Keil M, Silvestri A, Silvestrov M, Keilholz U, Haybaeck J, Erdmann G, Sachse C, Templin M, Hoffmann J, Boerries M, Schäfer R, Regenbrecht CRA. Heterogeneous pathway activation and drug response modelled in colorectal-tumor-derived 3D cultures. PLoS Genet 2019;15:e1008076. [PMID: 30925167 DOI: 10.1371/journal.pgen.1008076] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 9.3] [Reference Citation Analysis]
33 Brudvik KW, Mise Y, Chung MH, Chun YS, Kopetz SE, Passot G, Conrad C, Maru DM, Aloia TA, Vauthey JN. RAS Mutation Predicts Positive Resection Margins and Narrower Resection Margins in Patients Undergoing Resection of Colorectal Liver Metastases. Ann Surg Oncol. 2016;23:2635-2643. [PMID: 27016292 DOI: 10.1245/s10434-016-5187-2] [Cited by in Crossref: 61] [Cited by in F6Publishing: 57] [Article Influence: 10.2] [Reference Citation Analysis]
34 Bang YH, Kim JE, Lee JS, Kim SY, Kim KP, Kim TW, Hong YS. Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines. Sci Rep 2021;11:7118. [PMID: 33782470 DOI: 10.1038/s41598-021-86482-x] [Reference Citation Analysis]
35 Mahmood RD, Shaw D, Descamps T, Zhou C, Morgan RD, Mullamitha S, Saunders M, Mescallado N, Backen A, Morris K, Little RA, Cheung S, Watson Y, O'Connor JPB, Jackson A, Parker GJM, Dive C, Jayson GC. Effect of oxaliplatin plus 5-fluorouracil or capecitabine on circulating and imaging biomarkers in patients with metastatic colorectal cancer: a prospective biomarker study. BMC Cancer 2021;21:354. [PMID: 33794823 DOI: 10.1186/s12885-021-08097-9] [Reference Citation Analysis]
36 Siu HWD, Tebbutt N, Chantrill L, Karapetis C, Steer C, Wilson K, Espinoza D, Bailey L, Yip S, Cuff J, Pavlakis N, Thavaneswaran S, Briscoe K, Srivastav R, Shannon J, Segelov E, Tie J, Caird S, Francesconi A, Price T, Wuttke M, Ladwa R, Sjoquist K, Burge M. MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG). BMC Cancer 2021;21:932. [PMID: 34407800 DOI: 10.1186/s12885-021-08644-4] [Reference Citation Analysis]
37 Cohen R, Pudlarz T, Delattre JF, Colle R, André T. Molecular Targets for the Treatment of Metastatic Colorectal Cancer. Cancers (Basel) 2020;12:E2350. [PMID: 32825275 DOI: 10.3390/cancers12092350] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
38 Torres NB, Altafini C. Drug combinatorics and side effect estimation on the signed human drug-target network. BMC Syst Biol 2016;10:74. [PMID: 27526853 DOI: 10.1186/s12918-016-0326-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
39 Huang A, Yang Y, Shi JY, Li YK, Xu JX, Cheng Y, Gu J. Mucinous adenocarcinoma: A unique clinicopathological subtype in colorectal cancer. World J Gastrointest Surg 2021; 13(12): 1567-1583 [DOI: 10.4240/wjgs.v13.i12.1567] [Reference Citation Analysis]
40 Lee MKC, Loree JM. Current and emerging biomarkers in metastatic colorectal cancer. Curr Oncol 2019;26:S7-S15. [PMID: 31819705 DOI: 10.3747/co.26.5719] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
41 Mori Y, Nyuya A, Yasui K, Toshima T, Kawai T, Taniguchi F, Kimura K, Inada R, Nishizaki M, Haraga J, Nakamura K, Umeda Y, Kishimoto H, Fujiwara T, Katata Y, Yamaguchi Y, Nagasaka T. Clinical outcomes of women with ovarian metastases of colorectal cancer treated with oophorectomy with respect to their somatic mutation profiles. Oncotarget 2018;9:16477-88. [PMID: 29662660 DOI: 10.18632/oncotarget.24735] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
42 Bellyei S, Boronkai Á, Pozsgai E, Fodor D, Mangel L. Effective chemotherapy and targeted therapy supplemented with stereotactic radiotherapy of a patient with metastatic colon cancer following renal transplantation: a case report. J Med Case Rep 2021;15:125. [PMID: 33741057 DOI: 10.1186/s13256-021-02702-y] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
43 Taji Heravi A, Gryaznov D, Schandelmaier S, Kasenda B, Briel M; Adherence to SPIRIT Recommendations (ASPIRE) Study Group. Evaluation of Planned Subgroup Analysis in Protocols of Randomized Clinical Trials. JAMA Netw Open 2021;4:e2131503. [PMID: 34705015 DOI: 10.1001/jamanetworkopen.2021.31503] [Reference Citation Analysis]
44 Brammeld JS, Petljak M, Martincorena I, Williams SP, Alonso LG, Dalmases A, Bellosillo B, Robles-Espinoza CD, Price S, Barthorpe S, Tarpey P, Alifrangis C, Bignell G, Vidal J, Young J, Stebbings L, Beal K, Stratton MR, Saez-Rodriguez J, Garnett M, Montagut C, Iorio F, McDermott U. Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations. Genome Res 2017;27:613-25. [PMID: 28179366 DOI: 10.1101/gr.213546.116] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
45 Jin KT, Chen B, Liu YY, Lan HU, Yan JP. Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer. Cancer Cell Int 2021;21:83. [PMID: 33522929 DOI: 10.1186/s12935-021-01763-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
46 Vogel A, Kirstein MM. First-line molecular therapies in the treatment of metastatic colorectal cancer - a literature-based review of phases II and III trials. Innov Surg Sci 2018;3:85-6. [PMID: 31579770 DOI: 10.1515/iss-2018-0012] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
47 Fiala O, Veskrnova V, Chloupkova R, Poprach A, Kiss I, Kopeckova K, Dusek L, Slavicek L, Kohoutek M, Finek J, Svoboda M, Petruzelka L, Boubliková L, Dvorak J, Melichar B, Buchler T. Impact of Delayed Addition of Anti-EGFR Monoclonal Antibodies on the Outcome of First-Line Therapy in Metastatic Colorectal Cancer Patients: a Retrospective Registry-Based Analysis. Target Oncol 2018;13:735-43. [PMID: 30353488 DOI: 10.1007/s11523-018-0597-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
48 Martin-Liberal J, Rodon J. Clinical research in small genomically stratified patient populations. Eur J Cancer 2017;80:73-82. [PMID: 28591680 DOI: 10.1016/j.ejca.2017.05.008] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
49 Rankin A, Klempner SJ, Erlich R, Sun JX, Grothey A, Fakih M, George TJ Jr, Lee J, Ross JS, Stephens PJ, Miller VA, Ali SM, Schrock AB. Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer. Oncologist 2016;21:1306-14. [PMID: 27682134 DOI: 10.1634/theoncologist.2016-0148] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
50 Chang KC, Marton MJ. Past, current and future approaches to querying MAPK pathway activation: status and clinical implications. Per Med 2014;11:745-60. [PMID: 29764047 DOI: 10.2217/pme.14.52] [Reference Citation Analysis]
51 Guo TA, Wu YC, Tan C, Jin YT, Sheng WQ, Cai SJ, Liu FQ, Xu Y. Clinicopathologic features and prognostic value of KRAS, NRAS and BRAF mutations and DNA mismatch repair status: A single-center retrospective study of 1,834 Chinese patients with Stage I-IV colorectal cancer. Int J Cancer 2019;145:1625-34. [PMID: 31162857 DOI: 10.1002/ijc.32489] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
52 Vemala RNG, Katti SV, Sirohi B, Manikandan D, Nandakumar G. Molecular Oncology in Management of Colorectal Cancer. Indian J Surg Oncol 2021;12:169-80. [PMID: 33994743 DOI: 10.1007/s13193-021-01289-6] [Reference Citation Analysis]
53 Lau-Min K, Prakash P, Jo E, Thrift AP, Hilsenbeck S, Musher BL. Outcomes Among Minority Patients With Metastatic Colorectal Cancer in a Safety-net Health Care System. Clin Colorectal Cancer 2020;19:e49-57. [PMID: 32165040 DOI: 10.1016/j.clcc.2019.09.002] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
54 Li Z, Huang Y, Zhao R, Cui Y, Zhou Y, Wu X. Chemotherapy plus Panitumumab Versus Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer: A Meta-analysis. Sci Rep 2018;8:510. [PMID: 29323221 DOI: 10.1038/s41598-017-19001-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
55 Ahmed S, Bathe O, Berry S, Buie D, Davies J, Doll C, Dowden S, Gill S, Gordon V, Hebbard P, Jones E, Kennecke H, Koski S, Krahn M, Le D, Lim H, Lund C, Luo Y, Mcffadden A, Mcghie J, Mulder K, Park J, Rashidi F, Sami A, Tan KT, Wong R. Consensus statement: the 16th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Saskatoon, Saskatchewan; September 5-6, 2014. Curr Oncol 2015;22:e113-23. [PMID: 25908916 DOI: 10.3747/co.22.2362] [Reference Citation Analysis]
56 Yasumoto M, Sakamoto E, Ogasawara S, Isobe T, Kizaki J, Sumi A, Kusano H, Akiba J, Torimura T, Akagi Y, Itadani H, Kobayashi T, Hasako S, Kumazaki M, Mizuarai S, Oie S, Yano H. Muscle RAS oncogene homolog (MRAS) recurrent mutation in Borrmann type IV gastric cancer. Cancer Med 2017;6:235-44. [PMID: 27891760 DOI: 10.1002/cam4.959] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
57 Aparicio J, Esposito F, Serrano S, Falco E, Escudero P, Ruiz-Casado A, Manzano H, Fernandez-Montes A. Metastatic Colorectal Cancer. First Line Therapy for Unresectable Disease. J Clin Med 2020;9:E3889. [PMID: 33265959 DOI: 10.3390/jcm9123889] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
58 Zarkavelis G, Boussios S, Papadaki A, Katsanos KH, Christodoulou DK, Pentheroudakis G. Current and future biomarkers in colorectal cancer. Ann Gastroenterol 2017;30:613-21. [PMID: 29118555 DOI: 10.20524/aog.2017.0191] [Cited by in Crossref: 22] [Cited by in F6Publishing: 42] [Article Influence: 4.4] [Reference Citation Analysis]
59 Bronkhorst AJ, Ungerer V, Holdenrieder S. The emerging role of cell-free DNA as a molecular marker for cancer management. Biomol Detect Quantif. 2019;17:100087. [PMID: 30923679 DOI: 10.1016/j.bdq.2019.100087] [Cited by in Crossref: 142] [Cited by in F6Publishing: 124] [Article Influence: 47.3] [Reference Citation Analysis]
60 Karthaus M, Hofheinz RD, Mineur L, Letocha H, Greil R, Thaler J, Fernebro E, Oliner KS, Boedigheimer M, Twomey B, Zhang Y, Demonty G, Köhne CH. Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer. Br J Cancer 2016;115:1215-22. [PMID: 27764839 DOI: 10.1038/bjc.2016.343] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
61 Rogers JE, Silva NN, Eng C. Cetuximab in combination with cisplatin and 5-Fluorouracil induces dramatic response in metastatic refractory squamous cell carcinoma of the anal canal. J Gastrointest Oncol 2015;6:E82-5. [PMID: 26487956 DOI: 10.3978/j.issn.2078-6891.2015.035] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
62 Felsenstein M, Hruban RH, Wood LD. New Developments in the Molecular Mechanisms of Pancreatic Tumorigenesis. Adv Anat Pathol. 2018;25:131-142. [PMID: 28914620 DOI: 10.1097/pap.0000000000000172] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
63 Leto SM, Trusolino L. Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies. J Mol Med (Berl) 2014;92:709-22. [PMID: 24811491 DOI: 10.1007/s00109-014-1161-2] [Cited by in Crossref: 58] [Cited by in F6Publishing: 51] [Article Influence: 7.3] [Reference Citation Analysis]
64 Ounissi D, Weslati M, Boughriba R, Hazgui M, Bouraoui S. Clinicopathological characteristics and mutational profile of KRAS and NRAS in Tunisian patients with sporadic colorectal cancer. Turk J Med Sci 2021;51:148-58. [PMID: 32892548 DOI: 10.3906/sag-2003-42] [Reference Citation Analysis]
65 Kim JS, Kim JE, Kim K, Lee J, Park JO, Lim HY, Park YS, Kang WK, Kim ST. The Impact of Cetuximab Plus AKT- or mTOR- Inhibitor in a Patient-Derived Colon Cancer Cell Model with Wild-Type RAS and PIK3CA Mutation. J Cancer 2017;8:2713-9. [PMID: 28928860 DOI: 10.7150/jca.19458] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
66 Sanz L, Ibáñez-Pérez R, Guerrero-Ochoa P, Lacadena J, Anel A. Antibody-Based Immunotoxins for Colorectal Cancer Therapy. Biomedicines 2021;9:1729. [PMID: 34829955 DOI: 10.3390/biomedicines9111729] [Reference Citation Analysis]
67 Ding Y, Li W, Wang K, Xu C, Hao M, Ding L. Perspectives of the Application of Liquid Biopsy in Colorectal Cancer. Biomed Res Int 2020;2020:6843180. [PMID: 32258135 DOI: 10.1155/2020/6843180] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
68 Lovinfosse P, Koopmansch B, Lambert F, Jodogne S, Kustermans G, Hatt M, Visvikis D, Seidel L, Polus M, Albert A, Delvenne P, Hustinx R. (18)F-FDG PET/CT imaging in rectal cancer: relationship with the RAS mutational status. Br J Radiol 2016;89:20160212. [PMID: 27146067 DOI: 10.1259/bjr.20160212] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
69 Kloth M, Buettner R. Changing histopathological diagnostics by genome-based tumor classification. Genes (Basel) 2014;5:444-59. [PMID: 24879454 DOI: 10.3390/genes5020444] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
70 Omolo B, Yang M, Lo FY, Schell MJ, Austin S, Howard K, Madan A, Yeatman TJ. Adaptation of a RAS pathway activation signature from FF to FFPE tissues in colorectal cancer. BMC Med Genomics 2016;9:65. [PMID: 27756306 DOI: 10.1186/s12920-016-0225-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
71 García-Albéniz X, Alonso V, Escudero P, Méndez M, Gallego J, Rodríguez JR, Salud A, Fernández-Plana J, Manzano H, Zanui M, Falcó E, Feliu J, Gil M, Fernández-Martos C, Bohn U, Alonso C, Calderero V, Rojo F, Cuatrecasas M, Maurel J. Prospective Biomarker Study in Advanced RAS Wild-Type Colorectal Cancer: POSIBA Trial (GEMCAD 10-02). Oncologist 2019;24:e1115-22. [PMID: 31235483 DOI: 10.1634/theoncologist.2018-0728] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
72 Majewski IJ, Nuciforo P, Mittempergher L, Bosma AJ, Eidtmann H, Holmes E, Sotiriou C, Fumagalli D, Jimenez J, Aura C, Prudkin L, Díaz-Delgado MC, de la Peña L, Loi S, Ellis C, Schultz N, de Azambuja E, Harbeck N, Piccart-Gebhart M, Bernards R, Baselga J. PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer. J Clin Oncol 2015;33:1334-9. [PMID: 25559818 DOI: 10.1200/JCO.2014.55.2158] [Cited by in Crossref: 142] [Cited by in F6Publishing: 88] [Article Influence: 20.3] [Reference Citation Analysis]
73 Guo T, Wu Y, Huang D, Jin Y, Sheng W, Cai S, Zhou X, Zhu X, Liu F, Xu Y. Prognostic Value of KRAS Exon 3 and Exon 4 Mutations in Colorectal Cancer Patients. J Cancer 2021;12:5331-7. [PMID: 34335949 DOI: 10.7150/jca.59193] [Reference Citation Analysis]
74 Lee SY, Oh SC. Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer. Biomed Res Int. 2016;2016:7590245. [PMID: 27127793 DOI: 10.1155/2016/7590245] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
75 Neerincx M, Poel D, Sie DLS, van Grieken NCT, Shankaraiah RC, van der Wolf-de Lijster FSW, van Waesberghe JTM, Burggraaf JD, Eijk PP, Verhoef C, Ylstra B, Meijer GA, van de Wiel MA, Buffart TE, Verheul HMW. Combination of a six microRNA expression profile with four clinicopathological factors for response prediction of systemic treatment in patients with advanced colorectal cancer. PLoS One 2018;13:e0201809. [PMID: 30075027 DOI: 10.1371/journal.pone.0201809] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
76 Sorbye H, Dragomir A, Sundström M, Pfeiffer P, Thunberg U, Bergfors M, Aasebø K, Eide GE, Ponten F, Qvortrup C, Glimelius B. High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort. PLoS One 2015;10:e0131046. [PMID: 26121270 DOI: 10.1371/journal.pone.0131046] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 7.4] [Reference Citation Analysis]
77 Wang X, Wei Q, Gao J, Li J, Li J, Gong J, Li Y, Shen L. Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study. Chin J Cancer 2017;36:81. [PMID: 29037218 DOI: 10.1186/s40880-017-0247-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
78 Li W, Qiu T, Zhi W, Shi S, Zou S, Ling Y, Shan L, Ying J, Lu N. Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages. BMC Cancer 2015;15:340. [PMID: 25929517 DOI: 10.1186/s12885-015-1345-3] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 5.1] [Reference Citation Analysis]
79 Sheffels E, Kortum RL. The Role of Wild-Type RAS in Oncogenic RAS Transformation. Genes (Basel) 2021;12:662. [PMID: 33924994 DOI: 10.3390/genes12050662] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
80 Atreya CE, Greene C, McWhirter RM, Ikram NS, Allen IE, Van Loon K, Venook AP, Yeh BM, Behr SC. Differential Radiographic Appearance of BRAF V600E-Mutant Metastatic Colorectal Cancer in Patients Matched by Primary Tumor Location. J Natl Compr Canc Netw 2016;14:1536-43. [PMID: 27956538 DOI: 10.6004/jnccn.2016.0165] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
81 Pander J, van Huis-Tanja L, Böhringer S, van der Straaten T, Gelderblom H, Punt C, Guchelaar HJ. Genome Wide Association Study for Predictors of Progression Free Survival in Patients on Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in First-Line Therapy of Metastatic Colorectal Cancer. PLoS One 2015;10:e0131091. [PMID: 26222057 DOI: 10.1371/journal.pone.0131091] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
82 Janku F, Huang HJ, Fujii T, Shelton DN, Madwani K, Fu S, Tsimberidou AM, Piha-Paul SA, Wheler JJ, Zinner RG, Naing A, Hong DS, Karp DD, Cabrilo G, Kopetz ES, Subbiah V, Luthra R, Kee BK, Eng C, Morris VK, Karlin-Neumann GA, Meric-Bernstam F. Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction. Ann Oncol 2017;28:642-50. [PMID: 27993791 DOI: 10.1093/annonc/mdw670] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 5.4] [Reference Citation Analysis]
83 Modest DP, Rivera F, Bachet JB, de Braud F, Pietrantonio F, Koukakis R, Demonty G, Douillard JY. Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials. Int J Cancer 2019;145:576-85. [PMID: 30614531 DOI: 10.1002/ijc.32110] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
84 Rowland A, Dias MM, Wiese MD, Kichenadasse G, McKinnon RA, Karapetis CS, Sorich MJ. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer. 2015;112:1888-1894. [PMID: 25989278 DOI: 10.1038/bjc.2015.173] [Cited by in Crossref: 188] [Cited by in F6Publishing: 168] [Article Influence: 26.9] [Reference Citation Analysis]
85 Van Emburgh BO, Sartore-Bianchi A, Di Nicolantonio F, Siena S, Bardelli A. Acquired resistance to EGFR-targeted therapies in colorectal cancer. Mol Oncol 2014;8:1084-94. [PMID: 24913799 DOI: 10.1016/j.molonc.2014.05.003] [Cited by in Crossref: 79] [Cited by in F6Publishing: 80] [Article Influence: 9.9] [Reference Citation Analysis]
86 Taieb J, Lapeyre-Prost A, Laurent Puig P, Zaanan A. Exploring the best treatment options for BRAF-mutant metastatic colon cancer. Br J Cancer 2019;121:434-42. [PMID: 31353365 DOI: 10.1038/s41416-019-0526-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
87 Li L, Ma BB. Colorectal cancer in Chinese patients: current and emerging treatment options. Onco Targets Ther. 2014;7:1817-1828. [PMID: 25336973 DOI: 10.2147/OTT.S48409ott-7-1817] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
88 Debska-Szmich S, Krakowska M, Potemski P. Selection of Patients for Anti-Epidermal Growth Factor Receptor Treatment in Colorectal Cancer: The Potential Pitfalls of Retrospective Analyses of RAS Mutations. J Clin Oncol 2015;33:3517. [PMID: 26304896 DOI: 10.1200/JCO.2015.62.2977] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
89 Bruera G, Massacese S, Pepe F, Malapelle U, Dal Mas A, Ciacco E, Calvisi G, Troncone G, Simmaco M, Ricevuto E. Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers. Ther Adv Med Oncol 2019;11:1758835919846421. [PMID: 31205502 DOI: 10.1177/1758835919846421] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
90 Au TH, Wang K, Stenehjem D, Garrido-Laguna I. Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies. J Gastrointest Oncol 2017;8:387-404. [PMID: 28736627 DOI: 10.21037/jgo.2017.01.04] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
91 Lo Nigro C, Ricci V, Vivenza D, Granetto C, Fabozzi T, Miraglio E, Merlano MC. Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy. World J Gastroenterol 2016; 22(30): 6944-6954 [PMID: 27570430 DOI: 10.3748/wjg.v22.i30.6944] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 36] [Article Influence: 6.8] [Reference Citation Analysis]
92 Tanioka H, Asano M, Yoshida R, Waki N, Uno F, Ishizaki M, Yamashita K, Morishita Y, Nagasaka T. Cetuximab retreatment in patients with metastatic colorectal cancer who exhibited a clinical benefit in response to prior cetuximab: A retrospective study. Oncol Lett 2018;16:3674-80. [PMID: 30127977 DOI: 10.3892/ol.2018.9127] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
93 Vuijk FA, van de Water C, Lent-van Vliet S, van der Valk MJM, Simmer F, van de Velde CJH, Vahrmeijer AL, Nagtegaal ID, Hilling DE. Intra-Tumoral Genomic Heterogeneity in Rectal Cancer: Mutational Status Is Dependent on Preoperative Biopsy Depth and Location. Cancers (Basel) 2021;13:2271. [PMID: 34065112 DOI: 10.3390/cancers13092271] [Reference Citation Analysis]
94 Sharma V, Sharma A, Raina V, Dabkara D, Mohanti BK, Shukla NK, Pathy S, Thulkar S, Deo SVS, Kumar S, Sahoo RK. Metastatic colo-rectal cancer: real life experience from an Indian tertiary care center. BMC Cancer 2021;21:630. [PMID: 34049505 DOI: 10.1186/s12885-021-08398-z] [Reference Citation Analysis]
95 Nakamura Y, Shitara K. Development of circulating tumour DNA analysis for gastrointestinal cancers. ESMO Open 2020;5:e000600. [PMID: 32830648 DOI: 10.1136/esmoopen-2019-000600] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
96 Yip HYK, Papa A. Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments. Cells 2021;10:659. [PMID: 33809714 DOI: 10.3390/cells10030659] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
97 Li L, Ma BB. Colorectal cancer in Chinese patients: current and emerging treatment options. Onco Targets Ther. 2014;7:1817-1828. [PMID: 25336973 DOI: 10.2147/OTT.S48409] [Cited by in Crossref: 3] [Cited by in F6Publishing: 22] [Article Influence: 0.4] [Reference Citation Analysis]
98 Doll S, Kriegmair MC, Santos A, Wierer M, Coscia F, Neil HM, Porubsky S, Geyer PE, Mund A, Nuhn P, Mann M. Rapid proteomic analysis for solid tumors reveals LSD1 as a drug target in an end-stage cancer patient. Mol Oncol 2018;12:1296-307. [PMID: 29901861 DOI: 10.1002/1878-0261.12326] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
99 Schmiegel W, Scott RJ, Dooley S, Lewis W, Meldrum CJ, Pockney P, Draganic B, Smith S, Hewitt C, Philimore H, Lucas A, Shi E, Namdarian K, Chan T, Acosta D, Ping-Chang S, Tannapfel A, Reinacher-Schick A, Uhl W, Teschendorf C, Wolters H, Stern J, Viebahn R, Friess H, Janssen KP, Nitsche U, Slotta-Huspenina J, Pohl M, Vangala D, Baraniskin A, Dockhorn-Dworniczak B, Hegewisch-Becker S, Ronga P, Edelstein DL, Jones FS, Hahn S, Fox SB. Blood-based detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-based RAS testing. Mol Oncol. 2017;11:208-219. [PMID: 28106345 DOI: 10.1002/1878-0261.12023] [Cited by in Crossref: 73] [Cited by in F6Publishing: 66] [Article Influence: 14.6] [Reference Citation Analysis]
100 Palmieri LJ, Mineur L, Tougeron D, Rousseau B, Granger V, Gornet JM, Smith D, Lievre A, Galais MP, Doat S, Pernot S, Bignon-Bretagne AL, Metges JP, Baba-Hamed N, Michel P, Obled S, Vitellius C, Bouche O, Saban-Roche L, Buecher B, des Guetz G, Locher C, Trouilloud I, Goujon G, Dior M, Manfredi S, Soularue E, Phelip JM, Henriques J, Vernery D, Coriat R. Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study). Oncologist 2020;25:e266-75. [PMID: 32043796 DOI: 10.1634/theoncologist.2019-0328] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
101 Goldstein DA, El-Rayes BF. Considering Efficacy and Cost, Where Does Ramucirumab Fit in the Management of Metastatic Colorectal Cancer? Oncologist. 2015;20:981-982. [PMID: 26265225 DOI: 10.1634/theoncologist.2015-0028] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
102 Aleksakhina SN, Imyanitov EN. Cancer Therapy Guided by Mutation Tests: Current Status and Perspectives. Int J Mol Sci 2021;22:10931. [PMID: 34681592 DOI: 10.3390/ijms222010931] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
103 Zhou T, Ji Y. Incorporating external data into the analysis of clinical trials via Bayesian additive regression trees. Stat Med 2021;40:6421-42. [PMID: 34494288 DOI: 10.1002/sim.9191] [Reference Citation Analysis]
104 Shen Y, Han X, Wang J, Wang S, Yang H, Lu SH, Shi Y. Prognostic impact of mutation profiling in patients with stage II and III colon cancer. Sci Rep 2016;6:24310. [PMID: 27074743 DOI: 10.1038/srep24310] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
105 Sunakawa Y, Izawa N, Mizukami T, Horie Y, Hirakawa M, Arai H, Ogura T, Tsuda T, Nakajima TE. Profile of trifluridine/tipiracil hydrochloride in the treatment of metastatic colorectal cancer: efficacy, safety, and place in therapy. Onco Targets Ther 2017;10:4599-605. [PMID: 28979148 DOI: 10.2147/OTT.S106101] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
106 Corcoran RB, André T, Atreya CE, Schellens JHM, Yoshino T, Bendell JC, Hollebecque A, McRee AJ, Siena S, Middleton G, Muro K, Gordon MS, Tabernero J, Yaeger R, O'Dwyer PJ, Humblet Y, De Vos F, Jung AS, Brase JC, Jaeger S, Bettinger S, Mookerjee B, Rangwala F, Van Cutsem E. Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer. Cancer Discov 2018;8:428-43. [PMID: 29431699 DOI: 10.1158/2159-8290.CD-17-1226] [Cited by in Crossref: 235] [Cited by in F6Publishing: 135] [Article Influence: 58.8] [Reference Citation Analysis]
107 Strickler JH, Hurwitz HI. Palliative treatment of metastatic colorectal cancer: what is the optimal approach? Curr Oncol Rep 2014;16:363. [PMID: 24293074 DOI: 10.1007/s11912-013-0363-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
108 Lopez NE, Peterson CY. Advances in Biomarkers: Going Beyond the Carcinoembryonic Antigen. Clin Colon Rectal Surg 2016;29:196-204. [PMID: 27582644 DOI: 10.1055/s-0036-1584289] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
109 Yoon HH, Tougeron D, Shi Q, Alberts SR, Mahoney MR, Nelson GD, Nair SG, Thibodeau SN, Goldberg RM, Sargent DJ, Sinicrope FA; Alliance for Clinical Trials in Oncology. KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). Clin Cancer Res. 2014;20:3033-3043. [PMID: 24687927 DOI: 10.1158/1078-0432.ccr-13-3140] [Cited by in Crossref: 89] [Cited by in F6Publishing: 55] [Article Influence: 11.1] [Reference Citation Analysis]
110 Richman SD, Adams R, Quirke P, Butler R, Hemmings G, Chambers P, Roberts H, James MD, Wozniak S, Bathia R, Pugh C, Maughan T, Jasani B; FOCUS4 Trial Management Group. Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial. J Clin Pathol 2016;69:35-41. [PMID: 26350752 DOI: 10.1136/jclinpath-2015-203097] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
111 Gong J, Cho M, Fakih M. RAS and BRAF in metastatic colorectal cancer management. J Gastrointest Oncol 2016;7:687-704. [PMID: 27747083 DOI: 10.21037/jgo.2016.06.12] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 5.8] [Reference Citation Analysis]
112 Bouchahda M, Saffroy R, Karaboué A, Hamelin J, Innominato P, Saliba F, Lévi F, Bosselut N, Lemoine A. Undetectable RAS-Mutant Clones in Plasma: Possible Implication for Anti-EGFR Therapy and Prognosis in Patients With RAS-Mutant Metastatic Colorectal Cancer. JCO Precis Oncol 2020;4:PO. [PMID: 33015528 DOI: 10.1200/PO.19.00400] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
113 Gonzalez-Pons M, Cruz-Correa M. Colorectal Cancer Biomarkers: Where Are We Now? Biomed Res Int 2015;2015:149014. [PMID: 26106599 DOI: 10.1155/2015/149014] [Cited by in Crossref: 84] [Cited by in F6Publishing: 82] [Article Influence: 12.0] [Reference Citation Analysis]
114 Bridgewater JA, Pugh SA, Maishman T, Eminton Z, Mellor J, Whitehead A, Stanton L, Radford M, Corkhill A, Griffiths GO, Falk S, Valle JW, O'Reilly D, Siriwardena AK, Hornbuckle J, Rees M, Iveson TJ, Hickish T, Garden OJ, Cunningham D, Maughan TS, Primrose JN; New EPOC investigators. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2020;21:398-411. [PMID: 32014119 DOI: 10.1016/s1470-2045(19)30798-3] [Cited by in Crossref: 51] [Cited by in F6Publishing: 22] [Article Influence: 25.5] [Reference Citation Analysis]
115 Dadduzio V, Basso M, Rossi S, Cenci T, Capodimonti S, Strippoli A, Orlandi A, Cerchiaro E, Schinzari G, Cassano A, Martini M, Barone C. KRAS Exon 2 Mutations as Prognostic Indicators in Advanced Colorectal Cancer in Clinical Practice: A Mono-Institutional Study. Mol Diagn Ther 2016;20:65-74. [PMID: 26610798 DOI: 10.1007/s40291-015-0178-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
116 Augustine TA, Baig M, Sood A, Budagov T, Atzmon G, Mariadason JM, Aparo S, Maitra R, Goel S. Telomere length is a novel predictive biomarker of sensitivity to anti-EGFR therapy in metastatic colorectal cancer. Br J Cancer 2015;112:313-8. [PMID: 25412235 DOI: 10.1038/bjc.2014.561] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
117 Ahn DH, Goldberg RM. Colorectal clinical trials: what is on the horizon? Future Oncol 2016;12:525-31. [PMID: 26777152 DOI: 10.2217/fon.15.327] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
118 Normanno N, Pinto C, Castiglione F, Fenizia F, Barberis M, Marchetti A, Fontanini G, De Rosa G, Taddei GL. The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences. J Transl Med 2015;13:287. [PMID: 26335936 DOI: 10.1186/s12967-015-0655-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
119 Guo F, Gong H, Zhao H, Chen J, Zhang Y, Zhang L, Shi X, Zhang A, Jin H, Zhang J, He Y. Mutation status and prognostic values of KRAS, NRAS, BRAF and PIK3CA in 353 Chinese colorectal cancer patients. Sci Rep 2018;8:6076. [PMID: 29666387 DOI: 10.1038/s41598-018-24306-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 6.3] [Reference Citation Analysis]
120 Katona BW, Hojnacki T, Glynn RA, Paulosky KE, Szigety KM, Cao Y, Zhang X, Feng Z, He X, Ma J, Hua X. Menin-mediated Repression of Glycolysis in Combination with Autophagy Protects Colon Cancer Against Small-molecule EGFR Inhibitors. Mol Cancer Ther 2020;19:2319-29. [PMID: 32879052 DOI: 10.1158/1535-7163.MCT-20-0101] [Reference Citation Analysis]
121 Grech G, Zhan X, Yoo BC, Bubnov R, Hagan S, Danesi R, Vittadini G, Desiderio DM. EPMA position paper in cancer: current overview and future perspectives. EPMA J 2015;6:9. [PMID: 25908947 DOI: 10.1186/s13167-015-0030-6] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 8.0] [Reference Citation Analysis]
122 Pai SG, Fuloria J. Novel therapeutic agents in the treatment of metastatic colorectal cancer. World J Gastrointest Oncol 2016; 8(1): 99-104 [PMID: 26798440 DOI: 10.4251/wjgo.v8.i1.99] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
123 Jing C, Jin YH, You Z, Qiong Q, Jun Z. Prognostic value of amphiregulin and epiregulin mRNA expression in metastatic colorectal cancer patients. Oncotarget 2016;7:55890-9. [PMID: 27344184 DOI: 10.18632/oncotarget.10151] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
124 Nguyen TT, Ung TT, Kim NH, Jung YD. Role of bile acids in colon carcinogenesis. World J Clin Cases 2018; 6(13): 577-588 [PMID: 30430113 DOI: 10.12998/wjcc.v6.i13.577] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 27] [Article Influence: 8.0] [Reference Citation Analysis]
125 Sforza V, Martinelli E, Ciardiello F, Gambardella V, Napolitano S, Martini G, della Corte C, Cardone C, Ferrara ML, Reginelli A, Liguori G, Belli G, Troiani T. Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. World J Gastroenterol 2016; 22(28): 6345-6361 [PMID: 27605871 DOI: 10.3748/wjg.v22.i28.6345] [Cited by in CrossRef: 60] [Cited by in F6Publishing: 56] [Article Influence: 10.0] [Reference Citation Analysis]
126 Fukata K, Yuasa N, Takeuchi E, Miyake H, Nagai H, Yoshioka Y, Miyata K. Clinical and prognostic differences between surgically resected right-sided and left-sided colorectal cancer. Surg Today 2020;50:267-74. [PMID: 31612331 DOI: 10.1007/s00595-019-01889-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
127 Yang M, Schell MJ, Loboda A, Nebozhyn M, Li J, Teer JK, Pledger WJ, Yeatman TJ. Repurposing EGFR Inhibitor Utility in Colorectal Cancer in Mutant APC and TP53 Subpopulations. Cancer Epidemiol Biomarkers Prev 2019;28:1141-52. [PMID: 31015202 DOI: 10.1158/1055-9965.EPI-18-1383] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
128 Kim N, Shin I, Kim Y, Jeon E, Lee J, Lee C, Nam Y, Lee S, Ju E, Kim C, Son W, Ryu S, Ko M, Sim T. Novel Small Molecules Capable of Blocking mtRAS-Signaling Pathway. Front Oncol 2021;11:768022. [PMID: 34956887 DOI: 10.3389/fonc.2021.768022] [Reference Citation Analysis]
129 Yang C, Fu ZX. Liposomal delivery and polyethylene glycol-liposomal oxaliplatin for the treatment of colorectal cancer (Review). Biomed Rep 2014;2:335-9. [PMID: 24748970 DOI: 10.3892/br.2014.249] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
130 Al-Shamsi HO, Alhazzani W, Wolff RA. Extended RAS testing in metastatic colorectal cancer-Refining the predictive molecular biomarkers. J Gastrointest Oncol 2015;6:314-21. [PMID: 26029459 DOI: 10.3978/j.issn.2078-6891.2015.016] [Cited by in F6Publishing: 14] [Reference Citation Analysis]
131 Peeters M, Karthaus M, Rivera F, Terwey JH, Douillard JY. Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status. Drugs 2015;75:731-48. [PMID: 25895463 DOI: 10.1007/s40265-015-0386-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
132 Harada K, Mizrak Kaya D, Shimodaira Y, Song S, Baba H, Ajani JA. Translating genomic profiling to gastrointestinal cancer treatment. Future Oncol 2017;13:919-34. [PMID: 28067073 DOI: 10.2217/fon-2016-0422] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
133 Antoniotti C, Ongaro E, Falcone A, Cremolini C. The Winding Roadmap of Biomarkers toward Clinic: Lessons from Predictors of Resistance to Anti-EGFRs in Metastatic Colorectal Cancer. Int J Mol Sci 2018;19:E2298. [PMID: 30081606 DOI: 10.3390/ijms19082298] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
134 Weyn C, Van Raemdonck S, Dendooven R, Maes V, Zwaenepoel K, Lambin S, Pauwels P. Clinical performance evaluation of a sensitive, rapid low-throughput test for KRAS mutation analysis using formalin-fixed, paraffin-embedded tissue samples. BMC Cancer 2017;17:139. [PMID: 28201998 DOI: 10.1186/s12885-017-3112-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
135 Jiang D, Shu C, Lei C, Wan Y, Sun L. Early-onset colorectal cancer: A distinct entity with unique genetic features. Oncol Lett 2020;20:33. [PMID: 32774506 DOI: 10.3892/ol.2020.11894] [Reference Citation Analysis]
136 Ettrich TJ, Hüttner FJ, Lisson C, Gani C, Prasad V, Seufferlein T. [Multimodal, interdisciplinary therapeutic concepts for liver metastasized colorectal cancer]. Dtsch Med Wochenschr 2021;146:1468-77. [PMID: 34741292 DOI: 10.1055/a-1391-5273] [Reference Citation Analysis]
137 Regad T. Targeting RTK Signaling Pathways in Cancer. Cancers (Basel) 2015;7:1758-84. [PMID: 26404379 DOI: 10.3390/cancers7030860] [Cited by in Crossref: 183] [Cited by in F6Publishing: 167] [Article Influence: 26.1] [Reference Citation Analysis]
138 Sunakawa Y, Yang D, Moran M, Astrow SH, Tsuji A, Stephens C, Zhang W, Cao S, Takahashi T, Denda T, Shimada K, Kochi M, Nakamura M, Kotaka M, Segawa Y, Masuishi T, Takeuchi M, Fujii M, Nakajima T, Ichikawa W, Lenz HJ. Combined assessment of EGFR-related molecules to predict outcome of 1st-line cetuximab-containing chemotherapy for metastatic colorectal cancer. Cancer Biol Ther 2016;17:751-9. [PMID: 27104867 DOI: 10.1080/15384047.2016.1178426] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
139 Gallo G, Vescio G, De Paola G, Sammarco G. Therapeutic Targets and Tumor Microenvironment in Colorectal Cancer. J Clin Med 2021;10:2295. [PMID: 34070480 DOI: 10.3390/jcm10112295] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
140 Neerincx M, Sie DL, van de Wiel MA, van Grieken NC, Burggraaf JD, Dekker H, Eijk PP, Ylstra B, Verhoef C, Meijer GA, Buffart TE, Verheul HM. MiR expression profiles of paired primary colorectal cancer and metastases by next-generation sequencing. Oncogenesis 2015;4:e170. [PMID: 26436952 DOI: 10.1038/oncsis.2015.29] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 5.1] [Reference Citation Analysis]
141 Le DM, Ahmed S, Ahmed S, Brunet B, Davies J, Doll C, Ferguson M, Ginther N, Gordon V, Hamilton T, Hebbard P, Helewa R, Kim CA, Lee-Ying R, Lim H, Loree JM, McGhie JP, Mulder K, Park J, Renouf D, Wong RPW, Zaidi A, Asif T. Report from the 20th annual Western Canadian Gastrointestinal Cancer Consensus Conference; Saskatoon, Saskatchewan; 28-29 September 2018. Curr Oncol 2019;26:e773-84. [PMID: 31896948 DOI: 10.3747/co.26.5517] [Reference Citation Analysis]
142 Mauri G, Bonazzina E, Amatu A, Tosi F, Bencardino K, Gori V, Massihnia D, Cipani T, Spina F, Ghezzi S, Siena S, Sartore-Bianchi A. The Evolutionary Landscape of Treatment for BRAFV600E Mutant Metastatic Colorectal Cancer. Cancers (Basel) 2021;13:E137. [PMID: 33406649 DOI: 10.3390/cancers13010137] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
143 Liang L, Liu M, Sun X, Yuan Y, Peng K, Rashid K, Yu Y, Cui Y, Chen Y, Liu T. Identification of key genes involved in tumor immune cell infiltration and cetuximab resistance in colorectal cancer. Cancer Cell Int 2021;21:135. [PMID: 33632198 DOI: 10.1186/s12935-021-01829-8] [Reference Citation Analysis]
144 Pillai RK, Lopategui JR, Dhall D, Guindi M, Slavin T, Lofton-Day CE, Patterson SD. The State of the Art in Colorectal Cancer Molecular Biomarker Testing. Adv Anat Pathol 2016;23:92-103. [PMID: 26849815 DOI: 10.1097/PAP.0000000000000107] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
145 Bertero L, Spadi R, Osella-Abate S, Mariani S, Castellano I, Gambella A, Racca P, Morino M, Cassoni P. Metastatic colorectal cancer prior to expanded RAS assessment: evidence from long-term outcome analysis of a real-life cohort within a dedicated colorectal cancer unit. World J Surg Oncol 2020;18:65. [PMID: 32241284 DOI: 10.1186/s12957-020-01844-5] [Reference Citation Analysis]
146 Kripp M, Prasnikar N, Vehling-Kaiser U, Quidde J, Al-Batran SE, Stein A, Neben K, Hannig CV, Tessen HW, Trarbach T, Hinke A, Hofheinz RD. AIO LQ-0110: a randomized phase II trial comparing oral doxycycline versus local administration of erythromycin as preemptive treatment strategies of panitumumab-mediated skin toxicity in patients with metastatic colorectal cancer. Oncotarget 2017;8:105061-71. [PMID: 29285233 DOI: 10.18632/oncotarget.21249] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
147 Llovet P, Sastre J, Ortega JS, Bando I, Ferrer M, García-Alfonso P, Donnay O, Carrato A, Jiménez A, Aranda E. Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy. Mol Diagn Ther. 2015;19:397-408. [PMID: 26341080 DOI: 10.1007/s40291-015-0165-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
148 Palomba G, Doneddu V, Cossu A, Paliogiannis P, Manca A, Casula M, Colombino M, Lanzillo A, Defraia E, Pazzola A, Sanna G, Putzu C, Ortu S, Scartozzi M, Ionta MT, Baldino G, Sarobba G, Capelli F, Sedda T, Virdis L, Barca M, Gramignano G, Budroni M, Tanda F, Palmieri G. Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study. J Transl Med. 2016;14:292. [PMID: 27737711 DOI: 10.1186/s12967-016-1053-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
149 Sclafani F, Brown G, Cunningham D, Rao S, Tekkis P, Tait D, Morano F, Baratelli C, Kalaitzaki E, Rasheed S, Watkins D, Starling N, Wotherspoon A, Chau I. Systemic Chemotherapy as Salvage Treatment for Locally Advanced Rectal Cancer Patients Who Fail to Respond to Standard Neoadjuvant Chemoradiotherapy. Oncologist 2017;22:728-36. [PMID: 28476941 DOI: 10.1634/theoncologist.2016-0396] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
150 Siena S, Sartore-Bianchi A, Marsoni S, Hurwitz HI, McCall SJ, Penault-Llorca F, Srock S, Bardelli A, Trusolino L. Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. Ann Oncol. 2018;29:1108-1119. [PMID: 29659677 DOI: 10.1093/annonc/mdy100] [Cited by in Crossref: 73] [Cited by in F6Publishing: 67] [Article Influence: 24.3] [Reference Citation Analysis]
151 Su J, Zhang E, Han L, Yin D, Liu Z, He X, Zhang Y, Lin F, Lin Q, Mao P, Mao W, Shen D. Long noncoding RNA BLACAT1 indicates a poor prognosis of colorectal cancer and affects cell proliferation by epigenetically silencing of p15. Cell Death Dis. 2017;8:e2665. [PMID: 28277544 DOI: 10.1038/cddis.2017.83] [Cited by in Crossref: 60] [Cited by in F6Publishing: 65] [Article Influence: 12.0] [Reference Citation Analysis]
152 Imamura Y, Lochhead P, Yamauchi M, Kuchiba A, Qian ZR, Liao X, Nishihara R, Jung S, Wu K, Nosho K, Wang YE, Peng S, Bass AJ, Haigis KM, Meyerhardt JA, Chan AT, Fuchs CS, Ogino S. Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review. Mol Cancer 2014;13:135. [PMID: 24885062 DOI: 10.1186/1476-4598-13-135] [Cited by in Crossref: 80] [Cited by in F6Publishing: 86] [Article Influence: 10.0] [Reference Citation Analysis]
153 Esposito C, Rachiglio AM, La Porta ML, Sacco A, Roma C, Iannaccone A, Tatangelo F, Forgione L, Pasquale R, Barbaro A, Botti G, Ciardiello F, Normanno N. The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies. Cancer Biol Ther 2013;14:1143-6. [PMID: 24025416 DOI: 10.4161/cbt.26340] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 4.7] [Reference Citation Analysis]
154 Keppens C, Dufraing K, van Krieken HJ, Siebers AG, Kafatos G, Lowe K, Demonty G, Dequeker EMC. European follow-up of incorrect biomarker results for colorectal cancer demonstrates the importance of quality improvement projects. Virchows Arch 2019;475:25-37. [PMID: 30719547 DOI: 10.1007/s00428-019-02525-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
155 Gbolahan O, O'Neil B. Update on systemic therapy for colorectal cancer: biologics take sides. Transl Gastroenterol Hepatol 2019;4:9. [PMID: 30976712 DOI: 10.21037/tgh.2019.01.12] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
156 Schütte M, Risch T, Abdavi-Azar N, Boehnke K, Schumacher D, Keil M, Yildiriman R, Jandrasits C, Borodina T, Amstislavskiy V, Worth CL, Schweiger C, Liebs S, Lange M, Warnatz HJ, Butcher LM, Barrett JE, Sultan M, Wierling C, Golob-Schwarzl N, Lax S, Uranitsch S, Becker M, Welte Y, Regan JL, Silvestrov M, Kehler I, Fusi A, Kessler T, Herwig R, Landegren U, Wienke D, Nilsson M, Velasco JA, Garin-Chesa P, Reinhard C, Beck S, Schäfer R, Regenbrecht CR, Henderson D, Lange B, Haybaeck J, Keilholz U, Hoffmann J, Lehrach H, Yaspo ML. Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors. Nat Commun 2017;8:14262. [PMID: 28186126 DOI: 10.1038/ncomms14262] [Cited by in Crossref: 145] [Cited by in F6Publishing: 134] [Article Influence: 29.0] [Reference Citation Analysis]
157 Kawazoe A, Shitara K, Fukuoka S, Kuboki Y, Bando H, Okamoto W, Kojima T, Fuse N, Yamanaka T, Doi T. A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer. BMC Cancer. 2015;15:258. [PMID: 25886136 DOI: 10.1186/s12885-015-1276-z] [Cited by in Crossref: 51] [Cited by in F6Publishing: 54] [Article Influence: 7.3] [Reference Citation Analysis]
158 Geredeli C, Yasar N. FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer. World J Surg Oncol 2018;16:67. [PMID: 29587749 DOI: 10.1186/s12957-018-1359-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
159 Zocche DM, Ramirez C, Fontao FM, Costa LD, Redal MA. Global impact of KRAS mutation patterns in FOLFOX treated metastatic colorectal cancer. Front Genet. 2015;6:116. [PMID: 25870609 DOI: 10.3389/fgene.2015.00116] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
160 Mauri G, Durinikova E, Amatu A, Tosi F, Cassingena A, Rizzetto F, Buzo K, Arcella P, Aquilano MC, Bonoldi E, Marsoni S, Siena S, Bardelli A, Sartore-Bianchi A, Arena S. Empowering Clinical Decision Making in Oligometastatic Colorectal Cancer: The Potential Role of Drug Screening of Patient-Derived Organoids. JCO Precis Oncol 2021;5:PO. [PMID: 34327296 DOI: 10.1200/PO.21.00143] [Reference Citation Analysis]
161 Messaritakis I, Sfakianaki M, Vogiatzoglou K, Koulouridi A, Koutoulaki C, Mavroudis D, Tzardi M, Gouvas N, Tsiaoussis J, Souglakos J. Evaluation of the Role of Circulating Tumor Cells and Microsatellite Instability Status in Predicting Outcome of Advanced CRC Patients. J Pers Med 2020;10:E235. [PMID: 33217974 DOI: 10.3390/jpm10040235] [Reference Citation Analysis]
162 Haigis KM. KRAS Alleles: The Devil Is in the Detail. Trends Cancer. 2017;3:686-697. [PMID: 28958387 DOI: 10.1016/j.trecan.2017.08.006] [Cited by in Crossref: 125] [Cited by in F6Publishing: 106] [Article Influence: 25.0] [Reference Citation Analysis]
163 Capalbo C, Marchetti P, Coppa A, Calogero A, Anastasi E, Buffone A, Belardinilli F, Gulino M, Frati P, Catalano C, Cortesi E, Giannini G, Gulino A. Vemurafenib and panitumumab combination tailored therapy in BRAF-mutated metastatic colorectal cancer: a case report. Cancer Biol Ther 2014;15:826-31. [PMID: 24755613 DOI: 10.4161/cbt.28878] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
164 Bosch-Vilaró A, Jacobs B, Pomella V, Abbasi Asbagh L, Kirkland R, Michel J, Singh S, Liu X, Kim P, Weitsman G, Barber PR, Vojnovic B, Ng T, Tejpar S. Feedback activation of HER3 attenuates response to EGFR inhibitors in colon cancer cells. Oncotarget 2017;8:4277-88. [PMID: 28032592 DOI: 10.18632/oncotarget.13834] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
165 Li QH, Wang YZ, Tu J, Liu CW, Yuan YJ, Lin R, He WL, Cai SR, He YL, Ye JN. Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance. Gastroenterol Rep (Oxf) 2020;8:179-91. [PMID: 32665850 DOI: 10.1093/gastro/goaa026] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
166 Procaccio L, Bergamo F, Daniel F, Rasola C, Munari G, Biason P, Crucitta S, Barsotti G, Zanella G, Angerilli V, Magro C, Paccagnella S, Di Antonio V, Loupakis F, Danesi R, Zagonel V, Del Re M, Lonardi S, Fassan M. A Real-World Application of Liquid Biopsy in Metastatic Colorectal Cancer: The Poseidon Study. Cancers (Basel) 2021;13:5128. [PMID: 34680277 DOI: 10.3390/cancers13205128] [Reference Citation Analysis]
167 Yaffee P, Osipov A, Tan C, Tuli R, Hendifar A. Review of systemic therapies for locally advanced and metastatic rectal cancer. J Gastrointest Oncol. 2015;6:185-200. [PMID: 25830038 DOI: 10.3978/j.issn.2078-6891.2014.112] [Cited by in F6Publishing: 28] [Reference Citation Analysis]
168 Barber LJ, Davies MN, Gerlinger M. Dissecting cancer evolution at the macro-heterogeneity and micro-heterogeneity scale. Curr Opin Genet Dev 2015;30:1-6. [PMID: 25555261 DOI: 10.1016/j.gde.2014.12.001] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 6.3] [Reference Citation Analysis]
169 Turhal NS, Savaş B, Çoşkun Ö, Baş E, Karabulut B, Nart D, Korkmaz T, Yavuzer D, Demir G, Doğusoy G, Artaç M. Prevalence of K-Ras mutations in hepatocellular carcinoma: A Turkish Oncology Group pilot study. Mol Clin Oncol 2015;3:1275-9. [PMID: 26807232 DOI: 10.3892/mco.2015.633] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
170 Fujii T, Barzi A, Sartore-Bianchi A, Cassingena A, Siravegna G, Karp DD, Piha-Paul SA, Subbiah V, Tsimberidou AM, Huang HJ, Veronese S, Di Nicolantonio F, Pingle S, Vibat CRT, Hancock S, Berz D, Melnikova VO, Erlander MG, Luthra R, Kopetz ES, Meric-Bernstam F, Siena S, Lenz HJ, Bardelli A, Janku F. Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. Clin Cancer Res 2017;23:3657-66. [PMID: 28096270 DOI: 10.1158/1078-0432.CCR-16-2592] [Cited by in Crossref: 33] [Cited by in F6Publishing: 21] [Article Influence: 6.6] [Reference Citation Analysis]
171 Goh V, Glynne-Jones R. Perfusion CT imaging of colorectal cancer. Br J Radiol. 2014;87:20130811. [PMID: 24434157 DOI: 10.1259/bjr.20130811] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
172 Yamaoka T, Ohba M, Ohmori T. Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms. Int J Mol Sci 2017;18:E2420. [PMID: 29140271 DOI: 10.3390/ijms18112420] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 10.6] [Reference Citation Analysis]
173 Nemecek R, Berkovcova J, Radova L, Kazda T, Mlcochova J, Vychytilova-Faltejskova P, Slaby O, Svoboda M. Mutational analysis of primary and metastatic colorectal cancer samples underlying the resistance to cetuximab-based therapy. Onco Targets Ther 2016;9:4695-703. [PMID: 27555788 DOI: 10.2147/OTT.S102891] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
174 Karimi M, Wang C, Bahadini B, Hajjar G, Fakih M. Integrating Academic and Community Practices in the Management of Colorectal Cancer: The City of Hope Model. J Clin Med 2020;9:E1687. [PMID: 32498251 DOI: 10.3390/jcm9061687] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
175 Joosse SA, Gorges TM, Pantel K. Biology, detection, and clinical implications of circulating tumor cells. EMBO Mol Med. 2015;7:1-11. [PMID: 25398926 DOI: 10.15252/emmm.201303698] [Cited by in Crossref: 298] [Cited by in F6Publishing: 280] [Article Influence: 42.6] [Reference Citation Analysis]
176 Nassabein R, Mansour L, Richard C, Vandenbroucke-Menu F, Aubin F, Ayoub JP, Dagenais M, Lapointe R, Letourneau R, Plasse M, Roy A, Turcotte S, Tehfe M. Outcomes of Older Patients with Resectable Colorectal Liver Metastases Cancer (CRLM): Single Center Experience. Curr Oncol 2021;28:1899-908. [PMID: 34069871 DOI: 10.3390/curroncol28030176] [Reference Citation Analysis]
177 Kong X, Li Y, Zhang X. Increased Expression of the YPEL3 Gene in Human Colonic Adenocarcinoma Tissue and the Effects on Proliferation, Migration, and Invasion of Colonic Adenocarcinoma Cells In Vitro via the Wnt/b-Catenin Signaling Pathway. Med Sci Monit 2018;24:4767-75. [PMID: 29988027 DOI: 10.12659/MSM.908173] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
178 Alshammari K, Aung KL, Zhang T, Razak ARA, Serra S, Stockley T, Wang L, Nguyen J, Spreafico A, Hansen AR, Zwir D, Siu LL, Bedard PL. Phase II Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Metastatic Colorectal Cancer. Clin Colorectal Cancer 2021;20:334-41. [PMID: 34417144 DOI: 10.1016/j.clcc.2021.07.004] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
179 Stintzing S. Management of colorectal cancer. F1000Prime Rep 2014;6:108. [PMID: 25580262 DOI: 10.12703/P6-108] [Cited by in Crossref: 51] [Cited by in F6Publishing: 31] [Article Influence: 6.4] [Reference Citation Analysis]
180 Kim TW, Elme A, Kusic Z, Park JO, Udrea AA, Kim SY, Ahn JB, Valencia RV, Krishnan S, Bilic A. A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer. Br J Cancer. 2016;115:1206-1214. [PMID: 27736842 DOI: 10.1038/bjc.2016.309] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
181 Grassadonia A, Di Marino P, Ficorella C, Cortellini A, Cannita K, Parisi A, Gamucci T, Zoratto F, Vici P, Barba M, Porreca E, Neri M, Veronese A, Natoli C, De Tursi M, Tinari N. Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: a retrospective multicenter study. J Cancer 2019;10:5926-34. [PMID: 31762802 DOI: 10.7150/jca.34550] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
182 Taniguchi H, Yamazaki K, Yoshino T, Muro K, Yatabe Y, Watanabe T, Ebi H, Ochiai A, Baba E, Tsuchihara K; Japanese Society of Medical Oncology. Japanese Society of Medical Oncology Clinical Guidelines: RAS (KRAS/NRAS) mutation testing in colorectal cancer patients.Cancer Sci. 2015;106:324-327. [PMID: 25800101 DOI: 10.1111/cas.12595] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
183 Buller DM, Ristau BT. Improving patient selection for adjuvant therapy in high-risk renal cell carcinoma. Ann Transl Med 2019;7:S104. [PMID: 31576311 DOI: 10.21037/atm.2019.04.75] [Reference Citation Analysis]
184 Olsen DA, Thomsen CEB, Andersen RF, Madsen JS, Jakobsen A, Brandslund I. Decreased concentrations of intracellular signaling proteins in colon cancer patients with BRAF mutations. Sci Rep 2020;10:20113. [PMID: 33208845 DOI: 10.1038/s41598-020-77109-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
185 Cohen R, Cervera P, Svrcek M, Pellat A, Dreyer C, de Gramont A, André T. BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment? Curr Treat Options Oncol 2017;18:9. [PMID: 28214977 DOI: 10.1007/s11864-017-0453-5] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 6.6] [Reference Citation Analysis]
186 Thomsen CEB, Appelt AL, Andersen RF, Lindebjerg J, Jensen LH, Jakobsen A. The prognostic value of simultaneous tumor and serum RAS/RAF mutations in localized colon cancer. Cancer Med 2017;6:928-36. [PMID: 28378527 DOI: 10.1002/cam4.1051] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
187 Pietrantonio F, Cremolini C, Aprile G, Lonardi S, Orlandi A, Mennitto A, Berenato R, Antoniotti C, Casagrande M, Marsico V, Marmorino F, Cardellino GG, Bergamo F, Tomasello G, Formica V, Longarini R, Giommoni E, Caporale M, Di Bartolomeo M, Loupakis F, de Braud F. Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope. Oncologist 2015;20:1261-5. [PMID: 26446234 DOI: 10.1634/theoncologist.2015-0171] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
188 Woolston A, Khan K, Spain G, Barber LJ, Griffiths B, Gonzalez-Exposito R, Hornsteiner L, Punta M, Patil Y, Newey A, Mansukhani S, Davies MN, Furness A, Sclafani F, Peckitt C, Jiménez M, Kouvelakis K, Ranftl R, Begum R, Rana I, Thomas J, Bryant A, Quezada S, Wotherspoon A, Khan N, Fotiadis N, Marafioti T, Powles T, Lise S, Calvo F, Guettler S, von Loga K, Rao S, Watkins D, Starling N, Chau I, Sadanandam A, Cunningham D, Gerlinger M. Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer. Cancer Cell 2019;36:35-50.e9. [PMID: 31287991 DOI: 10.1016/j.ccell.2019.05.013] [Cited by in Crossref: 65] [Cited by in F6Publishing: 71] [Article Influence: 32.5] [Reference Citation Analysis]
189 Zaanan A, Bachet JB, André T, Sinicrope FA. Prognostic Impact of Deficient DNA Mismatch Repair and Mutations in KRAS, and BRAFV600E in Patients with Lymph Node-Positive Colon Cancer. Curr Colorectal Cancer Rep 2014;10:346-53. [PMID: 25386108 DOI: 10.1007/s11888-014-0237-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
190 Lai AZ, Schrock AB, Erlich RL, Ross JS, Miller VA, Yakirevich E, Ali SM, Braiteh F. Detection of an ALK Fusion in Colorectal Carcinoma by Hybrid Capture-Based Assay of Circulating Tumor DNA. Oncologist 2017;22:774-9. [PMID: 28507204 DOI: 10.1634/theoncologist.2016-0376] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
191 Zheng G, Tseng LH, Haley L, Ibrahim J, Bynum J, Xian R, Gocke CD, Eshleman JR, Lin MT. Clinical validation of coexisting driver mutations in colorectal cancers. Hum Pathol 2019;86:12-20. [PMID: 30481508 DOI: 10.1016/j.humpath.2018.11.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
192 De Stefano A, Carlomagno C. Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer. World J Gastroenterol 2014; 20(29): 9732-9743 [PMID: 25110411 DOI: 10.3748/wjg.v20.i29.9732] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
193 Mitani S, Taniguchi H, Sugiyama K, Masuishi T, Honda K, Narita Y, Kadowaki S, Ura T, Ando M, Tajika M, Yatabe Y, Muro K. The impact of the Glasgow Prognostic Score on survival in second-line chemotherapy for metastatic colorectal cancer patients with BRAF V600E mutation. Ther Adv Med Oncol 2019;11:1758835918820298. [PMID: 30719102 DOI: 10.1177/1758835918820298] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
194 Ros J, Baraibar I, Martini G, Salvà F, Saoudi N, Cuadra-Urteaga JL, Dienstmann R, Tabernero J, Élez E. The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer. Curr Treat Options Oncol 2021;22:113. [PMID: 34741675 DOI: 10.1007/s11864-021-00913-5] [Reference Citation Analysis]
195 van 't Erve I, Wesdorp NJ, Medina JE, Ferreira L, Leal A, Huiskens J, Bolhuis K, van Waesberghe JTM, Swijnenburg RJ, van den Broek D, Velculescu VE, Kazemier G, Punt CJA, Meijer GA, Fijneman RJA. KRAS A146 Mutations Are Associated With Distinct Clinical Behavior in Patients With Colorectal Liver Metastases. JCO Precis Oncol 2021;5:PO. [PMID: 34820593 DOI: 10.1200/PO.21.00223] [Reference Citation Analysis]
196 Cremolini C, Schirripa M, Antoniotti C, Moretto R, Salvatore L, Masi G, Falcone A, Loupakis F. First-line chemotherapy for mCRC—a review and evidence-based algorithm. Nat Rev Clin Oncol 2015;12:607-19. [PMID: 26215044 DOI: 10.1038/nrclinonc.2015.129] [Cited by in Crossref: 91] [Cited by in F6Publishing: 86] [Article Influence: 13.0] [Reference Citation Analysis]
197 Roszkowski K, Zurawski B, Jozwicki W, Basta P, Lewandowska MA. Impact of specific KRAS mutation in exon 2 on clinical outcome of chemotherapy- and radiotherapy-treated colorectal adenocarcinoma patients. Mol Diagn Ther 2014;18:559-66. [PMID: 24859378 DOI: 10.1007/s40291-014-0107-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
198 Giordano G, Febbraro A, Venditti M, Campidoglio S, Olivieri N, Raieta K, Parcesepe P, Imbriani GC, Remo A, Pancione M. Targeting angiogenesis and tumor microenvironment in metastatic colorectal cancer: role of aflibercept. Gastroenterol Res Pract. 2014;2014:526178. [PMID: 25136356 DOI: 10.1155/2014/526178] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 3.8] [Reference Citation Analysis]
199 Modest DP, Hiddemann W, Heinemann V. [Chemotherapy of metastatic colorectal cancer]. Internist (Berl) 2014;55:37-42. [PMID: 24399471 DOI: 10.1007/s00108-013-3314-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
200 Osumi H, Shinozaki E, Mashima T, Wakatsuki T, Suenaga M, Ichimura T, Ogura M, Ota Y, Nakayama I, Takahari D, Chin K, Miki Y, Yamaguchi K. Phase II trial of biweekly cetuximab and irinotecan as third-line therapy for pretreated KRAS exon 2 wild-type colorectal cancer. Cancer Sci 2018;109:2567-75. [PMID: 29908105 DOI: 10.1111/cas.13698] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
201 Mazard T, Cayrefourcq L, Perriard F, Senellart H, Linot B, de la Fouchardière C, Terrebonne E, François E, Obled S, Guimbaud R, Mineur L, Fonck M, Daurès JP, Ychou M, Assenat E, Alix-Panabières C. Clinical Relevance of Viable Circulating Tumor Cells in Patients with Metastatic Colorectal Cancer: The COLOSPOT Prospective Study. Cancers (Basel) 2021;13:2966. [PMID: 34199250 DOI: 10.3390/cancers13122966] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
202 Santoro V, Jia R, Thompson H, Nijhuis A, Jeffery R, Kiakos K, Silver AR, Hartley JA, Hochhauser D. Role of Reactive Oxygen Species in the Abrogation of Oxaliplatin Activity by Cetuximab in Colorectal Cancer. J Natl Cancer Inst 2016;108:djv394. [PMID: 26719345 DOI: 10.1093/jnci/djv394] [Cited by in Crossref: 22] [Cited by in F6Publishing: 32] [Article Influence: 3.1] [Reference Citation Analysis]
203 Sun L, Huang S, Li D, Mao Y, Wang Y, Wu J. Efficacy and Safety of Fruquintinib Plus PD-1 Inhibitors Versus Regorafenib Plus PD-1 Inhibitors in Refractory Microsatellite Stable Metastatic Colorectal Cancer. Front Oncol 2021;11:754881. [PMID: 34692541 DOI: 10.3389/fonc.2021.754881] [Reference Citation Analysis]
204 Parseghian CM, Loree JM, Morris VK, Liu X, Clifton KK, Napolitano S, Henry JT, Pereira AA, Vilar E, Johnson B, Kee B, Raghav K, Dasari A, Wu J, Garg N, Raymond VM, Banks KC, Talasaz AA, Lanman RB, Strickler JH, Hong DS, Corcoran RB, Overman MJ, Kopetz S. Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. Ann Oncol 2019;30:243-9. [PMID: 30462160 DOI: 10.1093/annonc/mdy509] [Cited by in Crossref: 69] [Cited by in F6Publishing: 63] [Article Influence: 34.5] [Reference Citation Analysis]
205 Fornaro L, Faviana P, De Gregorio V, Vivaldi C, Paolicchi E, Masi G, Loupakis F, Sensi E, Lupi C, Fontanini G, Wang Y, Danesi R, Falcone A, Crea F. Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer. BMC Cancer 2015;15:874. [PMID: 26553291 DOI: 10.1186/s12885-015-1889-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
206 Johnson DB, Puzanov I. Treatment of NRAS-mutant melanoma. Curr Treat Options Oncol 2015;16:15. [PMID: 25796376 DOI: 10.1007/s11864-015-0330-z] [Cited by in Crossref: 79] [Cited by in F6Publishing: 65] [Article Influence: 11.3] [Reference Citation Analysis]
207 Ridouane Y, Lopes G, Ku G, Masud H, Haaland B. Targeted first-line therapies for advanced colorectal cancer: a Bayesian meta-analysis. Oncotarget 2017;8:66458-66. [PMID: 29029527 DOI: 10.18632/oncotarget.20185] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
208 Coimbra FJ, Ribeiro HS, Marques MC, Herman P, Chojniak R, Kalil AN, Wiermann EG, Cavallero SR, Coelho FF, Fernandes PH, Silvestrini AA, Almeida MF, de Araújo AL, Pitombo M, Teixeira HM, Waechter FL, Ferreira FG, Diniz AL, D'Ippolito G, D'Ippolito G, Begnami MD, Prolla G, Balzan SM, de Oliveira TB, Szultan LA, Lendoire J, Torres OJ. FIRST BRAZILIAN CONSENSUS ON MULTIMODAL TREATMENT OF COLORECTAL LIVER METASTASES. MODULE 1: PRE-TREATMENT EVALUATION. Arq Bras Cir Dig 2015;28:222-30. [PMID: 26734788 DOI: 10.1590/S0102-6720201500040002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
209 Nisa L, Häfliger P, Poliaková M, Giger R, Francica P, Aebersold DM, Charles RP, Zimmer Y, Medová M. PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models. Mol Cancer 2017;16:93. [PMID: 28532501 DOI: 10.1186/s12943-017-0660-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
210 Jarząbek T, Rucińska M, Rogowski W, Lewandowska M, Tujakowski J, Habib M, Kowalczyk A, Byszek A, Dziadziuszko R, Nawrocki S. CA-SSR1 Polymorphism in Intron 1 of the EGFR Gene in Patients with Malignant Tumors Who Develop Acneiform Rash Associated with the Use of Cetuximab. Mol Diagn Ther 2015;19:79-89. [PMID: 25721848 DOI: 10.1007/s40291-015-0132-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
211 Davis TB, Yang M, Schell MJ, Wang H, Ma L, Pledger WJ, Yeatman TJ. PTPRS Regulates Colorectal Cancer RAS Pathway Activity by Inactivating Erk and Preventing Its Nuclear Translocation. Sci Rep 2018;8:9296. [PMID: 29915291 DOI: 10.1038/s41598-018-27584-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
212 Vincenzi B, Cremolini C, Sartore-Bianchi A, Russo A, Mannavola F, Perrone G, Pantano F, Loupakis F, Rossini D, Ongaro E, Bonazzina E, Dell'Aquila E, Imperatori M, Zoccoli A, Bronte G, De Maglio G, Fontanini G, Natoli C, Falcone A, Santini D, Onetti-Muda A, Siena S, Tonini G, Aprile G. Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients. Oncotarget 2015;6:31604-12. [PMID: 26384309 DOI: 10.18632/oncotarget.5231] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
213 Tintelnot J, Metz S, Trentmann M, Oberle A, von Wenserski L, Schultheiß C, Braig F, Kriegs M, Fehse B, Riecken K, Bokemeyer C, Stein A, Binder M. Cancer Cells Expressing Oncogenic Rat Sarcoma Show Drug-Addiction Toward Epidermal Growth Factor Receptor Antibodies Mediated by Sustained MAPK Signaling. Front Oncol 2019;9:1559. [PMID: 32039027 DOI: 10.3389/fonc.2019.01559] [Reference Citation Analysis]
214 García-Foncillas J, Tabernero J, Élez E, Aranda E, Benavides M, Camps C, Jantus-Lewintre E, López R, Muinelo-Romay L, Montagut C, Antón A, López G, Díaz-Rubio E, Rojo F, Vivancos A. Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer. Br J Cancer 2018;119:1464-70. [PMID: 30467411 DOI: 10.1038/s41416-018-0293-5] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 7.5] [Reference Citation Analysis]
215 Price TJ, Beeke C, Townsend AR, Lo L, Amitesh R, Padbury R, Roder D, Maddern G, Moore J, Karapetis C. BRAF Mutation Testing and Metastatic Colorectal Cancer in the Community Setting: Is There an Urgent Need for More Education? Mol Diagn Ther 2016;20:75-82. [PMID: 26714964 DOI: 10.1007/s40291-015-0179-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
216 Modest DP, Ricard I, Heinemann V, Hegewisch-Becker S, Schmiegel W, Porschen R, Stintzing S, Graeven U, Arnold D, von Weikersthal LF, Giessen-Jung C, Stahler A, Schmoll HJ, Jung A, Kirchner T, Tannapfel A, Reinacher-Schick A. Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group. Ann Oncol 2016;27:1746-53. [PMID: 27358379 DOI: 10.1093/annonc/mdw261] [Cited by in Crossref: 101] [Cited by in F6Publishing: 92] [Article Influence: 16.8] [Reference Citation Analysis]
217 Camp ER, Ellis LM. CCR 20th Anniversary Commentary: RAS as a Biomarker for EGFR--Targeted Therapy for Colorectal Cancer-From Concept to Practice. Clin Cancer Res 2015;21:3578-80. [PMID: 26275951 DOI: 10.1158/1078-0432.CCR-14-2900] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
218 Puthiamadathil JM, Weinberg BA. Emerging combination therapies for metastatic colorectal cancer - impact of trifluridine/tipiracil. Cancer Manag Res 2017;9:461-9. [PMID: 29056855 DOI: 10.2147/CMAR.S113320] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
219 Stintzing S, Ivanova B, Ricard I, Jung A, Kirchner T, Tannapfel A, Juette H, Hegewisch-Becker S, Arnold D, Reinacher-Schick A. Amphiregulin (AREG) and Epiregulin (EREG) Gene Expression as Predictor for Overall Survival (OS) in Oxaliplatin/Fluoropyrimidine Plus Bevacizumab Treated mCRC Patients-Analysis of the Phase III AIO KRK-0207 Trial. Front Oncol 2018;8:474. [PMID: 30467535 DOI: 10.3389/fonc.2018.00474] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
220 Yoon YS, Kim JC. Recent applications of chemosensitivity tests for colorectal cancer treatment. World J Gastroenterol 2014; 20(44): 16398-16408 [PMID: 25469008 DOI: 10.3748/wjg.v20.i44.16398] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
221 Lu M, Zessin AS, Glover W, Hsu DS. Activation of the mTOR Pathway by Oxaliplatin in the Treatment of Colorectal Cancer Liver Metastasis. PLoS One 2017;12:e0169439. [PMID: 28060954 DOI: 10.1371/journal.pone.0169439] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
222 Aghagolzadeh P, Radpour R. New trends in molecular and cellular biomarker discovery for colorectal cancer. World J Gastroenterol 2016; 22(25): 5678-5693 [PMID: 27433083 DOI: 10.3748/wjg.v22.i25.5678] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 37] [Article Influence: 7.2] [Reference Citation Analysis]
223 García-García C, Rivas MA, Ibrahim YH, Calvo MT, Gris-Oliver A, Rodríguez O, Grueso J, Antón P, Guzmán M, Aura C, Nuciforo P, Jessen K, Argilés G, Dienstmann R, Bertotti A, Trusolino L, Matito J, Vivancos A, Chicote I, Palmer HG, Tabernero J, Scaltriti M, Baselga J, Serra V. MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer. Clin Cancer Res 2015;21:5499-510. [PMID: 26272063 DOI: 10.1158/1078-0432.CCR-14-3091] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
224 Lastraioli E, Antonuzzo L, Fantechi B, Di Cerbo L, Di Costanzo A, Lavacchi D, Armenio M, Arcangeli A, Castiglione F, Messerini L, Di Costanzo F. KRAS and NRAS mutation detection in circulating DNA from patients with metastatic colorectal cancer using BEAMing assay: Concordance with standard biopsy and clinical evaluation. Oncol Lett 2021;21:15. [PMID: 33240421 DOI: 10.3892/ol.2020.12276] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
225 Kothari N, Schell MJ, Teer JK, Yeatman T, Shibata D, Kim R. Comparison of KRAS mutation analysis of colorectal cancer samples by standard testing and next-generation sequencing. J Clin Pathol 2014;67:764-7. [PMID: 25004944 DOI: 10.1136/jclinpath-2014-202405] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
226 Jeantet M, Tougeron D, Tachon G, Cortes U, Archambaut C, Fromont G, Karayan-Tapon L. High Intra- and Inter-Tumoral Heterogeneity of RAS Mutations in Colorectal Cancer. Int J Mol Sci 2016;17:E2015. [PMID: 27916952 DOI: 10.3390/ijms17122015] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
227 Galbiati S, Damin F, Ferraro L, Soriani N, Burgio V, Ronzoni M, Gianni L, Ferrari M, Chiari M. Microarray Approach Combined with ddPCR: An Useful Pipeline for the Detection and Quantification of Circulating Tumour dna Mutations. Cells 2019;8:E769. [PMID: 31344983 DOI: 10.3390/cells8080769] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
228 Toledo RA, Cubillo A, Vega E, Garralda E, Alvarez R, de la Varga LU, Pascual JR, Sánchez G, Sarno F, Prieto SH, Perea S, Lopéz-Casas PP, López-Ríos F, Hidalgo M. Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab. Oncotarget 2017;8:35289-300. [PMID: 27852040 DOI: 10.18632/oncotarget.13311] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 8.0] [Reference Citation Analysis]
229 Arnold D, Lueza B, Douillard JY, Peeters M, Lenz HJ, Venook A, Heinemann V, Van Cutsem E, Pignon JP, Tabernero J, Cervantes A, Ciardiello F. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol 2017;28:1713-29. [PMID: 28407110 DOI: 10.1093/annonc/mdx175] [Cited by in Crossref: 372] [Cited by in F6Publishing: 335] [Article Influence: 93.0] [Reference Citation Analysis]
230 Tejpar S, Shen L, Wang X, Schilsky RL. Integrating biomarkers in colorectal cancer trials in the West and China. Nat Rev Clin Oncol. 2015;12:553-560. [PMID: 25963094 DOI: 10.1038/nrclinonc.2015.88] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
231 Becker DJ, Lee KM, Lee SY, Lynch KE, Makarov DV, Sherman SE, Morrissey CD, Kelley MJ, Lynch JA. Uptake of KRAS Testing and Anti-EGFR Antibody Use for Colorectal Cancer in the VA. JCO Precis Oncol 2021;5:PO. [PMID: 34250412 DOI: 10.1200/PO.20.00359] [Reference Citation Analysis]
232 Fiala O, Hosek P, Sorejs O, Liska V, Buchler T, Poprach A, Kucera R, Topolcan O, Sedivcova M, Finek J. The Association of Baseline Serum Tumour Markers with Outcome of Patients with Metastatic Colorectal Cancer Treated with Anti-EGFR Monoclonal Antibodies in the First Line. J Cancer 2018;9:4255-62. [PMID: 30519327 DOI: 10.7150/jca.26217] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
233 Chibaudel B, Bonnetain F, Tournigand C, de Larauze MH, de Gramont A, Laurent-Puig P, Paget J, Hadengue A, Notelet D, Benetkiewicz M. STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer. BMC Cancer. 2015;15:496. [PMID: 26141683 DOI: 10.1186/s12885-015-1503-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
234 Rodriguez A, Esposito F, Oliveres H, Torres F, Maurel J. Are Quality of Randomized Clinical Trials and ESMO-Magnitude of Clinical Benefit Scale Two Sides of the Same Coin, to Grade Recommendations for Drug Approval? J Clin Med 2021;10:746. [PMID: 33668473 DOI: 10.3390/jcm10040746] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
235 Rodrigues D, Longatto-Filho A, Martins SF. Predictive Biomarkers in Colorectal Cancer: From the Single Therapeutic Target to a Plethora of Options. Biomed Res Int 2016;2016:6896024. [PMID: 27563673 DOI: 10.1155/2016/6896024] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
236 Sievers CK, Kratz JD, Zurbriggen LD, LoConte NK, Lubner SJ, Uboha N, Mulkerin D, Matkowskyj KA, Deming DA. The Multidisciplinary Management of Colorectal Cancer: Present and Future Paradigms. Clin Colon Rectal Surg 2016;29:232-8. [PMID: 27582648 DOI: 10.1055/s-0036-1584292] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
237 Roussille P, Tachon G, Villalva C, Milin S, Frouin E, Godet J, Berger A, Emambux S, Petropoulos C, Wager M, Karayan-Tapon L, Tougeron D. Pathological and Molecular Characteristics of Colorectal Cancer with Brain Metastases. Cancers (Basel) 2018;10:E504. [PMID: 30544743 DOI: 10.3390/cancers10120504] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
238 Deng Y, Wang L, Tan S, Kim GP, Dou R, Chen D, Cai Y, Fu X, Wang L, Zhu J, Wang J. KRAS as a predictor of poor prognosis and benefit from postoperative FOLFOX chemotherapy in patients with stage II and III colorectal cancer. Mol Oncol. 2015;9:1341-1347. [PMID: 25864038 DOI: 10.1016/j.molonc.2015.03.006] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
239 Nakayama I, Hirota T, Shinozaki E. BRAF Mutation in Colorectal Cancers: From Prognostic Marker to Targetable Mutation. Cancers (Basel) 2020;12:E3236. [PMID: 33152998 DOI: 10.3390/cancers12113236] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
240 Semrad TJ, Kim EJ. Molecular testing to optimize therapeutic decision making in advanced colorectal cancer. J Gastrointest Oncol. 2016;7:S11-S20. [PMID: 27034809 DOI: 10.3978/j.issn.2078-6891.2015.094] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
241 Orlandi A, Di Salvatore M, Bagalà C, Basso M, Strippoli A, Plastino F, Calegari MA, Cassano A, Astone A, Barone C. ERCC1 Induction after Oxaliplatin Exposure May Depend on KRAS Mutational Status in Colorectal Cancer Cell Line: In Vitro Veritas. J Cancer 2015;6:70-81. [PMID: 25553091 DOI: 10.7150/jca.10478] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
242 Sugimachi K, Sakimura S, Kuramitsu S, Hirata H, Niida A, Iguchi T, Eguchi H, Masuda T, Morita M, Toh Y, Maehara Y, Suzuki Y, Mimori K. Serial mutational tracking in surgically resected locally advanced colorectal cancer with neoadjuvant chemotherapy. Br J Cancer 2018;119:419-23. [PMID: 30072744 DOI: 10.1038/s41416-018-0208-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
243 Goldberg RM. Genomic Profiling in Gastrointestinal Cancer: Are We Ready To Use These Data to Make Treatment Decisions? Oncologist 2015;20:1448-56. [PMID: 26512044 DOI: 10.1634/theoncologist.2015-0263] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
244 Ardini E, Bosotti R, Borgia AL, De Ponti C, Somaschini A, Cammarota R, Amboldi N, Raddrizzani L, Milani A, Magnaghi P, Ballinari D, Casero D, Gasparri F, Banfi P, Avanzi N, Saccardo MB, Alzani R, Bandiera T, Felder E, Donati D, Pesenti E, Sartore-Bianchi A, Gambacorta M, Pierotti MA, Siena S, Veronese S, Galvani A, Isacchi A. The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition. Mol Oncol 2014;8:1495-507. [PMID: 24962792 DOI: 10.1016/j.molonc.2014.06.001] [Cited by in Crossref: 87] [Cited by in F6Publishing: 87] [Article Influence: 10.9] [Reference Citation Analysis]
245 Nagai Y, Yamamoto Y, Yasuhara T, Hata K, Nishikawa T, Tanaka T, Tanaka J, Kiyomatsu T, Kawai K, Nozawa H, Kazama S, Yamaguchi H, Ishihara S, Sunami E, Yamanaka T, Miyagawa K, Watanabe T. High RAD54B expression: an independent predictor of postoperative distant recurrence in colorectal cancer patients. Oncotarget 2015;6:21064-73. [PMID: 26046797 DOI: 10.18632/oncotarget.4222] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
246 Kawaguchi Y, De Bellis M, Panettieri E, Duwe G, Vauthey JN. Debate: Improvements in Systemic Therapies for Liver Metastases Will Increase the Role of Locoregional Treatments. Surg Oncol Clin N Am 2021;30:205-18. [PMID: 33220806 DOI: 10.1016/j.soc.2020.08.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
247 Sepulveda AR, Hamilton SR, Allegra CJ, Grody W, Cushman-Vokoun AM, Funkhouser WK, Kopetz SE, Lieu C, Lindor NM, Minsky BD, Monzon FA, Sargent DJ, Singh VM, Willis J, Clark J, Colasacco C, Rumble RB, Temple-Smolkin R, Ventura CB, Nowak JA. Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. J Mol Diagn 2017;19:187-225. [PMID: 28185757 DOI: 10.1016/j.jmoldx.2016.11.001] [Cited by in Crossref: 64] [Cited by in F6Publishing: 51] [Article Influence: 12.8] [Reference Citation Analysis]
248 Jones RP, Sutton PA, Evans JP, Clifford R, McAvoy A, Lewis J, Rousseau A, Mountford R, McWhirter D, Malik HZ. Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer. Br J Cancer. 2017;116:923-929. [PMID: 28208157 DOI: 10.1038/bjc.2017.37] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 9.8] [Reference Citation Analysis]
249 Koulis C, Yap R, Engel R, Jardé T, Wilkins S, Solon G, Shapiro JD, Abud H, McMurrick P. Personalized Medicine-Current and Emerging Predictive and Prognostic Biomarkers in Colorectal Cancer. Cancers (Basel) 2020;12:E812. [PMID: 32231042 DOI: 10.3390/cancers12040812] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
250 Pecci F, Cantini L, Bittoni A, Lenci E, Lupi A, Crocetti S, Giglio E, Giampieri R, Berardi R. Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer. Curr Treat Options Oncol 2021;22:69. [PMID: 34110510 DOI: 10.1007/s11864-021-00870-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
251 Boleij A, Tops BB, Rombout PD, Dequeker EM, Ligtenberg MJ, van Krieken JH; Dutch RAS EQA Initiative. RAS testing in metastatic colorectal cancer: excellent reproducibility amongst 17 Dutch pathology centers. Oncotarget 2015;6:15681-9. [PMID: 25944693 DOI: 10.18632/oncotarget.3804] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
252 García-Alfonso P, García-Carbonero R, García-Foncillas J, Pérez-Segura P, Salazar R, Vera R, Ramón Y Cajal S, Hernández-Losa J, Landolfi S, Musulén E, Cuatrecasas M, Navarro S. Update of the recommendations for the determination of biomarkers in colorectal carcinoma: National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology. Clin Transl Oncol 2020;22:1976-91. [PMID: 32418154 DOI: 10.1007/s12094-020-02357-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
253 Nakajima H, Kotani D, Bando H, Kato T, Oki E, Shinozaki E, Sunakawa Y, Yamazaki K, Yuki S, Nakamura Y, Yamanaka T, Yoshino T, Ohta T, Taniguchi H, Kagawa Y. REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer. BMC Cancer 2021;21:674. [PMID: 34098908 DOI: 10.1186/s12885-021-08395-2] [Reference Citation Analysis]
254 Zhou M, Yu P, Hernick Davin DB, Li Y, Wang Y, Fu L, Zhang J. Is FOLFOXIRI alone or combined with targeted therapy administered as first-line treatment a reasonable choice for most patients with mCRC? Systematic review and network meta-analysis. Oncotarget 2017;8:62339-48. [PMID: 28977949 DOI: 10.18632/oncotarget.17725] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
255 García-Foncillas J, Sunakawa Y, Aderka D, Wainberg Z, Ronga P, Witzler P, Stintzing S. Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors. Front Oncol 2019;9:849. [PMID: 31616627 DOI: 10.3389/fonc.2019.00849] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 14.3] [Reference Citation Analysis]
256 Bendell JC, Zakari A, Peyton JD, Boccia R, Moskowitz M, Gian V, Lipman A, Waterhouse D, LoCicero R, Earwood C, Lane CM, Meluch A. A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only. Oncologist 2016;21:279-80. [PMID: 26911408 DOI: 10.1634/theoncologist.2015-0439] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
257 Chiavenna SM, Jaworski JP, Vendrell A. State of the art in anti-cancer mAbs. J Biomed Sci 2017;24:15. [PMID: 28219375 DOI: 10.1186/s12929-016-0311-y] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 8.4] [Reference Citation Analysis]
258 Qin J, Shaukat I, Mainard D, Netter P, Barré L, Ouzzine M. Constitutive activation of EGFR is associated with tumor progression and plays a prominent role in malignant phenotype of chondrosarcoma. Oncotarget 2019;10:3166-82. [PMID: 31139331 DOI: 10.18632/oncotarget.26899] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
259 Sequist LV, Gray JE, Harb WA, Lopez-Chavez A, Doebele RC, Modiano MR, Jackman DM, Baggstrom MQ, Atmaca A, Felip E, Provencio M, Cobo M, Adiwijaya B, Kuesters G, Kamoun WS, Andreas K, Pipas JM, Santillana S, Cho BC, Park K, Shepherd FA. Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer. Oncologist 2019;24:1095-102. [PMID: 30975923 DOI: 10.1634/theoncologist.2018-0695] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
260 Furuse J, Kurata T, Okano N, Fujisaka Y, Naruge D, Shimizu T, Kitamura H, Iwasa T, Nagashima F, Nakagawa K. An early clinical trial of Salirasib, an oral RAS inhibitor, in Japanese patients with relapsed/refractory solid tumors. Cancer Chemother Pharmacol 2018;82:511-9. [PMID: 29992354 DOI: 10.1007/s00280-018-3618-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
261 Adua D, Di Fabio F, Ercolani G, Fiorentino M, Gruppioni E, Altimari A, Rojas Limpe FL, Normanno N, Pinna AD, Pinto C. Heterogeneity in the colorectal primary tumor and the synchronous resected liver metastases prior to and after treatment with an anti-EGFR monoclonal antibody. Mol Clin Oncol 2017;7:113-20. [PMID: 28685087 DOI: 10.3892/mco.2017.1270] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
262 Sama AR, Cohen SJ. Front-Line Treatment of Metastatic Colorectal Cancer. J Oncol Pract 2016;12:1231-3. [PMID: 27943685 DOI: 10.1200/JOP.2016.018705] [Reference Citation Analysis]
263 Serebriiskii IG, Connelly C, Frampton G, Newberg J, Cooke M, Miller V, Ali S, Ross JS, Handorf E, Arora S, Lieu C, Golemis EA, Meyer JE. Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients. Nat Commun 2019;10:3722. [PMID: 31427573 DOI: 10.1038/s41467-019-11530-0] [Cited by in Crossref: 60] [Cited by in F6Publishing: 52] [Article Influence: 20.0] [Reference Citation Analysis]
264 Franczak C, Dubouis L, Gilson P, Husson M, Rouyer M, Demange J, Leroux A, Merlin JL, Harlé A. Integrated routine workflow using next-generation sequencing and a fully-automated platform for the detection of KRAS, NRAS and BRAF mutations in formalin-fixed paraffin embedded samples with poor DNA quality in patients with colorectal carcinoma. PLoS One 2019;14:e0212801. [PMID: 30811471 DOI: 10.1371/journal.pone.0212801] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
265 Ciombor KK, Haraldsdottir S, Goldberg RM. How Can Next-Generation Sequencing (Genomics) Help Us in Treating Colorectal Cancer? Curr Colorectal Cancer Rep 2014;10:372-9. [PMID: 25395895 DOI: 10.1007/s11888-014-0244-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
266 Zhou J, Zhao R, Wen F, Zhang P, Tang R, Chen H, Zhang J, Li Q. Economic evaluation study (CHEER-compliant): Cost-effectiveness analysis of RAS screening for treatment of metastatic colorectal cancer based on the CALGB 80405 trial. Medicine (Baltimore) 2016;95:e3762. [PMID: 27399059 DOI: 10.1097/MD.0000000000003762] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
267 Strickler JH, Rushing CN, Uronis HE, Morse MA, Niedzwiecki D, Blobe GC, Moyer AN, Bolch E, Webb R, Haley S, Hatch AJ, Altomare IP, Sherrill GB, Chang DZ, Wells JL, Hsu SD, Jia J, Zafar SY, Nixon AB, Hurwitz HI. Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer. Oncologist 2021;26:465-e917. [PMID: 33469991 DOI: 10.1002/onco.13678] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
268 Vidwans SJ, Turski ML, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Subbiah V, Rodon J, Kurzrock R. A framework for genomic biomarker actionability and its use in clinical decision making. Oncoscience 2014;1:614-23. [PMID: 25593991 DOI: 10.18632/oncoscience.90] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
269 Lou E, D'Souza D, Nelson AC. Therapeutic Response of Metastatic Colorectal Cancer Harboring a KRAS Missense Mutation After Combination Chemotherapy With the EGFR Inhibitor Panitumumab. J Natl Compr Canc Netw. 2017;15:427-432. [PMID: 28404754 DOI: 10.6004/jnccn.2017.0043] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
270 Bathe OF, Farshidfar F. From genotype to functional phenotype: unraveling the metabolomic features of colorectal cancer. Genes (Basel) 2014;5:536-60. [PMID: 25055199 DOI: 10.3390/genes5030536] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
271 Hocking C, Hardingham JE, Broadbridge V, Wrin J, Townsend AR, Tebbutt N, Cooper J, Ruszkiewicz A, Lee C, Price TJ. Can we accurately report PTEN status in advanced colorectal cancer? BMC Cancer 2014;14:128. [PMID: 24564252 DOI: 10.1186/1471-2407-14-128] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
272 Ye JX, Liu Y, Qin Y, Zhong HH, Yi WN, Shi XY. KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients. World J Gastroenterol 2015; 21(5): 1595-1605 [PMID: 25663779 DOI: 10.3748/wjg.v21.i5.1595] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
273 Annunziata MC, De Stefano A, Fabbrocini G, Leo S, Marchetti P, Romano MC, Romano I. Current Recommendations and Novel Strategies for the Management of Skin Toxicities Related to Anti-EGFR Therapies in Patients with Metastatic Colorectal Cancer. Clin Drug Investig 2019;39:825-34. [PMID: 31264159 DOI: 10.1007/s40261-019-00811-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
274 Sasaki Y, Akasu T, Saito N, Kojima H, Matsuda K, Nakamori S, Komori K, Amagai K, Yamaguchi T, Ohue M, Nagashima K, Yamada Y. Prognostic and predictive value of extended RAS mutation and mismatch repair status in stage III colorectal cancer. Cancer Sci 2016;107:1006-12. [PMID: 27089049 DOI: 10.1111/cas.12950] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
275 Davis SL, Robertson KM, Pitts TM, Tentler JJ, Bradshaw-Pierce EL, Klauck PJ, Bagby SM, Hyatt SL, Selby HM, Spreafico A, Ecsedy JA, Arcaroli JJ, Messersmith WA, Tan AC, Eckhardt SG. Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models. Front Pharmacol 2015;6:120. [PMID: 26136684 DOI: 10.3389/fphar.2015.00120] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
276 Shi B, Zhou X, He L, Liang M, Luo Y, Jiang P. Reduced RCE1 expression predicts poor prognosis of colorectal carcinoma. BMC Cancer 2017;17:414. [PMID: 28615075 DOI: 10.1186/s12885-017-3393-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
277 Kawagoe S, Nakano M, Uchino K, Arimizu K, Kajitani T, Shimokawa H, Kusumoto T, Ikejiri K, Baba E. Analysis of Response Evaluation Criteria in Solid Tumors reduction ratio of primary chemotherapy in unresectable advanced or recurrent colorectal cancer. Mol Clin Oncol 2019;11:243-51. [PMID: 31396385 DOI: 10.3892/mco.2019.1894] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
278 Schirripa M, Bergamo F, Cremolini C, Casagrande M, Lonardi S, Aprile G, Yang D, Marmorino F, Pasquini G, Sensi E, Lupi C, De Maglio G, Borrelli N, Pizzolitto S, Fasola G, Bertorelle R, Rugge M, Fontanini G, Zagonel V, Loupakis F, Falcone A. BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection. Br J Cancer. 2015;112:1921-1928. [PMID: 25942399 DOI: 10.1038/bjc.2015.142] [Cited by in Crossref: 91] [Cited by in F6Publishing: 86] [Article Influence: 13.0] [Reference Citation Analysis]
279 Elez E, Hendlisz A, Delaunoit T, Sastre J, Cervantes A, Varea R, Chao G, Wallin J, Tabernero J. Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer. Br J Cancer 2016;114:372-80. [PMID: 26766738 DOI: 10.1038/bjc.2015.480] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
280 Moati E, Taly V, Garinet S, Didelot A, Taieb J, Laurent-Puig P, Zaanan A. Role of Circulating Tumor DNA in Gastrointestinal Cancers: Current Knowledge and Perspectives. Cancers (Basel) 2021;13:4743. [PMID: 34638228 DOI: 10.3390/cancers13194743] [Reference Citation Analysis]
281 Richman SD, Southward K, Chambers P, Cross D, Barrett J, Hemmings G, Taylor M, Wood H, Hutchins G, Foster JM, Oumie A, Spink KG, Brown SR, Jones M, Kerr D, Handley K, Gray R, Seymour M, Quirke P. HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. J Pathol. 2016;238:562-570. [PMID: 26690310 DOI: 10.1002/path.4679] [Cited by in Crossref: 95] [Cited by in F6Publishing: 92] [Article Influence: 15.8] [Reference Citation Analysis]
282 Kim D, Hong YS, Kim JE, Kim KP, Lee JL, Chun SM, Kim J, Jang SJ, Kim TW. Use of a High-Throughput Genotyping Platform (OncoMap) for RAS Mutational Analysis to Predict Cetuximab Efficacy in Patients with Metastatic Colorectal Cancer. Cancer Res Treat 2017;49:37-43. [PMID: 27121720 DOI: 10.4143/crt.2016.069] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
283 Mouliere F, El Messaoudi S, Pang D, Dritschilo A, Thierry AR. Multi-marker analysis of circulating cell-free DNA toward personalized medicine for colorectal cancer. Mol Oncol. 2014;8:927-941. [PMID: 24698732 DOI: 10.1016/j.molonc.2014.02.005] [Cited by in Crossref: 123] [Cited by in F6Publishing: 108] [Article Influence: 15.4] [Reference Citation Analysis]
284 Matikas A, Voutsina A, Lagoudaki E, Hatzidaki D, Trypaki M, Stoupis G, Tzardi M, Mavroudis D, Georgoulias V. Detection of KRAS Exon 2 Mutations in Circulating Tumor Cells Isolated by the ISET System from Patients with RAS Wild Type Metastatic Colorectal Cancer. Transl Oncol 2017;10:693-8. [PMID: 28692881 DOI: 10.1016/j.tranon.2017.06.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
285 Yu IS, Loree JM. FOLFOXIRI plus Bevacizumab Versus FOLFOX plus Panitumumab for Metastatic Left-Sided RAS/BRAF Wild-Type Colorectal Cancer: Which "Side" Are You On? Oncologist 2021;26:277-80. [PMID: 33539032 DOI: 10.1002/onco.13705] [Reference Citation Analysis]
286 Liu Z, Wang S, Dong D, Wei J, Fang C, Zhou X, Sun K, Li L, Li B, Wang M, Tian J. The Applications of Radiomics in Precision Diagnosis and Treatment of Oncology: Opportunities and Challenges. Theranostics. 2019;9:1303-1322. [PMID: 30867832 DOI: 10.7150/thno.30309] [Cited by in Crossref: 149] [Cited by in F6Publishing: 146] [Article Influence: 49.7] [Reference Citation Analysis]
287 Ciombor KK, Berlin J. Targeting metastatic colorectal cancer - present and emerging treatment options. Pharmgenomics Pers Med 2014;7:137-44. [PMID: 25045279 DOI: 10.2147/PGPM.S47582] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
288 Zhu J, Strickler JH. Clinical applications of liquid biopsies in gastrointestinal oncology. J Gastrointest Oncol 2016;7:675-86. [PMID: 27747082 DOI: 10.21037/jgo.2016.08.08] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
289 Tran NH, Cavalcante LL, Lubner SJ, Mulkerin DL, LoConte NK, Clipson L, Matkowskyj KA, Deming DA. Precision medicine in colorectal cancer: the molecular profile alters treatment strategies. Ther Adv Med Oncol 2015;7:252-62. [PMID: 26327923 DOI: 10.1177/1758834015591952] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 6.6] [Reference Citation Analysis]
290 Zaidi SH, Harrison TA, Phipps AI, Steinfelder R, Trinh QM, Qu C, Banbury BL, Georgeson P, Grasso CS, Giannakis M, Adams JB, Alwers E, Amitay EL, Barfield RT, Berndt SI, Borozan I, Brenner H, Brezina S, Buchanan DD, Cao Y, Chan AT, Chang-Claude J, Connolly CM, Drew DA, Farris AB 3rd, Figueiredo JC, French AJ, Fuchs CS, Garraway LA, Gruber S, Guinter MA, Hamilton SR, Harlid S, Heisler LE, Hidaka A, Hopper JL, Huang WY, Huyghe JR, Jenkins MA, Krzyzanowski PM, Lemire M, Lin Y, Luo X, Mardis ER, McPherson JD, Miller JK, Moreno V, Mu XJ, Nishihara R, Papadopoulos N, Pasternack D, Quist MJ, Rafikova A, Reid EEG, Shinbrot E, Shirts BH, Stein LD, Teney CD, Timms L, Um CY, Van Guelpen B, Van Tassel M, Wang X, Wheeler DA, Yung CK, Hsu L, Ogino S, Gsur A, Newcomb PA, Gallinger S, Hoffmeister M, Campbell PT, Thibodeau SN, Sun W, Hudson TJ, Peters U. Landscape of somatic single nucleotide variants and indels in colorectal cancer and impact on survival. Nat Commun 2020;11:3644. [PMID: 32686686 DOI: 10.1038/s41467-020-17386-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
291 Harlé A, Salleron J, Perkins G, Pilati C, Blons H, Laurent-Puig P, Merlin JL. Expression of pEGFR and pAKT as response-predictive biomarkers for RAS wild-type patients to anti-EGFR monoclonal antibodies in metastatic colorectal cancers. Br J Cancer 2015;113:680-5. [PMID: 26171935 DOI: 10.1038/bjc.2015.250] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
292 Osawa H. Response to regorafenib at an initial dose of 120 mg as salvage therapy for metastatic colorectal cancer. Mol Clin Oncol 2017;6:365-72. [PMID: 28451414 DOI: 10.3892/mco.2017.1145] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
293 Huang CC, Liu FR, Feng Q, Pan XY, Song SL, Yang JL. RGD4C peptide mediates anti-p21Ras scFv entry into tumor cells and produces an inhibitory effect on the human colon cancer cell line SW480. BMC Cancer 2021;21:321. [PMID: 33765976 DOI: 10.1186/s12885-021-08056-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
294 Gutierrez ME, Price KS, Lanman RB, Nagy RJ, Shah I, Mathura S, Mulcahy M, Norden AD, Goldberg SL. Genomic Profiling for KRAS, NRAS, BRAF, Microsatellite Instability, and Mismatch Repair Deficiency Among Patients With Metastatic Colon Cancer. JCO Precis Oncol 2019;3:PO. [PMID: 32923867 DOI: 10.1200/PO.19.00274] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
295 Magliacane G, Grassini G, Bartocci P, Francaviglia I, Dal Cin E, Barbieri G, Arrigoni G, Pecciarini L, Doglioni C, Cangi MG. Rapid targeted somatic mutation analysis of solid tumors in routine clinical diagnostics. Oncotarget 2015;6:30592-603. [PMID: 26435479 DOI: 10.18632/oncotarget.5190] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
296 Shibutani M, Maeda K, Nagahara H, Fukuoka T, Iseki Y, Matsutani S, Wang E, Hirakawa K, Ohira M. Complete Response of Pulmonary Metastases from Rectal Cancer to Tegafur-Uracil/Leucovorin plus Bevacizumab in an Elderly Patient: A Case Report. Case Rep Oncol 2018;11:461-6. [PMID: 30057541 DOI: 10.1159/000490698] [Reference Citation Analysis]
297 van Brummelen EMJ, de Boer A, Beijnen JH, Schellens JHM. BRAF Mutations as Predictive Biomarker for Response to Anti-EGFR Monoclonal Antibodies. Oncologist. 2017;22:864-872. [PMID: 28576857 DOI: 10.1634/theoncologist.2017-0031] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 7.2] [Reference Citation Analysis]
298 Rogers JE. Patient considerations in metastatic colorectal cancer - role of panitumumab. Onco Targets Ther 2017;10:2033-44. [PMID: 28435294 DOI: 10.2147/OTT.S115430] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
299 Maitland ML, Wilkerson J, Karovic S, Zhao B, Flynn J, Zhou M, Hilden P, Ahmed FS, Dercle L, Moskowitz CS, Tang Y, Connors DE, Adam SJ, Kelloff G, Gonen M, Fojo T, Schwartz LH, Oxnard GR. Enhanced Detection of Treatment Effects on Metastatic Colorectal Cancer with Volumetric CT Measurements for Tumor Burden Growth Rate Evaluation. Clin Cancer Res 2020;26:6464-74. [PMID: 32988968 DOI: 10.1158/1078-0432.CCR-20-1493] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
300 Negru S, Papadopoulou E, Apessos A, Stanculeanu DL, Ciuleanu E, Volovat C, Croitoru A, Kakolyris S, Aravantinos G, Ziras N, Athanasiadis E, Touroutoglou N, Pavlidis N, Kalofonos HP, Nasioulas G. KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer: a cohort study. BMJ Open 2014;4:e004652. [PMID: 24859998 DOI: 10.1136/bmjopen-2013-004652] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
301 Isnaldi E, Garuti A, Cirmena G, Scabini S, Rimini E, Ferrando L, Lia M, Murialdo R, Tixi L, Carminati E, Panaro A, Gallo M, Grillo F, Mastracci L, Repetto L, Fiocca R, Romairone E, Zoppoli G, Ballestrero A. Clinico-pathological associations and concomitant mutations of the RAS/RAF pathway in metastatic colorectal cancer. J Transl Med 2019;17:137. [PMID: 31036005 DOI: 10.1186/s12967-019-1879-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
302 Shi Z, Yu X, Yuan M, Lv W, Feng T, Bai R, Zhong H. Activation of the PERK-ATF4 pathway promotes chemo-resistance in colon cancer cells. Sci Rep 2019;9:3210. [PMID: 30824833 DOI: 10.1038/s41598-019-39547-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 5.7] [Reference Citation Analysis]
303 Allard MA, Saffroy R, de la Maisonneuve PB, Ricca L, Bosselut N, Hamelin J, Lecorche E, Bejarano MA, Innominato P, Sebagh M, Adam R, Morère JF, Lemoine A. Colorectal liver metastases are more often super wild type. Toward treatment based on metastatic site genotyping? Target Oncol 2015;10:415-21. [PMID: 25420993 DOI: 10.1007/s11523-014-0346-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
304 Tang D, Kroemer G, Kang R. Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges. Mol Cancer 2021;20:128. [PMID: 34607583 DOI: 10.1186/s12943-021-01422-7] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
305 Ruiz-Bañobre J, Kandimalla R, Goel A. Predictive Biomarkers in Metastatic Colorectal Cancer: A Systematic Review. JCO Precis Oncol 2019;3:PO. [PMID: 32914007 DOI: 10.1200/PO.18.00260] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
306 Cortellini A, Cannita K, Parisi A, Lanfiuti Baldi P, Venditti O, D'Orazio C, Dal Mas A, Calvisi G, Giordano AV, Vicentini V, Vicentini R, Felicioni L, Marchetti A, Buttitta F, Russo A, Ficorella C. Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice. Onco Targets Ther 2019;12:2159-70. [PMID: 30988620 DOI: 10.2147/OTT.S194745] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
307 Chen G, Yang Z, Eshleman JR, Netto GJ, Lin MT. Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future Perspective. Biomed Res Int 2016;2016:9850690. [PMID: 27699178 DOI: 10.1155/2016/9850690] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
308 Kirstein MM, Lange A, Prenzler A, Manns MP, Kubicka S, Vogel A. Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data. Oncologist. 2014;19:1156-1168. [PMID: 25326159 DOI: 10.1634/theoncologist.2014-0032] [Cited by in Crossref: 69] [Cited by in F6Publishing: 65] [Article Influence: 8.6] [Reference Citation Analysis]
309 Sinicrope FA, Okamoto K, Kasi PM, Kawakami H. Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer. Clin Gastroenterol Hepatol. 2016;14:651-658. [PMID: 26872400 DOI: 10.1016/j.cgh.2016.02.008] [Cited by in Crossref: 62] [Cited by in F6Publishing: 68] [Article Influence: 10.3] [Reference Citation Analysis]
310 Richman SD, Fairley J, Butler R, Deans ZC. How close are we to standardised extended RAS gene mutation testing? The UK NEQAS evaluation. J Clin Pathol 2017;70:58-62. [PMID: 27681846 DOI: 10.1136/jclinpath-2016-203822] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
311 Stintzing S, Zhang W, Heinemann V, Neureiter D, Kemmerling R, Kirchner T, Jung A, Folwaczny M, Yang D, Ning Y, Sebio A, Stremitzer S, Sunakawa Y, Matsusaka S, Yamauchi S, Loupakis F, Cremolini C, Falcone A, Lenz HJ. Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer. Mol Cancer Ther 2015;14:2374-81. [PMID: 26206335 DOI: 10.1158/1535-7163.MCT-15-0121] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
312 Stein A, Bokemeyer C. How to select the optimal treatment for first line metastatic colorectal cancer. World J Gastroenterol 2014; 20(4): 899-907 [PMID: 24574764 DOI: 10.3748/wjg.v20.i4.899] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
313 Le Rolle AF, Chiu TK, Zeng Z, Shia J, Weiser MR, Paty PB, Chiu VK. Oncogenic KRAS activates an embryonic stem cell-like program in human colon cancer initiation. Oncotarget 2016;7:2159-74. [PMID: 26744320 DOI: 10.18632/oncotarget.6818] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
314 Lacouture ME, Anadkat M, Jatoi A, Garawin T, Bohac C, Mitchell E. Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review. Clin Colorectal Cancer 2018;17:85-96. [PMID: 29576427 DOI: 10.1016/j.clcc.2017.12.004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 4.6] [Reference Citation Analysis]
315 Torres OJ, Marques MC, Santos FN, Farias IC, Coutinho AK, Oliveira CV, Kalil AN, Mello CA, Kruger JA, Fernandes GD, Quireze C Jr, Murad AM, Silva MJ, Zurstrassen CE, Freitas HC, Cruz MR, Weschenfelder R, Linhares MM, Castro LD, Vollmer C, Dixon E, Ribeiro HS, Coimbra FJ. BRAZILIAN CONSENSUS FOR MULTIMODAL TREATMENT OF COLORECTAL LIVER METASTASES. MODULE 3: CONTROVERSIES AND UNRESECTABLE METASTASES. Arq Bras Cir Dig 2016;29:173-9. [PMID: 27759781 DOI: 10.1590/0102-6720201600030011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
316 Shepshelovich D, Townsend AR, Espin-Garcia O, Latifovic L, O'Callaghan CJ, Jonker DJ, Tu D, Chen E, Morgen E, Price TJ, Shapiro J, Siu LL, Kubo M, Dobrovic A, Ratain MJ, Xu W, Mushiroda T, Liu G. Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer. Cancer Med 2018;7:5478-87. [PMID: 30318772 DOI: 10.1002/cam4.1819] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
317 Galvano A, Taverna S, Badalamenti G, Incorvaia L, Castiglia M, Barraco N, Passiglia F, Fulfaro F, Beretta G, Duro G, Vincenzi B, Tagliaferri P, Bazan V, Russo A. Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis. Ther Adv Med Oncol 2019;11:1758835919874653. [PMID: 31534493 DOI: 10.1177/1758835919874653] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
318 Miyamoto Y, Zhang W, Lenz HJ. Molecular Landscape and Treatment Options for Patients with Metastatic Colorectal Cancer. Indian J Surg Oncol 2017;8:580-90. [PMID: 29203992 DOI: 10.1007/s13193-016-0543-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
319 Van Krieken JH, Rouleau E, Ligtenberg MJ, Normanno N, Patterson SD, Jung A. RAS testing in metastatic colorectal cancer: advances in Europe. Virchows Arch 2016;468:383-96. [PMID: 26573425 DOI: 10.1007/s00428-015-1876-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
320 Kim E, Ilic N, Shrestha Y, Zou L, Kamburov A, Zhu C, Yang X, Lubonja R, Tran N, Nguyen C, Lawrence MS, Piccioni F, Bagul M, Doench JG, Chouinard CR, Wu X, Hogstrom L, Natoli T, Tamayo P, Horn H, Corsello SM, Lage K, Root DE, Subramanian A, Golub TR, Getz G, Boehm JS, Hahn WC. Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles. Cancer Discov 2016;6:714-26. [PMID: 27147599 DOI: 10.1158/2159-8290.CD-16-0160] [Cited by in Crossref: 87] [Cited by in F6Publishing: 49] [Article Influence: 14.5] [Reference Citation Analysis]
321 Wu F, Zhou C, Wu B, Zhang X, Wang K, Wang J, Xiao L, Wang G. Adding Adjuvants to Fluoropyrimidine-based Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: An Option Worthy of Serious Consideration. J Cancer 2021;12:417-27. [PMID: 33391438 DOI: 10.7150/jca.48337] [Reference Citation Analysis]
322 Chen D, Li L, Zhang X, Gao G, Shen L, Hu J, Yang M, Liu B, Qian X. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis. Medicine (Baltimore) 2018;97:e0097. [PMID: 29517682 DOI: 10.1097/MD.0000000000010097] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
323 Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, Ponzetti A, Cremolini C, Amatu A, Lauricella C, Lamba S, Hobor S, Avallone A, Valtorta E, Rospo G, Medico E, Motta V, Antoniotti C, Tatangelo F, Bellosillo B, Veronese S, Budillon A, Montagut C, Racca P, Marsoni S, Falcone A, Corcoran RB, Di Nicolantonio F, Loupakis F, Siena S, Sartore-Bianchi A, Bardelli A. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med. 2015;21:795-801. [PMID: 26030179 DOI: 10.1038/nm.3870] [Cited by in Crossref: 473] [Cited by in F6Publishing: 424] [Article Influence: 67.6] [Reference Citation Analysis]
324 Kiesewetter B, Raderer M, Steger GG, Bartsch R, Pirker R, Zöchbauer-Müller S, Prager G, Krainer M, Preusser M, Schmidinger M, Zielinski CC. The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna. ESMO Open 2016;1:e000066. [PMID: 27843624 DOI: 10.1136/esmoopen-2016-000066] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
325 Capalbo C, Belardinilli F, Raimondo D, Milanetti E, Malapelle U, Pisapia P, Magri V, Prete A, Pecorari S, Colella M, Coppa A, Bonfiglio C, Nicolussi A, Valentini V, Tessitore A, Cardinali B, Petroni M, Infante P, Santoni M, Filetti M, Colicchia V, Paci P, Mezi S, Longo F, Cortesi E, Marchetti P, Troncone G, Bellavia D, Canettieri G, Giannini G. A Simplified Genomic Profiling Approach Predicts Outcome in Metastatic Colorectal Cancer. Cancers (Basel). 2019;11. [PMID: 30691222 DOI: 10.3390/cancers11020147] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
326 Tarpgaard LS, Ørum-Madsen MS, Christensen IJ, Nordgaard C, Noer J, Guren TK, Glimelius B, Sorbye H, Ikdahl T, Kure EH, Tveit KM, Nielsen HJ, Pfeiffer P, Brünner N, Moreira JM. TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: a potential novel approach to the treatment of metastatic colorectal cancer. Oncotarget 2016;7:59441-57. [PMID: 27509063 DOI: 10.18632/oncotarget.11118] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
327 Song N, Liu S, Zhang J, Liu J, Xu L, Liu Y, Qu X. Cetuximab-induced MET activation acts as a novel resistance mechanism in colon cancer cells. Int J Mol Sci 2014;15:5838-51. [PMID: 24714091 DOI: 10.3390/ijms15045838] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
328 Bellio H, Bertaut A, Hervieu A, Zanetta S, Hennequin A, Vincent J, Palmier R, Bengrine-Lefevre L, Ghiringhelli F, Fumet JD. Phase I Dose-Escalation Trial of an Innovative Chemotherapy Regimen Combining a Fractionated Dose of Irinotecan Plus Bevacizumab, Oxaliplatin, 5-Fluorouracil, and Folinic Acid (bFOLFIRINOX-3) in Chemorefractory Metastatic Colorectal Cancer. Cancers (Basel) 2021;13:5472. [PMID: 34771635 DOI: 10.3390/cancers13215472] [Reference Citation Analysis]
329 Lubner SJ, Uboha NV, Deming DA. Primary and acquired resistance to biologic therapies in gastrointestinal cancers. J Gastrointest Oncol 2017;8:499-512. [PMID: 28736637 DOI: 10.21037/jgo.2017.01.16] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
330 Luo HY, Xu RH. Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer. World J Gastroenterol 2014; 20(14): 3858-3874 [PMID: 24744578 DOI: 10.3748/wjg.v20.i14.3858] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
331 Dai JY, Liang CJ, LeBlanc M, Prentice RL, Janes H. Case-only approach to identifying markers predicting treatment effects on the relative risk scale. Biometrics 2018;74:753-63. [PMID: 28960244 DOI: 10.1111/biom.12789] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
332 Zheng G, Tsai H, Tseng LH, Illei P, Gocke CD, Eshleman JR, Netto G, Lin MT. Test Feasibility of Next-Generation Sequencing Assays in Clinical Mutation Detection of Small Biopsy and Fine Needle Aspiration Specimens. Am J Clin Pathol 2016;145:696-702. [PMID: 27247373 DOI: 10.1093/ajcp/aqw043] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
333 Zoratto F, Rossi L, Giordani E, Strudel M, Papa A, Tomao S. From conventional chemotherapy to targeted therapy: use of monoclonal antibodies (moAbs) in gastrointestinal (GI) tumors. Tumour Biol 2014;35:8471-82. [PMID: 25062724 DOI: 10.1007/s13277-014-2367-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
334 Seligmann JF, Hatch AJ, Richman SD, Elliott F, Jacobs B, Brown S, Hurwitz H, Barrett JH, Quirke P, Nixon AB, Seymour MT. Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal Cancer. JAMA Oncol 2018;4:564-8. [PMID: 29075780 DOI: 10.1001/jamaoncol.2017.3168] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
335 El Agy F, El Bardai S, El Otmani I, Benbrahim Z, Karim MH, Mazaz K, Benjelloun EB, Ousadden A, El Abkari M, Ibrahimi SA, Chbani L. Mutation status and prognostic value of KRAS and NRAS mutations in Moroccan colon cancer patients: A first report. PLoS One 2021;16:e0248522. [PMID: 33784337 DOI: 10.1371/journal.pone.0248522] [Reference Citation Analysis]
336 Schmoll HJ, Stein A. Colorectal cancer in 2013: Towards improved drugs, combinations and patient selection. Nat Rev Clin Oncol. 2014;11:79-80. [PMID: 24445520 DOI: 10.1038/nrclinonc.2013.254] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 4.8] [Reference Citation Analysis]
337 Passot G, Soubrane O, Giuliante F, Zimmitti G, Goéré D, Yamashita S, Vauthey JN. Recent Advances in Chemotherapy and Surgery for Colorectal Liver Metastases. Liver Cancer 2016;6:72-9. [PMID: 27995091 DOI: 10.1159/000449349] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
338 Mack E, Stabla K, Riera-Knorrenschild J, Moll R, Neubauer A, Brendel C. A rational two-step approach to KRAS mutation testing in colorectal cancer using high resolution melting analysis and pyrosequencing. BMC Cancer 2016;16:585. [PMID: 27485514 DOI: 10.1186/s12885-016-2589-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
339 Lim SW, Lee S, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kim ST. Pemetrexed Monotherapy as Salvage Treatment in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy: A Phase II Single-arm Prospective Trial. J Cancer 2018;9:2910-5. [PMID: 30123359 DOI: 10.7150/jca.24948] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
340 Cercek A, Boucher TM, Gluskin JS, Aguiló A, Chou JF, Connell LC, Capanu M, Reidy-Lagunes D, D'Angelica M, Kemeny NE. Response rates of hepatic arterial infusion pump therapy in patients with metastatic colorectal cancer liver metastases refractory to all standard chemotherapies. J Surg Oncol 2016;114:655-63. [PMID: 27566258 DOI: 10.1002/jso.24399] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
341 Heinemann V, Singh M, Hardtstock F, Hecker D, Lebioda A, Schaller-kranz T, Bartsch R. Assessment of Metastatic Colorectal Cancer Patients’ Preferences for Biologic Treatments in Germany Using a Discrete Choice Experiment. Clinical Colorectal Cancer 2021. [DOI: 10.1016/j.clcc.2021.12.002] [Reference Citation Analysis]
342 Kocoglu H, Velibeyoglu FM, Karaca M, Tural D. Clinical efficacy and drug resistance of anti-epidermal growth factor receptor therapy in colorectal cancer. World J Gastrointest Oncol 2016; 8(1): 1-7 [PMID: 26798432 DOI: 10.4251/wjgo.v8.i1.1] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
343 Fukuoka S, Kojima T, Koga Y, Yamauchi M, Komatsu M, Komatsuzaki R, Sasaki H, Yasunaga M, Matsumura Y, Doi T, Ohtsu A. Preclinical efficacy of Sym004, novel anti-EGFR antibody mixture, in esophageal squamous cell carcinoma cell lines. Oncotarget 2017;8:11020-9. [PMID: 28038457 DOI: 10.18632/oncotarget.14209] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
344 Samawi HH, Brezden-Masley C, Afzal AR, Cheung WY, Dolley A. Real-world use of trifluridine/tipiracil for patients with metastatic colorectal cancer in Canada. Curr Oncol 2019;26:319-29. [PMID: 31708650 DOI: 10.3747/co.26.5107] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
345 Pathak S, S S, Banerjee A, Marotta F, Gopinath M, Murugesan R, Zhang H, B B, Girigoswami A, Sollano J, Sun XF. Review on comparative efficacy of bevacizumab, panitumumab and cetuximab antibody therapy with combination of FOLFOX-4 in KRAS-mutated colorectal cancer patients. Oncotarget 2018;9:7739-48. [PMID: 29484148 DOI: 10.18632/oncotarget.22471] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
346 Pal R, Wei N, Song N, Wu S, Kim RS, Wang Y, Gavin PG, Lucas PC, Srinivasan A, Allegra CJ, Jacobs SA, Paik S, Schmitz JC, Pogue-Geile KL. Molecular subtypes of colorectal cancer in pre-clinical models show differential response to targeted therapies: Treatment implications beyond KRAS mutations. PLoS One 2018;13:e0200836. [PMID: 30118499 DOI: 10.1371/journal.pone.0200836] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
347 Matsunaga M, Kaneta T, Miwa K, Ichikawa W, Fujita KI, Nagashima F, Furuse J, Kage M, Akagi Y, Sasaki Y. A comparison of four methods for detecting KRAS mutations in formalin-fixed specimens from metastatic colorectal cancer patients. Oncol Lett 2016;12:150-6. [PMID: 27347117 DOI: 10.3892/ol.2016.4576] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
348 Bignucolo A, De Mattia E, Cecchin E, Roncato R, Toffoli G. Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment. Int J Mol Sci 2017;18:E1522. [PMID: 28708103 DOI: 10.3390/ijms18071522] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
349 Russo M, Siravegna G, Blaszkowsky LS, Corti G, Crisafulli G, Ahronian LG, Mussolin B, Kwak EL, Buscarino M, Lazzari L, Valtorta E, Truini M, Jessop NA, Robinson HE, Hong TS, Mino-Kenudson M, Di Nicolantonio F, Thabet A, Sartore-Bianchi A, Siena S, Iafrate AJ, Bardelli A, Corcoran RB. Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer. Cancer Discov. 2016;6:147-153. [PMID: 26644315 DOI: 10.1158/2159-8290.cd-15-1283] [Cited by in Crossref: 233] [Cited by in F6Publishing: 142] [Article Influence: 33.3] [Reference Citation Analysis]
350 Fassan M, Scarpa A, Remo A, De Maglio G, Troncone G, Marchetti A, Doglioni C, Ingravallo G, Perrone G, Parente P, Luchini C, Mastracci L. Current prognostic and predictive biomarkers for gastrointestinal tumors in clinical practice. Pathologica 2020;112:248-59. [PMID: 33179625 DOI: 10.32074/1591-951X-158] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
351 Toffoli EC, Sheikhi A, Lameris R, King LA, van Vliet A, Walcheck B, Verheul HMW, Spanholtz J, Tuynman J, de Gruijl TD, van der Vliet HJ. Enhancement of NK Cell Antitumor Effector Functions Using a Bispecific Single Domain Antibody Targeting CD16 and the Epidermal Growth Factor Receptor. Cancers (Basel) 2021;13:5446. [PMID: 34771609 DOI: 10.3390/cancers13215446] [Reference Citation Analysis]
352 Zick A, Peretz T, Lotem M, Hubert A, Katz D, Temper M, Rottenberg Y, Uziely B, Nechushtan H, Meirovitz A, Sonnenblick A, Sapir E, Edelman D, Goldberg Y, Lossos A, Rosenberg S, Fried I, Finklstein R, Pikarsky E, Goldshmidt H. Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients. Medicine (Baltimore) 2017;96:e6931. [PMID: 28514312 DOI: 10.1097/MD.0000000000006931] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
353 Klupp F, Sass M, Bergmann F, Khajeh E, Ghamarnejad O, Hassenpflug M, Mehrabi A, Kulu Y. Impact of EGFR and EGFR ligand expression on treatment response in patients with metastatic colorectal cancer. Oncol Lett 2021;21:448. [PMID: 33868486 DOI: 10.3892/ol.2021.12709] [Reference Citation Analysis]
354 Cercek A, Gendel V, Jabbour S, Moore D, Chen C, Nosher J, Capanu M, Chou JF, Boucher T, Kemeny N, Carpizo DR. A Comparison of Yttrium-90 Microsphere Radioembolization to Hepatic Arterial Infusional Chemotherapy for Patients with Chemo-refractory Hepatic Colorectal Metastases. Curr Treat Options Oncol 2017;18:42. [PMID: 28608276 DOI: 10.1007/s11864-017-0481-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
355 Lee SF, Choi HCW, Chan SK, Lam KO, Lee VHF, Wong IOL, Chiang CL. Cost-Effectiveness of Anti-Epidermal Growth Factor Receptor Therapy Versus Bevacizumab in KRAS Wild-Type (WT), Pan-RAS WT, and Pan-RAS WT Left-Sided Metastatic Colorectal Cancer. Front Oncol 2021;11:651299. [PMID: 34012917 DOI: 10.3389/fonc.2021.651299] [Reference Citation Analysis]
356 Gasparini G, Buttitta F, D'Andrea MR, Tumolo S, Buonadonna A, Pavese I, Cordio S, De Tursi M, Mosconi S, Stumbo L, Felicioni L, Marchetti A. Optimizing single agent panitumumab therapy in pre-treated advanced colorectal cancer. Neoplasia 2014;16:751-6. [PMID: 25246275 DOI: 10.1016/j.neo.2014.08.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
357 Yao J, Zang W, Ge Y, Weygant N, Yu P, Li L, Rao G, Jiang Z, Yan R, He L, Yu Y, Jin M, Cheng G, An G. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients. Can J Gastroenterol Hepatol 2018;2018:4248971. [PMID: 29707525 DOI: 10.1155/2018/4248971] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
358 Ma CJ, Huang CW, Chang TK, Tsai HL, Su WC, Yeh YS, Chen PJ, Wang JY. Oncologic Outcomes in Metastatic Colorectal Cancer with Regorafenib with FOLFIRI as a Third- or Fourth-Line Setting. Transl Oncol 2019;12:502-12. [PMID: 30594039 DOI: 10.1016/j.tranon.2018.12.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
359 Amram ML, Montet X, Roth AD. Long-Term Survival with Regorafenib in KRAS-Mutated Metastatic Rectal Cancer. Case Rep Oncol 2017;10:1029-34. [PMID: 29279709 DOI: 10.1159/000484401] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
360 Gil Ferreira C, Aran V, Zalcberg-Renault I, Victorino AP, Salem JH, Bonamino MH, Vieira FM, Zalis M. KRAS mutations: variable incidences in a Brazilian cohort of 8,234 metastatic colorectal cancer patients. BMC Gastroenterol 2014;14:73. [PMID: 24720724 DOI: 10.1186/1471-230X-14-73] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
361 Sveen A, Kopetz S, Lothe RA. Biomarker-guided therapy for colorectal cancer: strength in complexity. Nat Rev Clin Oncol 2020;17:11-32. [PMID: 31289352 DOI: 10.1038/s41571-019-0241-1] [Cited by in Crossref: 67] [Cited by in F6Publishing: 68] [Article Influence: 22.3] [Reference Citation Analysis]
362 Udar N, Lofton-Day C, Dong J, Vavrek D, Jung AS, Meier K, Iyer A, Slaughter R, Gutekunst K, Bach BA, Peeters M, Douillard JY. Clinical validation of the next-generation sequencing-based Extended RAS Panel assay using metastatic colorectal cancer patient samples from the phase 3 PRIME study.J Cancer Res Clin Oncol. 2018;144:2001-2010. [PMID: 30019318 DOI: 10.1007/s00432-018-2688-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
363 Jin Z, Hubbard JM. Optimizing biologic sequencing in metastatic colorectal cancer: first line and beyond. Curr Oncol 2019;26:S33-42. [PMID: 31819708 DOI: 10.3747/co.26.5589] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
364 Grothey A, Ellis LM. Therapy: Colorectal cancer: how to teach an old drug new tricks. Nat Rev Gastroenterol Hepatol 2016;13:384-5. [PMID: 27251212 DOI: 10.1038/nrgastro.2016.87] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
365 Rosati G, Corsi D, Avallone A, Brugnatelli S, Dell'Aquila E, Cinausero M, Aprile G, Cicero G, Carlomagno C, Colombo A, Rapisardi S, Pinto C, Reggiardo G, Bilancia D. Reduced-dose of doublet chemotherapy combined with anti-EGFR antibodies in vulnerable older patients with metastatic colorectal cancer: Data from the REVOLT study. J Geriatr Oncol 2021:S1879-4068(21)00239-3. [PMID: 34716122 DOI: 10.1016/j.jgo.2021.10.007] [Reference Citation Analysis]
366 Price TJ, Bruhn MA, Lee CK, Hardingham JE, Townsend AR, Mann KP, Simes J, Weickhardt A, Wrin JW, Wilson K. Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer. Br J Cancer. 2015;112:963-970. [PMID: 25742472 DOI: 10.1038/bjc.2015.37] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
367 Cathomas G. PIK3CA in Colorectal Cancer. Front Oncol. 2014;4:35. [PMID: 24624362 DOI: 10.3389/fonc.2014.00035] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 6.5] [Reference Citation Analysis]
368 Menke-van der Houven van Oordt CW, Gootjes EC, Huisman MC, Vugts DJ, Roth C, Luik AM, Mulder ER, Schuit RC, Boellaard R, Hoekstra OS, van Dongen GA, Verheul HM. 89Zr-cetuximab PET imaging in patients with advanced colorectal cancer. Oncotarget 2015;6:30384-93. [PMID: 26309164 DOI: 10.18632/oncotarget.4672] [Cited by in Crossref: 64] [Cited by in F6Publishing: 64] [Article Influence: 10.7] [Reference Citation Analysis]
369 Nguyen HT, Le DT, Duong QH, Tatipamula VB, Van Nguyen B. High frequency of microsatellite instability and its substantial co-existence with KRAS and BRAF mutations in Vietnamese patients with colorectal cancer. Oncol Lett 2021;21:41. [PMID: 33262833 DOI: 10.3892/ol.2020.12302] [Reference Citation Analysis]
370 Mondaca S, Yaeger R. Genetics of rectal cancer and novel therapies: primer for radiologists. Abdom Radiol (NY) 2019;44:3743-50. [PMID: 31073721 DOI: 10.1007/s00261-019-02051-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
371 Miyamoto Y, Suyama K, Baba H. Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer. Int J Mol Sci 2017;18:E752. [PMID: 28368335 DOI: 10.3390/ijms18040752] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 9.8] [Reference Citation Analysis]
372 Corcoran RB. New therapeutic strategies for BRAF mutant colorectal cancers. J Gastrointest Oncol 2015;6:650-9. [PMID: 26697198 DOI: 10.3978/j.issn.2078-6891.2015.076] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
373 Chatani PD, Yang JC. Mutated RAS: Targeting the "Untargetable" with T Cells. Clin Cancer Res 2020;26:537-44. [PMID: 31511296 DOI: 10.1158/1078-0432.CCR-19-2138] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
374 Le Rolle AF, Klempner SJ, Garrett CR, Seery T, Sanford EM, Balasubramanian S, Ross JS, Stephens PJ, Miller VA, Ali SM, Chiu VK. Identification and characterization of RET fusions in advanced colorectal cancer. Oncotarget 2015;6:28929-37. [PMID: 26078337 DOI: 10.18632/oncotarget.4325] [Cited by in Crossref: 61] [Cited by in F6Publishing: 59] [Article Influence: 10.2] [Reference Citation Analysis]
375 Parisi A, Porzio G, Pulcini F, Cannita K, Ficorella C, Mattei V, Delle Monache S. What Is Known about Theragnostic Strategies in Colorectal Cancer. Biomedicines 2021;9:140. [PMID: 33535557 DOI: 10.3390/biomedicines9020140] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
376 Bakkers C, Simkens GAAM, De Hingh IHJT. Systemic therapy in addition to cytoreduction and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: recent insights from clinical studies and translational research. J Gastrointest Oncol 2021;12:S206-13. [PMID: 33968438 DOI: 10.21037/jgo-20-133] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
377 Wang H, Ma B, Gao P, Song Y, Xu Q, Hu Y, Zhang C, Wang Z. Efficacy and safety of anti-epidermal growth factor receptor therapy compared with anti-vascular endothelial growth factor therapy for metastatic colorectal cancer in first-line and second-line therapies: a meta-analysis. Onco Targets Ther 2016;9:5405-16. [PMID: 27621654 DOI: 10.2147/OTT.S111240] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
378 Lisby AN, Flickinger JC Jr, Bashir B, Weindorfer M, Shelukar S, Crutcher M, Snook AE, Waldman SA. GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer. Expert Rev Precis Med Drug Dev 2021;6:117-29. [PMID: 34027103 DOI: 10.1080/23808993.2021.1876518] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
379 Boeckx N, Peeters M, Van Camp G, Pauwels P, Op de Beeck K, Deschoolmeester V. Prognostic and Predictive Value of RAS Gene Mutations in Colorectal Cancer: Moving Beyond KRAS Exon 2. Drugs 2015;75:1739-56. [PMID: 26347132 DOI: 10.1007/s40265-015-0459-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
380 Schirripa M, Lenz HJ. Biomarker in Colorectal Cancer. Cancer J 2016;22:156-64. [PMID: 27341592 DOI: 10.1097/PPO.0000000000000190] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 4.4] [Reference Citation Analysis]
381 Kruger S, Haas M, Ormanns S, Bächmann S, Siveke JT, Kirchner T, Heinemann V, Boeck S. Translational research in pancreatic ductal adenocarcinoma: Current evidence and future concepts. World J Gastroenterol 2014; 20(31): 10769-10777 [PMID: 25152580 DOI: 10.3748/wjg.v20.i31.10769] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
382 van Geel RM, Beijnen JH, Bernards R, Schellens JH. Treatment Individualization in Colorectal Cancer. Curr Colorectal Cancer Rep 2015;11:335-44. [PMID: 26617477 DOI: 10.1007/s11888-015-0288-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
383 Bleeker FE, Lamba S, Zanon C, Molenaar RJ, Hulsebos TJ, Troost D, van Tilborg AA, Vandertop WP, Leenstra S, van Noorden CJ, Bardelli A. Mutational profiling of kinases in glioblastoma. BMC Cancer 2014;14:718. [PMID: 25256166 DOI: 10.1186/1471-2407-14-718] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 4.6] [Reference Citation Analysis]
384 Battaglin F, Puccini A, Naseem M, Schirripa M, Berger MD, Tokunaga R, McSkane M, Khoukaz T, Soni S, Zhang W, Lenz HJ. Pharmacogenomics in colorectal cancer: current role in clinical practice and future perspectives. J Cancer Metastasis Treat 2018;4:12. [PMID: 34532592 DOI: 10.20517/2394-4722.2018.04] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
385 Saridaki Z, Saegart X, De Vriendt V, Hatzidaki D, Palmans S, De Smedt L, De Hertogh G, Tejpar S. KRAS, NRAS, BRAF mutation comparison of endoscopic and surgically removed primary CRC paired samples: is endoscopy biopsy material adequate for molecular evaluation? Br J Cancer 2015;113:914-20. [PMID: 26325103 DOI: 10.1038/bjc.2015.307] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
386 Cai WQ, Zeng LS, Wang LF, Wang YY, Cheng JT, Zhang Y, Han ZW, Zhou Y, Huang SL, Wang XW, Peng XC, Xiang Y, Ma Z, Cui SZ, Xin HW. The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells. Front Oncol 2020;10:1249. [PMID: 32793499 DOI: 10.3389/fonc.2020.01249] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
387 Schell MJ, Yang M, Teer JK, Lo FY, Madan A, Coppola D, Monteiro AN, Nebozhyn MV, Yue B, Loboda A, Bien-Willner GA, Greenawalt DM, Yeatman TJ. A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC. Nat Commun 2016;7:11743. [PMID: 27302369 DOI: 10.1038/ncomms11743] [Cited by in Crossref: 88] [Cited by in F6Publishing: 82] [Article Influence: 14.7] [Reference Citation Analysis]
388 Liu X, George GC, Tsimberidou AM, Naing A, Wheler JJ, Kopetz S, Fu S, Piha-Paul SA, Eng C, Falchook GS, Janku F, Garrett C, Karp D, Kurzrock R, Zinner R, Raghav K, Subbiah V, Hess K, Meric-Bernstam F, Hong DS, Overman MJ. Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. BMC Cancer 2015;15:713. [PMID: 26474549 DOI: 10.1186/s12885-015-1701-3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 3.9] [Reference Citation Analysis]
389 Jung E, Choi J, Kim JS, Han TS. MicroRNA-Based Therapeutics for Drug-Resistant Colorectal Cancer. Pharmaceuticals (Basel) 2021;14:136. [PMID: 33567635 DOI: 10.3390/ph14020136] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
390 Janowski E, Timofeeva O, Chasovskikh S, Goldberg M, Kim A, Banovac F, Pang D, Dritschilo A, Unger K. Yttrium-90 radioembolization for colorectal cancer liver metastases in KRAS wild-type and mutant patients: Clinical and ccfDNA studies. Oncol Rep 2017;37:57-65. [PMID: 28004119 DOI: 10.3892/or.2016.5284] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
391 Fang L, Lu W, Choi HH, Yeung SC, Tung JY, Hsiao CD, Fuentes-Mattei E, Menter D, Chen C, Wang L, Wang J, Lee MH. ERK2-Dependent Phosphorylation of CSN6 Is Critical in Colorectal Cancer Development. Cancer Cell 2015;28:183-97. [PMID: 26267535 DOI: 10.1016/j.ccell.2015.07.004] [Cited by in Crossref: 36] [Cited by in F6Publishing: 41] [Article Influence: 5.1] [Reference Citation Analysis]
392 Awh CC, Lane AM, Hawken S, Zanke B, Kim IK. Author reply: To PMID 23972322. Ophthalmology 2014;121:e39. [PMID: 24793507 DOI: 10.1016/j.ophtha.2014.02.029] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
393 Ahn DH, Ciombor KK, Mikhail S, Bekaii-Saab T. Genomic diversity of colorectal cancer: Changing landscape and emerging targets. World J Gastroenterol 2016; 22(25): 5668-5677 [PMID: 27433082 DOI: 10.3748/wjg.v22.i25.5668] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
394 Chibaudel B, Tournigand C, Bonnetain F, Richa H, Benetkiewicz M, André T, de Gramont A. Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review. Ther Adv Med Oncol 2015;7:153-69. [PMID: 26673925 DOI: 10.1177/1758834015572343] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
395 Zhang CM, Lv JF, Gong L, Yu LY, Chen XP, Zhou HH, Fan L. Role of Deficient Mismatch Repair in the Personalized Management of Colorectal Cancer. Int J Environ Res Public Health 2016;13:E892. [PMID: 27618077 DOI: 10.3390/ijerph13090892] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]
396 Peeters M, Price T, Taieb J, Geissler M, Rivera F, Canon JL, Pentheroudakis G, Koukakis R, Burdon P, Siena S. Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials. Br J Cancer. 2018;119:303-312. [PMID: 30013091 DOI: 10.1038/s41416-018-0165-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
397 Loree JM, Kopetz S, Raghav KP. Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pie. J Gastrointest Oncol 2017;8:199-212. [PMID: 28280626 DOI: 10.21037/jgo.2017.01.01] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
398 Mondaca S, Yaeger R. Colorectal cancer genomics and designing rational trials. Ann Transl Med 2018;6:159. [PMID: 29911107 DOI: 10.21037/atm.2018.03.27] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
399 Hatch AJ, Sibley AB, Starr MD, Brady JC, Jiang C, Jia J, Bowers DL, Pang H, Owzar K, Niedzwiecki D, Innocenti F, Venook AP, Hurwitz HI, Nixon AB; Alliance for Clinical Trials in Oncology. Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). Cancer Med 2016;5:2249-60. [PMID: 27465221 DOI: 10.1002/cam4.806] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
400 Salvatore L, Aprile G, Arnoldi E, Aschele C, Carnaghi C, Cosimelli M, Maiello E, Normanno N, Sciallero S, Valvo F, Beretta GD. Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM). ESMO Open 2017;2:e000147. [PMID: 28761730 DOI: 10.1136/esmoopen-2016-000147] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
401 Muller C, Yurgelun M, Kupfer SS. Precision Treatment and Prevention of Colorectal Cancer-Hope or Hype? Gastroenterology 2020;158:441-6. [PMID: 31622623 DOI: 10.1053/j.gastro.2019.09.046] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
402 Liang X, Lan C, Jiao G, Fu W, Long X, An Y, Wang K, Zhou J, Chen T, Li Y, Xu J, Huang Q, Xu B, Xiao J. Therapeutic inhibition of SGK1 suppresses colorectal cancer. Exp Mol Med 2017;49:e399. [PMID: 29170478 DOI: 10.1038/emm.2017.184] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
403 Rotella V, Fornaro L, Vasile E, Tibaldi C, Boldrini L, Chella A, D'Incecco A, Cirigliano G, Chioni A, Lupi C, Sensi E, Ginocchi L, Giovannelli S, Pennucci MC, Fontanini G, Baldini E. EGFR and K-Ras mutations in women with lung adenocarcinoma: implications for treatment strategy definition. J Exp Clin Cancer Res 2014;33:77. [PMID: 25300933 DOI: 10.1186/s13046-014-0077-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
404 Padhan N, Nordling TE, Sundström M, Åkerud P, Birgisson H, Nygren P, Nelander S, Claesson-Welsh L. High sensitivity isoelectric focusing to establish a signaling biomarker for the diagnosis of human colorectal cancer. BMC Cancer 2016;16:683. [PMID: 27562229 DOI: 10.1186/s12885-016-2725-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
405 Maron SB, Alpert L, Kwak HA, Lomnicki S, Chase L, Xu D, O'Day E, Nagy RJ, Lanman RB, Cecchi F, Hembrough T, Schrock A, Hart J, Xiao SY, Setia N, Catenacci DVT. Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR-Amplified Gastroesophageal Adenocarcinoma. Cancer Discov 2018;8:696-713. [PMID: 29449271 DOI: 10.1158/2159-8290.CD-17-1260] [Cited by in Crossref: 62] [Cited by in F6Publishing: 37] [Article Influence: 15.5] [Reference Citation Analysis]
406 Geng R, Tan X, Zuo Z, Wu J, Pan Z, Shi W, Liu R, Yao C, Wang G, Lin J, Qiu L, Huang W, Chen S. Synthetic lethal short hairpin RNA screening reveals that ring finger protein 183 confers resistance to trametinib in colorectal cancer cells. Chin J Cancer 2017;36:63. [PMID: 28756770 DOI: 10.1186/s40880-017-0228-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
407 Tembuyser L, Dequeker EM. Endorsing good quality assurance practices in molecular pathology: risks and recommendations for diagnostic laboratories and external quality assessment providers. Virchows Arch 2016;468:31-41. [PMID: 26306715 DOI: 10.1007/s00428-015-1839-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
408 Kim SH, Park KH, Shin SJ, Lee KY, Kim TI, Kim NK, Rha SY, Roh JK, Ahn JB. p16 Hypermethylation and KRAS Mutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients with Metastatic Colorectal Cancer. Cancer Res Treat 2016;48:208-15. [PMID: 25943321 DOI: 10.4143/crt.2014.314] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
409 Mohan S, Heitzer E, Ulz P, Lafer I, Lax S, Auer M, Pichler M, Gerger A, Eisner F, Hoefler G, Bauernhofer T, Geigl JB, Speicher MR. Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing. PLoS Genet 2014;10:e1004271. [PMID: 24676216 DOI: 10.1371/journal.pgen.1004271] [Cited by in Crossref: 129] [Cited by in F6Publishing: 109] [Article Influence: 16.1] [Reference Citation Analysis]
410 Atreya CE, Corcoran RB, Kopetz S. Expanded RAS: refining the patient population. J Clin Oncol 2015;33:682-5. [PMID: 25584005 DOI: 10.1200/JCO.2014.58.9325] [Cited by in Crossref: 46] [Cited by in F6Publishing: 25] [Article Influence: 6.6] [Reference Citation Analysis]
411 Hu H, Liu X, Cai W, Wu D, Xu J, Yuan Y. A Retrospective Exploration of Targeted Maintenance Therapy in Advanced Colorectal Cancer: Based on the Background of Chinese Patient Assistance Program. Front Oncol 2020;10:522. [PMID: 32391263 DOI: 10.3389/fonc.2020.00522] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
412 Snyder A, Kemeny N, Shamseddine A, Al-Olayan A, El-Merhi F, Kelsen DP, Jamali F, Sidani M, Mukherji D, El-Naghy M, O'Reilly EM, Saltz LB, Abou-Alfa GK. Liver-directed conversion therapy in metastatic colon cancer. J Gastrointest Oncol 2015;6:322-8. [PMID: 26029460 DOI: 10.3978/j.issn.2078-6891.2015.006] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
413 O'Brien CP, Finn SP. Application of statistical process control to qualitative molecular diagnostic assays. Front Mol Biosci 2014;1:18. [PMID: 25988159 DOI: 10.3389/fmolb.2014.00018] [Reference Citation Analysis]
414 Hiyoshi Y, Miyamoto Y, Kiyozumi Y, Eto K, Nagai Y, Iwatsuki M, Iwagami S, Baba Y, Yoshida N, Baba H. Risk factors and prognostic significance of lateral pelvic lymph node metastasis in advanced rectal cancer. Int J Clin Oncol 2020;25:110-7. [PMID: 31407167 DOI: 10.1007/s10147-019-01523-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
415 Gallagher RI, Espina V. Reverse phase protein arrays: mapping the path towards personalized medicine. Mol Diagn Ther 2014;18:619-30. [PMID: 25358623 DOI: 10.1007/s40291-014-0122-3] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
416 Katona BW, Liu Y, Ma A, Jin J, Hua X. EZH2 inhibition enhances the efficacy of an EGFR inhibitor in suppressing colon cancer cells. Cancer Biol Ther 2014;15:1677-87. [PMID: 25535899 DOI: 10.4161/15384047.2014.972776] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 4.4] [Reference Citation Analysis]
417 Guarini C, Grassi T, Pezzicoli G, Porta C. Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer. Int J Mol Sci 2021;22:6813. [PMID: 34202896 DOI: 10.3390/ijms22136813] [Reference Citation Analysis]
418 Tack V, Schuuring E, Keppens C, Hart N', Pauwels P, van Krieken H, Dequeker EMC. Accreditation, setting and experience as indicators to assure quality in oncology biomarker testing laboratories. Br J Cancer 2018;119:605-14. [PMID: 30140047 DOI: 10.1038/s41416-018-0204-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
419 Suetsugu T, Matsuhashi N, Takahashi T, Tanahashi T, Matsui S, Imai H, Tanaka Y, Yamaguchi K, Yoshida K. Pathological complete response to mFOLFOX6 plus cetuximab therapy for unresectable colon cancer with multiple paraaortic lymph node metastases. Mol Clin Oncol 2018;9:587-91. [PMID: 30546885 DOI: 10.3892/mco.2018.1742] [Reference Citation Analysis]
420 Schandelmaier S, Schmitt AM, Herbrand AK, Glinz D, Ewald H, Briel M, Guyatt GH, Hemkens LG, Kasenda B. Characteristics and interpretation of subgroup analyses based on tumour characteristics in randomised trials testing target-specific anticancer drugs: design of a systematic survey. BMJ Open 2020;10:e034565. [PMID: 32474426 DOI: 10.1136/bmjopen-2019-034565] [Reference Citation Analysis]
421 Wood G, Grenader T, Nash S, Adams R, Kaplan R, Fisher D, Maughan T, Bridgewater J. Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status: a post-hoc analysis of the MRC COIN study. Anticancer Drugs 2017;28:546-50. [PMID: 28252533 DOI: 10.1097/CAD.0000000000000488] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
422 Previs RA, Sood AK, Mills GB, Westin SN. The rise of genomic profiling in ovarian cancer. Expert Rev Mol Diagn 2016;16:1337-51. [PMID: 27828713 DOI: 10.1080/14737159.2016.1259069] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
423 Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, Lee CC, Fecher LA, Gallia GL, Gibbs P, Le D, Giuntoli RL, Goggins M, Hogarty MD, Holdhoff M, Hong SM, Jiao Y, Juhl HH, Kim JJ, Siravegna G, Laheru DA, Lauricella C, Lim M, Lipson EJ, Marie SK, Netto GJ, Oliner KS, Olivi A, Olsson L, Riggins GJ, Sartore-Bianchi A, Schmidt K, Shih lM, Oba-Shinjo SM, Siena S, Theodorescu D, Tie J, Harkins TT, Veronese S, Wang TL, Weingart JD, Wolfgang CL, Wood LD, Xing D, Hruban RH, Wu J, Allen PJ, Schmidt CM, Choti MA, Velculescu VE, Kinzler KW, Vogelstein B, Papadopoulos N, Diaz LA Jr. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6:224ra24. [PMID: 24553385 DOI: 10.1126/scitranslmed.3007094] [Cited by in Crossref: 2295] [Cited by in F6Publishing: 2162] [Article Influence: 286.9] [Reference Citation Analysis]
424 Corrias G, Micheletti G, Barberini L, Suri JS, Saba L. Texture analysis imaging "what a clinical radiologist needs to know". Eur J Radiol 2022;146:110055. [PMID: 34902669 DOI: 10.1016/j.ejrad.2021.110055] [Reference Citation Analysis]
425 Janes H, Pepe MS, McShane LM, Sargent DJ, Heagerty PJ. The Fundamental Difficulty With Evaluating the Accuracy of Biomarkers for Guiding Treatment. J Natl Cancer Inst 2015;107:djv157. [PMID: 26109106 DOI: 10.1093/jnci/djv157] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
426 Ottaiano A, De Stefano A, Capozzi M, Nappi A, De Divitiis C, Romano C, Silvestro L, Cassata A, Casaretti R, Tafuto S, Caraglia M, Berretta M, Nasti G, Avallone A. First Biologic Drug in the Treatment of RAS Wild-Type Metastatic Colorectal Cancer: Anti-EGFR or Bevacizumab? Results From a Meta-Analysis. Front Pharmacol 2018;9:441. [PMID: 29773991 DOI: 10.3389/fphar.2018.00441] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
427 Martin JH, Phillips E, Thomas D, Somogyi AA. Adding the 'medicines' back into personalized medicine to improve cancer treatment outcomes. Br J Clin Pharmacol 2015;80:929-31. [PMID: 26507561 DOI: 10.1111/bcp.12690] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
428 Takahashi N, Iwasa S, Taniguchi H, Sasaki Y, Shoji H, Honma Y, Takashima A, Okita N, Kato K, Hamaguchi T, Shimada Y, Yamada Y. Prognostic role of ERBB2, MET and VEGFA expression in metastatic colorectal cancer patients treated with anti-EGFR antibodies. Br J Cancer 2016;114:1003-11. [PMID: 27002940 DOI: 10.1038/bjc.2016.74] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
429 Siena S, Sartore-Bianchi A, Garcia-Carbonero R, Karthaus M, Smith D, Tabernero J, Van Cutsem E, Guan X, Boedigheimer M, Ang A, Twomey B, Bach BA, Jung AS, Bardelli A. Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer. Ann Oncol 2018;29:119-26. [PMID: 28945848 DOI: 10.1093/annonc/mdx504] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 13.7] [Reference Citation Analysis]
430 Pfeiffer P, Gruenberger T, Glynne-Jones R. Synchronous liver metastases in patients with rectal cancer: can we establish which treatment first? Ther Adv Med Oncol 2018;10:1758835918787993. [PMID: 30093921 DOI: 10.1177/1758835918787993] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
431 Ciombor KK, Goldberg RM. Current evidence and controversies in the incorporation of biologics for metastatic colorectal cancer. Hepat Oncol 2014;1:331-45. [PMID: 30190967 DOI: 10.2217/hep.14.13] [Reference Citation Analysis]
432 Kuipers EJ, Grady WM, Lieberman D, Seufferlein T, Sung JJ, Boelens PG, van de Velde CJ, Watanabe T. Colorectal cancer. Nat Rev Dis Primers. 2015;1:15065. [PMID: 27189416 DOI: 10.1038/nrdp.2015.65] [Cited by in Crossref: 485] [Cited by in F6Publishing: 484] [Article Influence: 69.3] [Reference Citation Analysis]
433 Clifford R, Govindarajah N, Parsons JL, Gollins S, West NP, Vimalachandran D. Systematic review of treatment intensification using novel agents for chemoradiotherapy in rectal cancer. Br J Surg 2018;105:1553-72. [PMID: 30311641 DOI: 10.1002/bjs.10993] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
434 Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer. 2017;17:79-92. [PMID: 28050011 DOI: 10.1038/nrc.2016.126] [Cited by in Crossref: 338] [Cited by in F6Publishing: 307] [Article Influence: 67.6] [Reference Citation Analysis]
435 Sorolla A, Wang E, Golden E, Duffy C, Henriques ST, Redfern AD, Blancafort P. Precision medicine by designer interference peptides: applications in oncology and molecular therapeutics. Oncogene 2020;39:1167-84. [PMID: 31636382 DOI: 10.1038/s41388-019-1056-3] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 8.7] [Reference Citation Analysis]
436 Bellio H, Fumet JD, Ghiringhelli F. Targeting BRAF and RAS in Colorectal Cancer. Cancers (Basel) 2021;13:2201. [PMID: 34063682 DOI: 10.3390/cancers13092201] [Reference Citation Analysis]
437 Harlé A, Filhine-Tresarrieu P, Husson M, Boidot R, Rouyer M, Dubois C, Leroux A, Merlin JL. Rare RAS Mutations in Metastatic Colorectal Cancer Detected During Routine RAS Genotyping Using Next Generation Sequencing. Target Oncol 2016;11:363-70. [PMID: 26661077 DOI: 10.1007/s11523-015-0404-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
438 Jeong WJ, Cha PH, Choi KY. Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer. World J Gastroenterol 2014; 20(29): 9862-9871 [PMID: 25110417 DOI: 10.3748/wjg.v20.i29.9862] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
439 Kim ST, Lee SJ, Lee J, Park SH, Park JO, Lim HY, Kang WK, Park YS. The Impact of Microsatellite Instability Status and Sidedness of the Primary Tumor on the Effect of Cetuximab-Containing Chemotherapy in Patients with Metastatic Colorectal Cancer. J Cancer 2017;8:2809-15. [PMID: 28928870 DOI: 10.7150/jca.18286] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
440 Mizukami T, Izawa N, Nakajima TE, Sunakawa Y. Targeting EGFR and RAS/RAF Signaling in the Treatment of Metastatic Colorectal Cancer: From Current Treatment Strategies to Future Perspectives. Drugs 2019;79:633-45. [PMID: 30968289 DOI: 10.1007/s40265-019-01113-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
441 Lipsyc M, Yaeger R. Impact of somatic mutations on patterns of metastasis in colorectal cancer. J Gastrointest Oncol 2015;6:645-9. [PMID: 26697197 DOI: 10.3978/j.issn.2078-6891.2015.045] [Cited by in F6Publishing: 21] [Reference Citation Analysis]
442 Chan DL, Pavlakis N, Shapiro J, Price TJ, Karapetis CS, Tebbutt NC, Segelov E. Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature. PLoS One. 2015;10:e0135599. [PMID: 26275292 DOI: 10.1371/journal.pone.0135599] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
443 Kim JY, Jung HH, Do IG, Bae S, Lee SK, Kim SW, Lee JE, Nam SJ, Ahn JS, Park YH, Im YH. Prognostic value of ERBB4 expression in patients with triple negative breast cancer. BMC Cancer 2016;16:138. [PMID: 26907936 DOI: 10.1186/s12885-016-2195-3] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
444 Papadopoulou E, Metaxa-Mariatou V, Tsaousis G, Tsoulos N, Tsirigoti A, Efstathiadou C, Apessos A, Agiannitopoulos K, Pepe G, Bourkoula E, Nasioulas G. Molecular predictive markers in tumors of the gastrointestinal tract. World J Gastrointest Oncol 2016; 8(11): 772-785 [PMID: 27895815 DOI: 10.4251/wjgo.v8.i11.772] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
445 Zhao B, Wang L, Qiu H, Zhang M, Sun L, Peng P, Yu Q, Yuan X. Mechanisms of resistance to anti-EGFR therapy in colorectal cancer. Oncotarget 2017;8:3980-4000. [PMID: 28002810 DOI: 10.18632/oncotarget.14012] [Cited by in Crossref: 121] [Cited by in F6Publishing: 115] [Article Influence: 30.3] [Reference Citation Analysis]
446 Gagan J, Van Allen EM. Next-generation sequencing to guide cancer therapy. Genome Med 2015;7:80. [PMID: 26221189 DOI: 10.1186/s13073-015-0203-x] [Cited by in Crossref: 162] [Cited by in F6Publishing: 146] [Article Influence: 23.1] [Reference Citation Analysis]
447 Zhang R, Wang Z, Yu Q, Shen J, He W, Zhou D, Yu Q, Fan J, Gao S, Duan L. Atractylenolide II reverses the influence of lncRNA XIST/miR-30a-5p/ROR1 axis on chemo-resistance of colorectal cancer cells. J Cell Mol Med 2019;23:3151-65. [PMID: 30907503 DOI: 10.1111/jcmm.14148] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
448 Han van Krieken J, Kafatos G, Bennett J, Mineur L, Tomášek J, Rouleau E, Fabian P, De Maglio G, García-Alfonso P, Aprile G, Parkar P, Downey G, Demonty G, Trojan J. Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review. BMC Cancer 2017;17:798. [PMID: 29183279 DOI: 10.1186/s12885-017-3740-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
449 Djanani A, Eller S, Öfner D, Troppmair J, Maglione M. The Role of BRAF in Metastatic Colorectal Carcinoma-Past, Present, and Future. Int J Mol Sci 2020;21:E9001. [PMID: 33256240 DOI: 10.3390/ijms21239001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
450 Macaulay R, Ahuja A, Ademisoye E, Juarez-Garcia A, Shaw JW. Relative value assessment: characterizing the benefit of oncology therapies through diverse survival metrics from a US perspective. Clinicoecon Outcomes Res 2019;11:199-219. [PMID: 30936729 DOI: 10.2147/CEOR.S177343] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
451 Luzum JA, Cheung JC. Does cardiology hold pharmacogenetics to an inconsistent standard? A comparison of evidence among recommendations. Pharmacogenomics 2018;19:1203-16. [PMID: 30196751 DOI: 10.2217/pgs-2018-0097] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
452 Sengupta S, Sun SQ, Huang KL, Oh C, Bailey MH, Varghese R, Wyczalkowski MA, Ning J, Tripathi P, McMichael JF, Johnson KJ, Kandoth C, Welch J, Ma C, Wendl MC, Payne SH, Fenyö D, Townsend RR, Dipersio JF, Chen F, Ding L. Integrative omics analyses broaden treatment targets in human cancer. Genome Med 2018;10:60. [PMID: 30053901 DOI: 10.1186/s13073-018-0564-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
453 Franczak C, Kandathil SM, Gilson P, Husson M, Rouyer M, Demange J, Leroux A, Merlin JL, Harlé A. Uncommon mutational profiles of metastatic colorectal cancer detected during routine genotyping using next generation sequencing. Sci Rep 2019;9:7083. [PMID: 31068650 DOI: 10.1038/s41598-019-43646-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
454 Wang YX, Chen YR, Liu SS, Ye YP, Jiao HL, Wang SY, Xiao ZY, Wei WT, Qiu JF, Liang L, Liao WT, Ding YQ. MiR-384 inhibits human colorectal cancer metastasis by targeting KRAS and CDC42. Oncotarget 2016;7:84826-38. [PMID: 27769041 DOI: 10.18632/oncotarget.12704] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 7.8] [Reference Citation Analysis]
455 Sakitani K, Hirata Y, Hikiba Y, Hayakawa Y, Ihara S, Suzuki H, Suzuki N, Serizawa T, Kinoshita H, Sakamoto K, Nakagawa H, Tateishi K, Maeda S, Ikenoue T, Kawazu S, Koike K. Inhibition of autophagy exerts anti-colon cancer effects via apoptosis induced by p53 activation and ER stress. BMC Cancer 2015;15:795. [PMID: 26496833 DOI: 10.1186/s12885-015-1789-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
456 Noel MS. Biologics in bowel cancer. J Gastrointest Oncol 2017;8:449-56. [PMID: 28736632 DOI: 10.21037/jgo.2017.05.03] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
457 Tashiro T, Okuyama H, Endo H, Kawada K, Ashida Y, Ohue M, Sakai Y, Inoue M. In vivo and ex vivo cetuximab sensitivity assay using three-dimensional primary culture system to stratify KRAS mutant colorectal cancer. PLoS One 2017;12:e0174151. [PMID: 28301591 DOI: 10.1371/journal.pone.0174151] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
458 Xie W, Xie L, Song X. The diagnostic accuracy of circulating free DNA for the detection of KRAS mutation status in colorectal cancer: A meta-analysis. Cancer Med 2019;8:1218-31. [PMID: 30791218 DOI: 10.1002/cam4.1989] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
459 Tang NP, Li H, Qiu YL, Zhou GM, Wang Y, Ma J, Chang Y, Mei QB. Risk/benefit profile of panitumumab-based therapy in patients with metastatic colorectal cancer: evidence from five randomized controlled trials. Tumour Biol 2014;35:10409-18. [PMID: 25053599 DOI: 10.1007/s13277-014-2354-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
460 Oyanagi H, Shimada Y, Nagahashi M, Ichikawa H, Tajima Y, Abe K, Nakano M, Kameyama H, Takii Y, Kawasaki T, Homma KI, Ling Y, Okuda S, Takabe K, Wakai T. SMAD4 alteration associates with invasive-front pathological markers and poor prognosis in colorectal cancer. Histopathology 2019;74:873-82. [PMID: 30636020 DOI: 10.1111/his.13805] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
461 Johnson B, Kopetz S. Applying Precision to the Management of BRAF-Mutant Metastatic Colorectal Cancer.Target Oncol. 2020;15:567-577. [PMID: 32889679 DOI: 10.1007/s11523-020-00747-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
462 Kjersem JB, Skovlund E, Ikdahl T, Guren T, Kersten C, Dalsgaard AM, Yilmaz MK, Fokstuen T, Tveit KM, Kure EH. FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab. BMC Cancer. 2014;14:340. [PMID: 24884501 DOI: 10.1186/1471-2407-14-340] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
463 Gaborit N, Lindzen M, Yarden Y. Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3. Hum Vaccin Immunother 2016;12:576-92. [PMID: 26529100 DOI: 10.1080/21645515.2015.1102809] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
464 Alonso V, Escudero P, Fernández-Martos C, Salud A, Méndez M, Gallego J, Rodriguez JR, Martín-Richard M, Fernández-Plana J, Manzano H, Méndez JC, Zanui M, Falcó E, Gil-Raga M, Rojo F, Cuatrecasas M, Feliu J, García-Albéniz X, Maurel J. Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients. Neoplasia 2018;20:678-86. [PMID: 29842993 DOI: 10.1016/j.neo.2018.05.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
465 Bruera G, Pepe F, Malapelle U, Pisapia P, Mas AD, Di Giacomo D, Calvisi G, Troncone G, Ricevuto E. KRAS, NRAS and BRAF mutations detected by next generation sequencing, and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy. Oncotarget 2018;9:26279-90. [PMID: 29899858 DOI: 10.18632/oncotarget.25180] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
466 Schirripa M, Cohen SA, Battaglin F, Lenz HJ. Biomarker-driven and molecular targeted therapies for colorectal cancers. Semin Oncol 2018;45:124-32. [PMID: 30262397 DOI: 10.1053/j.seminoncol.2017.06.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
467 Xu RH, Shen L, Wang KM, Wu G, Shi CM, Ding KF, Lin LZ, Wang JW, Xiong JP, Wu CP, Li J, Liu YP, Wang D, Ba Y, Feng JP, Bai YX, Bi JW, Ma LW, Lei J, Yang Q, Yu H. Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial. Chin J Cancer 2017;36:97. [PMID: 29273089 DOI: 10.1186/s40880-017-0263-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
468 Garofano F, Gonzalez-Carmona MA, Skowasch D, Schmidt-Wolf R, Abramian A, Hauser S, Strassburg CP, Schmidt-Wolf IGH. Clinical Trials with Combination of Cytokine-Induced Killer Cells and Dendritic Cells for Cancer Therapy. Int J Mol Sci 2019;20:E4307. [PMID: 31484350 DOI: 10.3390/ijms20174307] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
469 López-Gómez M, Moreno-Rubio J, Suárez-García I, Cejas P, Madero R, Casado E, Jiménez AM, Sereno M, Gómez-Raposo C, Zambrana F, Merino M, Fernández-Luengas D, Feliu J. Gene expression differences in primary colorectal tumors and matched liver metastases: chemotherapy related or tumoral heterogeneity? Clin Transl Oncol 2015;17:322-9. [PMID: 25301403 DOI: 10.1007/s12094-014-1233-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
470 Qin S, Li J, Wang L, Xu J, Cheng Y, Bai Y, Li W, Xu N, Lin LZ, Wu Q, Li Y, Yang J, Pan H, Ouyang X, Qiu W, Wu K, Xiong J, Dai G, Liang H, Hu C, Zhang J, Tao M, Yao Q, Wang J, Chen J, Eggleton SP, Liu T. Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial. J Clin Oncol 2018;36:3031-9. [PMID: 30199311 DOI: 10.1200/JCO.2018.78.3183] [Cited by in Crossref: 64] [Cited by in F6Publishing: 32] [Article Influence: 16.0] [Reference Citation Analysis]
471 Lheureux S, Denoyelle C, Ohashi PS, De Bono JS, Mottaghy FM. Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician. Eur J Nucl Med Mol Imaging 2017;44:41-54. [PMID: 28396911 DOI: 10.1007/s00259-017-3695-3] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
472 Johnson B, Loree JM, Jacome AA, Mendis S, Syed M, Morris Ii VK, Parseghian CM, Dasari A, Pant S, Raymond VM, Vilar E, Overman M, Kee B, Eng C, Raghav K, Kopetz S. Atypical, Non-V600 BRAF Mutations as a Potential Mechanism of Resistance to EGFR Inhibition in Metastatic Colorectal Cancer. JCO Precis Oncol 2019;3:PO. [PMID: 32914034 DOI: 10.1200/PO.19.00102] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
473 Metges JP, Lebot MA, Faroux R, Riaud F, Gamelin E, Capitain O, Guérin Meyer V, Leynia P, Douillard JY, Senellart H, Rochard S, Louvigné C, Campion L, Dupuis O, Grollier C, Achour NA, Person B, Raoul JL, Boucher E, Bertrand C, Ramée JF, Guivarch L, Etienne PL, Roussel S, Desclos H, Julien MN, Labarre MI, Klein V, Bessard R, Stampfli C, Royet F, Faycal J, Gouva S, Le Bihan G, Couturier M, Gourlaouen A, Bertholom C, Porneuf M, Jobard E, Peguet E, Grasset D, Bouret JF, Bicheler V, Ulvoas A, Miglianico L, Chouzenoux C, Deguiral P, Derenne L, Martin D, Langlet PM, Bodin C, Rossi V, Barré S, Cojocarasu O, Naveau Ploux C, Vidal AM, Cumin I, Egreteau J, Brouard A, Matysiak Budnik T, Thomaré P, Le Bris Michel AS, Piriou G, Largeau R, Elhannani C, Crespeau E, Suberville F, Bourgeois H, Riche C, Lagadec DD, Marhuenda F, Grudé F. Evaluation in usual practice of the bevacizumab-FOLFIRI combination for the first-line treatment of patients with unresectable metastatic colorectal cancer treated in 2006: focus on resected patients and oncogeriatrics: AVASTIN OUEST cohort of the Observatory of Cancer of the Brittany and Pays de la Loire Areas (Observatoire dédié au Cancer Bretagne / Pays de la Loire). Oncologie (Paris) 2014;16:267-76. [PMID: 26190928 DOI: 10.1007/s10269-014-2391-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
474 Matikas A, Voutsina A, Trypaki M, Georgoulias V. Role of circulating free DNA in colorectal cancer. World J Gastrointest Oncol 2016; 8(12): 810-818 [PMID: 28035251 DOI: 10.4251/wjgo.v8.i12.810] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
475 Yu B, O'Toole SA, Trent RJ. Somatic DNA mutation analysis in targeted therapy of solid tumours. Transl Pediatr 2015;4:125-38. [PMID: 26835368 DOI: 10.3978/j.issn.2224-4336.2015.04.04] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
476 Stiegelbauer V, Perakis S, Deutsch A, Ling H, Gerger A, Pichler M. MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer. World J Gastroenterol 2014; 20(33): 11727-11735 [PMID: 25206276 DOI: 10.3748/wjg.v20.i33.11727] [Cited by in CrossRef: 53] [Cited by in F6Publishing: 53] [Article Influence: 6.6] [Reference Citation Analysis]
477 Ketzer S, Schimmel K, Koopman M, Guchelaar HJ. Clinical Pharmacokinetics and Pharmacodynamics of the Epidermal Growth Factor Receptor Inhibitor Panitumumab in the Treatment of Colorectal Cancer. Clin Pharmacokinet 2018;57:455-73. [PMID: 28853050 DOI: 10.1007/s40262-017-0590-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
478 Stein A, Atanackovic D, Hildebrandt B, Stübs P, Brugger W, Hapke G, Steffens CC, Illerhaus G, Bluemner E, Stöhlmacher J, Bokemeyer C. Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer. Br J Cancer 2015;113:872-7. [PMID: 26335608 DOI: 10.1038/bjc.2015.299] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
479 El Bali M, Bakkach J, Bennani Mechita M. Colorectal Cancer: From Genetic Landscape to Targeted Therapy. J Oncol 2021;2021:9918116. [PMID: 34326875 DOI: 10.1155/2021/9918116] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
480 De Divitiis C, Nasti G, Montano M, Fisichella R, Iaffaioli RV, Berretta M. Prognostic and predictive response factors in colorectal cancer patients: Between hope and reality. World J Gastroenterol 2014; 20(41): 15049-15059 [PMID: 25386053 DOI: 10.3748/wjg.v20.i41.15049] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 40] [Article Influence: 5.3] [Reference Citation Analysis]
481 Boussios S, Ozturk MA, Moschetta M, Karathanasi A, Zakynthinakis-Kyriakou N, Katsanos KH, Christodoulou DK, Pavlidis N. The Developing Story of Predictive Biomarkers in Colorectal Cancer. J Pers Med 2019;9:E12. [PMID: 30736475 DOI: 10.3390/jpm9010012] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 15.3] [Reference Citation Analysis]
482 Boleij A, Tack V, Taylor A, Kafatos G, Jenkins-Anderson S, Tembuyser L, Dequeker E, van Krieken JH. RAS testing practices and RAS mutation prevalence among patients with metastatic colorectal cancer: results from a Europe-wide survey of pathology centres. BMC Cancer. 2016;16:825. [PMID: 27784278 DOI: 10.1186/s12885-016-2810-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
483 Hohla F, Winder T, Greil R, Rick FG, Block NL, Schally AV. Targeted therapy in advanced metastatic colorectal cancer: Current concepts and perspectives. World J Gastroenterol 2014; 20(20): 6102-6112 [PMID: 24876732 DOI: 10.3748/wjg.v20.i20.6102] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 34] [Article Influence: 4.4] [Reference Citation Analysis]
484 Fanelli GN, Dal Pozzo CA, Depetris I, Schirripa M, Brignola S, Biason P, Balistreri M, Dal Santo L, Lonardi S, Munari G, Loupakis F, Fassan M. The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer. Cancer Cell Int. 2020;20:30. [PMID: 32015690 DOI: 10.1186/s12935-020-1117-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
485 Randle RW, Doud AN, Levine EA, Clark CJ, Swett KR, Shen P, Stewart JH, Votanopoulos KI. Peritoneal surface disease with synchronous hepatic involvement treated with Cytoreductive Surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2015;22:1634-1638. [PMID: 25120252 DOI: 10.1245/s10434-014-3987-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
486 Jesinghaus M. [Morphomolecular characterization of colorectal neoplasms]. Pathologe 2019;40:265-70. [PMID: 31705232 DOI: 10.1007/s00292-019-00694-7] [Reference Citation Analysis]
487 de Gramont A, Watson S, Ellis LM, Rodón J, Tabernero J, de Gramont A, Hamilton SR. Pragmatic issues in biomarker evaluation for targeted therapies in cancer. Nat Rev Clin Oncol 2015;12:197-212. [PMID: 25421275 DOI: 10.1038/nrclinonc.2014.202] [Cited by in Crossref: 126] [Cited by in F6Publishing: 98] [Article Influence: 15.8] [Reference Citation Analysis]
488 Oliveres H, Pesántez D, Maurel J. Lessons to Learn for Adequate Targeted Therapy Development in Metastatic Colorectal Cancer Patients. Int J Mol Sci 2021;22:5019. [PMID: 34065119 DOI: 10.3390/ijms22095019] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
489 Giampieri R, Mandolesi A, Abouelkhair KM, Loretelli C, Del Prete M, Faloppi L, Maristella B, Ibrahim EM, Scarpelli M, Cascinu S, Scartozzi M. Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab. J Transl Med 2015;13:140. [PMID: 25943333 DOI: 10.1186/s12967-015-0501-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
490 Sunakawa Y, Mogushi K, Lenz HJ, Zhang W, Tsuji A, Takahashi T, Denda T, Shimada K, Kochi M, Nakamura M, Kotaka M, Segawa Y, Tanioka H, Negoro Y, Moran M, Astrow SH, Hsiang J, Stephens C, Fujii M, Ichikawa W. Tumor Sidedness and Enriched Gene Groups for Efficacy of First-line Cetuximab Treatment in Metastatic Colorectal Cancer. Mol Cancer Ther 2018;17:2788-95. [PMID: 30275242 DOI: 10.1158/1535-7163.MCT-18-0694] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
491 Yin J, Dawood S, Cohen R, Meyers J, Zalcberg J, Yoshino T, Seymour M, Maughan T, Saltz L, Van Cutsem E, Venook A, Schmoll HJ, Goldberg R, Hoff P, Hecht JR, Hurwitz H, Punt C, Diaz Rubio E, Koopman M, Cremolini C, Heinemann V, Tournigard C, Bokemeyer C, Fuchs C, Tebbutt N, Souglakos J, Doulliard JY, Kabbinavar F, Chibaudel B, de Gramont A, Shi Q, Grothey A, Adams R. Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis. Ther Adv Med Oncol 2021;13:17588359211020547. [PMID: 34262614 DOI: 10.1177/17588359211020547] [Reference Citation Analysis]
492 Ramon L, David C, Fontaine K, Lallet E, Marcaillou C, Martin-Lannerée S, Decaulne V, Vazart C, Gélibert AH, Abdelali RB, Costa JM, Rousseau F, Thiébaut R, Yost L, Gaston-Mathé Y. Technical Validation of a Reverse-Transcription Quantitative Polymerase Chain Reaction In Vitro Diagnostic Test for the Determination of MiR-31-3p Expression Levels in Formalin-Fixed Paraffin-Embedded Metastatic Colorectal Cancer Tumor Specimens. Biomark Insights 2018;13:1177271918763357. [PMID: 29568219 DOI: 10.1177/1177271918763357] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
493 Fiala O, Sorejs O, Hosek P, Liska V, Vycital O, Bruha J, Kucera R, Topolcan O, Finek J, Maceckova D, Pitule P. Association of miR-125b, miR-17 and let-7c Dysregulations With Response to Anti-epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With Metastatic Colorectal Cancer. Cancer Genomics Proteomics 2020;17:605-13. [PMID: 32859639 DOI: 10.21873/cgp.20217] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
494 Tsunedomi R, Hazama S, Okayama N, Oka M, Nagano H. Rapid and sensitive detection of UGT1A1 polymorphisms associated with irinotecan toxicity by a novel DNA microarray. Cancer Sci 2017;108:1504-9. [PMID: 28474802 DOI: 10.1111/cas.13272] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
495 Ottaiano A, Capozzi M, Tafuto S, De Stefano A, De Divitiis C, Romano C, Avallone A, Nasti G. Folfiri-Aflibercept vs. Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice. Front Oncol 2019;9:766. [PMID: 31456948 DOI: 10.3389/fonc.2019.00766] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
496 Pang SW, Awi NJ, Armon S, Lim WW, Low JS, Peh KB, Peh SC, Teow SY. Current Update of Laboratory Molecular Diagnostics Advancement in Management of Colorectal Cancer (CRC). Diagnostics (Basel) 2019;10:E9. [PMID: 31877940 DOI: 10.3390/diagnostics10010009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
497 Huiskens J, van Gulik TM, van Lienden KP, Engelbrecht MR, Meijer GA, van Grieken NC, Schriek J, Keijser A, Mol L, Molenaar IQ, Verhoef C, de Jong KP, Dejong KH, Kazemier G, Ruers TM, de Wilt JH, van Tinteren H, Punt CJ. Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases, a study protocol of the randomised phase 3 CAIRO5 study of the Dutch Colorectal Cancer Group (DCCG). BMC Cancer 2015;15:365. [PMID: 25943574 DOI: 10.1186/s12885-015-1323-9] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 5.4] [Reference Citation Analysis]
498 Thomsen M, Skovlund E, Sorbye H, Bolstad N, Nustad KJ, Glimelius B, Pfeiffer P, Kure EH, Johansen JS, Tveit KM, Christoffersen T, Guren TK. Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome. Br J Cancer. 2018;118:1609-1616. [PMID: 29872151 DOI: 10.1038/s41416-018-0115-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
499 Scott AJ, Lieu CH, Messersmith WA. Therapeutic Approaches to RAS Mutation. Cancer J 2016;22:165-74. [PMID: 27341593 DOI: 10.1097/PPO.0000000000000187] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
500 Pietrantonio F, Maggi C, Di Bartolomeo M, Facciorusso MG, Perrone F, Testi A, Iacovelli R, Miceli R, Bossi I, Leone G, Milione M, Pelosi G, de Braud F. Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status. PLoS One 2014;9:e92147. [PMID: 24691006 DOI: 10.1371/journal.pone.0092147] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
501 Aprile G, Lutrino SE, Ferrari L, Casagrande M, Bonotto M, Ongaro E, Puglisi F. Evidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients. World J Gastroenterol 2013; 19(46): 8474-8488 [PMID: 24379565 DOI: 10.3748/wjg.v19.i46.8474] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
502 de Macedo MP, de Melo FM, Ribeiro Jda S, de Mello CA, de Souza Begnami MD, Soares FA, Carraro DM, da Cunha IW. RAS mutations vary between lesions in synchronous primary colorectal cancer: testing only one lesion is not sufficient to guide anti-EGFR treatment decisions. Oncoscience 2015;2:125-30. [PMID: 25859555 DOI: 10.18632/oncoscience.118] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
503 Vittal A, Middinti A, Kasi Loknath Kumar A. Are All Mutations the Same? A Rare Case Report of Coexisting Mutually Exclusive KRAS and BRAF Mutations in a Patient with Metastatic Colon Adenocarcinoma. Case Rep Oncol Med 2017;2017:2321052. [PMID: 28811946 DOI: 10.1155/2017/2321052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
504 Morris VK, Lucas FAS, Overman MJ, Eng C, Morelli MP, Jiang ZQ, Luthra R, Meric-Bernstam F, Maru D, Scheet P, Kopetz S, Vilar E. Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer. Ann Oncol 2014;25:2008-14. [PMID: 25009008 DOI: 10.1093/annonc/mdu252] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 4.0] [Reference Citation Analysis]
505 Gillis NK, McLeod HL. The pharmacogenomics of drug resistance to protein kinase inhibitors. Drug Resist Updat 2016;28:28-42. [PMID: 27620953 DOI: 10.1016/j.drup.2016.06.008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
506 Dréanic J, Dhooge M, Barret M, Brezault C, Mir O, Chaussade S, Coriat R. Anti-epidermal or anti-vascular endothelial growth factor as first-line metastatic colorectal cancer in modified Glasgow prognostic score 2' patients. J Cachexia Sarcopenia Muscle 2015;6:231-6. [PMID: 26401469 DOI: 10.1002/jcsm.12022] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
507 Özdoğan M, Papadopoulou E, Tsoulos N, Tsantikidi A, Mariatou VM, Tsaousis G, Kapeni E, Bourkoula E, Fotiou D, Kapetsis G, Boukovinas I, Touroutoglou N, Fassas A, Adamidis A, Kosmidis P, Trafalis D, Galani E, Lypas G, Orhan B, Tansan S, Özatlı T, Kırca O, Çakır O, Nasioulas G. Comprehensive tumor molecular profile analysis in clinical practice. BMC Med Genomics 2021;14:105. [PMID: 33853586 DOI: 10.1186/s12920-021-00952-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
508 Sayagués JM, Del Carmen S, Del Mar Abad M, Corchete LA, Bengoechea O, Anduaga MF, Baldeón MJ, Cruz JJ, Alcazar JA, Angoso M, González M, García J, Muñoz-Bellvis L, Orfao A, Sarasquete ME. Combined assessment of the TNM stage and BRAF mutational status at diagnosis in sporadic colorectal cancer patients. Oncotarget 2018;9:24081-96. [PMID: 29844874 DOI: 10.18632/oncotarget.25300] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
509 Schrock AB, Pavlick D, Klempner SJ, Chung JH, Forcier B, Welsh A, Young L, Leyland-Jones B, Bordoni R, Carvajal RD, Chao J, Kurzrock R, Sicklick JK, Ross JS, Stephens PJ, Devoe C, Braiteh F, Ali SM, Miller VA. Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus. Clin Cancer Res 2018;24:1881-90. [PMID: 29363525 DOI: 10.1158/1078-0432.CCR-17-3103] [Cited by in Crossref: 31] [Cited by in F6Publishing: 16] [Article Influence: 7.8] [Reference Citation Analysis]
510 Koukakis R, Gatta F, Hechmati G, Siena S. Skin toxicity and quality of life during treatment with panitumumab for RAS wild-type metastatic colorectal carcinoma: Results from three randomised clinical trials. Qual Life Res. 2016;25:2645-2656. [PMID: 27083443 DOI: 10.1007/s11136-016-1288-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
511 Price T, Ang A, Boedigheimer M, Kim TW, Li J, Cascinu S, Ruff P, Satya Suresh A, Thomas A, Tjulandin S, Peeters M. Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy. Cancer Biol Ther 2020;21:891-8. [PMID: 33026965 DOI: 10.1080/15384047.2020.1798695] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
512 Ho MY, Renouf DJ, Cheung WY, Lim HJ, Speers CH, Zhou C, Kennecke HF. Patterns of practice with third-line anti-EGFR antibody for metastatic colorectal cancer. Curr Oncol 2016;23:329-33. [PMID: 27803597 DOI: 10.3747/co.23.3030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
513 Martinelli E, Cardone C, Troiani T, Normanno N, Pisconti S, Sforza V, Bordonaro AR, Rachiglio AM, Lambiase M, Latiano TP, Modoni G, Cordio S, Giuliani F, Biglietto M, Montesarchio V, Barone C, Tonini G, Cinieri S, Febbraro A, Rizzi D, De Vita F, Orditura M, Colucci G, Maiello E, Ciardiello F, Iaffaioli V, Nasti G, Nappi A, Botti G, Tatangelo F, Chicchinelli N, Montrone M, Sebastio A, Guarino T, Simone G, Graziano P, Chiarazzo C, Maggio G, Longhitano L, Manusia M, Cartenì G, Nappi O, Micheli P, Leo L, Rossi S, Cassano A, Tommaselli E, Giordano G, Sponziello F, Marino A, Rinaldi A, Romito S, Muda AO, Lorusso V, Leo S, Barni S, Grimaldi G, Aieta M. Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial. ESMO Open 2016;1:e000086. [PMID: 28848656 DOI: 10.1136/esmoopen-2016-000086] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
514 Barry GS, Cheang MC, Chang HL, Kennecke HF. Genomic markers of panitumumab resistance including ERBB2/ HER2 in a phase II study of KRAS wild-type (wt) metastatic colorectal cancer (mCRC). Oncotarget 2016;7:18953-64. [PMID: 26980732 DOI: 10.18632/oncotarget.8006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
515 Melosky B. Meeting An Unmet Need in Metastatic Colorectal Carcinoma with Regorafenib. Asia Pac J Oncol Nurs 2016;3:58-65. [PMID: 27981140 DOI: 10.4103/2347-5625.178174] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
516 Yoshino T, Muro K, Yamaguchi K, Nishina T, Denda T, Kudo T, Okamoto W, Taniguchi H, Akagi K, Kajiwara T, Hironaka S, Satoh T. Clinical Validation of a Multiplex Kit for RAS Mutations in Colorectal Cancer: Results of the RASKET (RAS KEy Testing) Prospective, Multicenter Study. EBioMedicine 2015;2:317-23. [PMID: 26137573 DOI: 10.1016/j.ebiom.2015.02.007] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 4.7] [Reference Citation Analysis]
517 Han Y, Lu S, Yu F, Liu X, Sun H, Wang J, Zhu X, Lu H, Yue H, Wang J, Lin J, Zhou C, Tang H, Peng Z. A comparative analysis and guidance for individualized chemotherapy of stage II and III colorectal cancer patients based on pathological markers. Sci Rep 2016;6:37240. [PMID: 27845412 DOI: 10.1038/srep37240] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
518 Ardito F, Razionale F, Salvatore L, Cenci T, Vellone M, Basso M, Panettieri E, Calegari MA, Tortora G, Martini M, Giuliante F. Discordance of KRAS Mutational Status between Primary Tumors and Liver Metastases in Colorectal Cancer: Impact on Long-Term Survival Following Radical Resection. Cancers (Basel) 2021;13:2148. [PMID: 33946899 DOI: 10.3390/cancers13092148] [Reference Citation Analysis]
519 Hummel M, Hegewisch-Becker S, Neumann J, Vogel A. [BRAF-V600E testing in metastatic colorectal cancer and new, chemotherapy-free therapy options. German version]. Pathologe 2021. [PMID: 33956173 DOI: 10.1007/s00292-021-00942-9] [Reference Citation Analysis]
520 Jiang W, Yu Q, Ning R, Zhao W, Wei C. Efficacy of bevacizumab versus epidermal growth factor receptor inhibitors for wild-type RAS metastatic colorectal cancer: a meta-analysis. Onco Targets Ther 2018;11:4271-81. [PMID: 30100734 DOI: 10.2147/OTT.S168695] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
521 Kou T, Kanai M, Yamamoto Y, Kamada M, Nakatsui M, Sakuma T, Mochizuki H, Hiroshima A, Sugiyama A, Nakamura E, Miyake H, Minamiguchi S, Takaori K, Matsumoto S, Haga H, Seno H, Kosugi S, Okuno Y, Muto M. Clinical sequencing using a next-generation sequencing-based multiplex gene assay in patients with advanced solid tumors. Cancer Sci 2017;108:1440-6. [PMID: 28440963 DOI: 10.1111/cas.13265] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 6.4] [Reference Citation Analysis]
522 Buchler T, Chloupkova R, Poprach A, Fiala O, Kiss I, Kopeckova K, Dusek L, Veskrnova V, Slavicek L, Kohoutek M, Finek J, Svoboda M, Petruzelka L, Melichar B. Sequential therapy with bevacizumab and EGFR inhibitors for metastatic colorectal carcinoma: a national registry-based analysis. Cancer Manag Res 2019;11:359-68. [PMID: 30643461 DOI: 10.2147/CMAR.S183093] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
523 Villéger R, Lopès A, Veziant J, Gagnière J, Barnich N, Billard E, Boucher D, Bonnet M. Microbial markers in colorectal cancer detection and/or prognosis. World J Gastroenterol 2018; 24(22): 2327-2347 [PMID: 29904241 DOI: 10.3748/wjg.v24.i22.2327] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 36] [Article Influence: 11.0] [Reference Citation Analysis]
524 Taniguchi H, Okamoto W, Muro K, Akagi K, Hara H, Nishina T, Kajiwara T, Denda T, Hironaka S, Kudo T, Satoh T, Yamanaka T, Abe Y, Fukushima Y, Yoshino T. Clinical Validation of Newly Developed Multiplex Kit Using Luminex xMAP Technology for Detecting Simultaneous RAS and BRAF Mutations in Colorectal Cancer: Results of the RASKET-B Study. Neoplasia 2018;20:1219-26. [PMID: 30412858 DOI: 10.1016/j.neo.2018.10.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
525 Taniguchi H, Baba Y, Sagiya Y, Gotou M, Nakamura K, Sawada H, Yamanaka K, Sakakibara Y, Mori I, Hikichi Y, Soeda J, Baba H. Biologic Response of Colorectal Cancer Xenograft Tumors to Sequential Treatment with Panitumumab and Bevacizumab. Neoplasia 2018;20:668-77. [PMID: 29802988 DOI: 10.1016/j.neo.2018.04.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
526 Siano M, Molinari F, Martin V, Mach N, Früh M, Freguia S, Corradino I, Ghielmini M, Frattini M, Espeli V. Multicenter Phase II Study of Panitumumab in Platinum Pretreated, Advanced Head and Neck Squamous Cell Cancer. Oncologist 2017;22:782-e70. [PMID: 28592616 DOI: 10.1634/theoncologist.2017-0069] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
527 Vivancos A, Aranda E, Benavides M, Élez E, Gómez-España MA, Toledano M, Alvarez M, Parrado MRC, García-Barberán V, Diaz-Rubio E. Comparison of the Clinical Sensitivity of the Idylla Platform and the OncoBEAM RAS CRC Assay for KRAS Mutation Detection in Liquid Biopsy Samples. Sci Rep 2019;9:8976. [PMID: 31222012 DOI: 10.1038/s41598-019-45616-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
528 Phillips SP, Hamberg K. Doubly blind: a systematic review of gender in randomised controlled trials. Glob Health Action 2016;9:29597. [PMID: 27087576 DOI: 10.3402/gha.v9.29597] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 6.3] [Reference Citation Analysis]
529 Taieb J, Jung A, Sartore-Bianchi A, Peeters M, Seligmann J, Zaanan A, Burdon P, Montagut C, Laurent-Puig P. The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer. Drugs 2019;79:1375-94. [PMID: 31347092 DOI: 10.1007/s40265-019-01165-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 9.0] [Reference Citation Analysis]
530 Alcaide J, Delgado M, Legerén M, Jurado JM, Blancas I, Pereda T, López J, Garrido M, Sánchez MJ, García JL, Rueda A. Efficacy and safety of aflibercept in metastatic colorectal cancer pretreated with bevacizumab: A report of five cases. Oncol Lett 2016;12:3127-34. [PMID: 27899972 DOI: 10.3892/ol.2016.5068] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
531 Zhou M, Yu P, Hou K, Fu L, Chen Y, Qu J, Qu X, Liu Y, Zhang J. Effect of RAS status on anti-EGFR monoclonal antibodies + 5-FU infusion-based chemotherapy in first-line treatment of metastatic colorectal cancer: A meta-analysis. Meta Gene 2016;9:110-9. [PMID: 27331015 DOI: 10.1016/j.mgene.2016.05.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
532 Shinozaki E, Yoshino T, Yamazaki K, Muro K, Yamaguchi K, Nishina T, Yuki S, Shitara K, Bando H, Mimaki S, Nakai C, Matsushima K, Suzuki Y, Akagi K, Yamanaka T, Nomura S, Fujii S, Esumi H, Sugiyama M, Nishida N, Mizokami M, Koh Y, Abe Y, Ohtsu A, Tsuchihara K. Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study. Br J Cancer 2017;117:1450-8. [PMID: 28972961 DOI: 10.1038/bjc.2017.308] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 6.8] [Reference Citation Analysis]
533 Sunakawa Y, Schirripa M, Lenz HJ. Understanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancer. Crit Rev Oncol Hematol 2016;100:117-26. [PMID: 26850575 DOI: 10.1016/j.critrevonc.2016.01.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
534 Battaglin F, Schirripa M, Buggin F, Pietrantonio F, Morano F, Boscolo G, Tonini G, Lutrino ES, Lucchetti J, Salvatore L, Passardi A, Cremolini C, Arnoldi E, Scartozzi M, Pella N, Boni L, Bergamo F, Zagonel V, Loupakis F, Lonardi S. The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients. BMC Cancer 2018;18:98. [PMID: 29370781 DOI: 10.1186/s12885-018-4001-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
535 Xu JM, Wang Y, Wang YL, Wang Y, Liu T, Ni M, Li MS, Lin L, Ge FJ, Gong C, Gu JY, Jia R, Wang HF, Chen YL, Liu RR, Zhao CH, Tan ZL, Jin Y, Zhu YP, Ogino S, Qian ZR. PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer. Clin Cancer Res 2017;23:4602-16. [PMID: 28424201 DOI: 10.1158/1078-0432.CCR-16-2738] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
536 Morano F, Corallo S, Lonardi S, Raimondi A, Cremolini C, Rimassa L, Murialdo R, Zaniboni A, Sartore-Bianchi A, Tomasello G, Racca P, Clavarezza M, Adamo V, Perrone F, Gloghini A, Tamborini E, Busico A, Martinetti A, Palermo F, Loupakis F, Milione M, Fucà G, Di Bartolomeo M, de Braud F, Pietrantonio F. Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy. J Clin Oncol 2019;37:3099-110. [PMID: 31539295 DOI: 10.1200/JCO.19.01254] [Cited by in Crossref: 28] [Cited by in F6Publishing: 13] [Article Influence: 9.3] [Reference Citation Analysis]
537 Yuan J, Dong X, Yap J, Hu J. The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy. J Hematol Oncol. 2020;13:113. [PMID: 32807225 DOI: 10.1186/s13045-020-00949-4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 34] [Article Influence: 14.5] [Reference Citation Analysis]
538 Giordano G, Parcesepe P, Bruno G, Piscazzi A, Lizzi V, Remo A, Pancione M, D'Andrea MR, De Santis E, Coppola L, Pietrafesa M, Fersini A, Ambrosi A, Landriscina M. Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era. Int J Mol Sci 2021;22:7717. [PMID: 34299337 DOI: 10.3390/ijms22147717] [Reference Citation Analysis]
539 Kwan AK, Piazza GA, Keeton AB, Leite CA. The path to the clinic: a comprehensive review on direct KRASG12C inhibitors. J Exp Clin Cancer Res 2022;41. [DOI: 10.1186/s13046-021-02225-w] [Reference Citation Analysis]
540 Xu W, Gong Y, Kuang M, Wu P, Cao C, Chen J, Tang C. Survival Benefit and Safety of Bevacizumab in Combination with Erlotinib as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: A Meta-Analysis. Clin Drug Investig 2017;37:155-65. [PMID: 27665469 DOI: 10.1007/s40261-016-0465-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
541 Tops BB, Normanno N, Kurth H, Amato E, Mafficini A, Rieber N, Le Corre D, Rachiglio AM, Reiman A, Sheils O, Noppen C, Lacroix L, Cree IA, Scarpa A, Ligtenberg MJ, Laurent-Puig P. Development of a semi-conductor sequencing-based panel for genotyping of colon and lung cancer by the Onconetwork consortium. BMC Cancer 2015;15:26. [PMID: 25637035 DOI: 10.1186/s12885-015-1015-5] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 5.7] [Reference Citation Analysis]
542 Catenacci DV. Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity. Mol Oncol. 2015;9:967-996. [PMID: 25557400 DOI: 10.1016/j.molonc.2014.09.011] [Cited by in Crossref: 93] [Cited by in F6Publishing: 79] [Article Influence: 11.6] [Reference Citation Analysis]
543 Rachiglio AM, Lambiase M, Fenizia F, Roma C, Cardone C, Iannaccone A, De Luca A, Carotenuto M, Frezzetti D, Martinelli E, Maiello E, Ciardiello F, Normanno N. Genomic Profiling of KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer Patients Reveals Novel Mutations in Genes Potentially Associated with Resistance to Anti-EGFR Agents. Cancers (Basel) 2019;11:E859. [PMID: 31226844 DOI: 10.3390/cancers11060859] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
544 Sousa N, Sousa O, Santos LL, Henrique R, Teixeira MR, Dinis-Ribeiro M, Teixeira-Pinto A. Lapatinib-capecitabine versus capecitabine alone as radiosensitizers in RAS wild-type resectable rectal cancer, an adaptive randomized phase II trial (LaRRC trial): study protocol for a randomized controlled trial. Trials 2016;17:459. [PMID: 27655166 DOI: 10.1186/s13063-016-1583-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
545 González Astorga B, Salvà Ballabrera F, Aranda Aguilar E, Élez Fernández E, García-Alfonso P, González Flores E, Vera García R, Fernández Montes A, López Muñoz AM, Salud Salvia A. Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept. Clin Transl Oncol 2021;23:1520-8. [PMID: 33630242 DOI: 10.1007/s12094-021-02568-y] [Reference Citation Analysis]
546 Hammond WA, Swaika A, Mody K. Pharmacologic resistance in colorectal cancer: a review. Ther Adv Med Oncol. 2016;8:57-84. [PMID: 26753006 DOI: 10.1177/1758834015614530] [Cited by in Crossref: 203] [Cited by in F6Publishing: 194] [Article Influence: 33.8] [Reference Citation Analysis]
547 Turpin A, Genin M, Hebbar M, Occelli F, Lanier C, Vasseur F, Descarpentries C, Pannier D, Ploquin A. Spatial heterogeneity of KRAS mutations in colorectal cancers in northern France. Cancer Manag Res 2019;11:8337-44. [PMID: 31571990 DOI: 10.2147/CMAR.S211119] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
548 López-Cortés A, Guerrero S, Redal MA, Alvarado AT, Quiñones LA. State of Art of Cancer Pharmacogenomics in Latin American Populations. Int J Mol Sci 2017;18:E639. [PMID: 28545225 DOI: 10.3390/ijms18060639] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
549 Recondo GJ, Díaz-Cantón E, de la Vega M, Greco M, Recondo GS, Valsecchi ME. Advances and new perspectives in the treatment of metastatic colon cancer. World J Gastrointest Oncol 2014; 6(7): 211-224 [PMID: 25024813 DOI: 10.4251/wjgo.v6.i7.211] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
550 Awidi M, Ababneh N, Shomaf M, Al Fararjeh F, Owaidi L, AlKhatib M, Al Tarawneh B, Awidi A. KRAS and NRAS mutational gene profile of metastatic colorectal cancer patients in Jordan. PLoS One 2019;14:e0226473. [PMID: 31881025 DOI: 10.1371/journal.pone.0226473] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
551 Bokemeyer C, Köhne CH, Ciardiello F, Lenz HJ, Heinemann V, Klinkhardt U, Beier F, Duecker K, van Krieken JH, Tejpar S. FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer. Eur J Cancer 2015;51:1243-52. [PMID: 25937522 DOI: 10.1016/j.ejca.2015.04.007] [Cited by in Crossref: 139] [Cited by in F6Publishing: 131] [Article Influence: 19.9] [Reference Citation Analysis]
552 Kim BH, Kim JM, Kang GH, Chang HJ, Kang DW, Kim JH, Bae JM, Seo AN, Park HS, Kang YK, Lee KH, Cho MY, Do IG, Lee HS, Chang HK, Park DY, Kang HJ, Sohn JH, Chang MS, Jung ES, Jin SY, Yu E, Han HS, Kim YW. Standardized Pathology Report for Colorectal Cancer, 2nd Edition. J Pathol Transl Med 2020;54:1-19. [PMID: 31722452 DOI: 10.4132/jptm.2019.09.28] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
553 Xue P, Zeng F, Duan Q, Xiao J, Liu L, Yuan P, Fan L, Sun H, Malyarenko OS, Lu H, Xiu R, Liu S, Shao C, Zhang J, Yan W, Wang Z, Zheng J, Zhu F. BCKDK of BCAA Catabolism Cross-talking With the MAPK Pathway Promotes Tumorigenesis of Colorectal Cancer. EBioMedicine 2017;20:50-60. [PMID: 28501528 DOI: 10.1016/j.ebiom.2017.05.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
554 Bouché O, Ben Abdelghani M, Labourey JL, Triby S, Bensadoun RJ, Jouary T, Des Guetz G. Management of skin toxicities during panitumumab treatment in metastatic colorectal cancer. World J Gastroenterol 2019; 25(29): 4007-4018 [PMID: 31413534 DOI: 10.3748/wjg.v25.i29.4007] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
555 Van Heertum RL, Scarimbolo R, Ford R, Berdougo E, O'Neal M. Companion diagnostics and molecular imaging-enhanced approaches for oncology clinical trials. Drug Des Devel Ther 2015;9:5215-23. [PMID: 26392755 DOI: 10.2147/DDDT.S87561] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
556 Belli V, Matrone N, Napolitano S, Migliardi G, Cottino F, Bertotti A, Trusolino L, Martinelli E, Morgillo F, Ciardiello D, De Falco V, Giunta EF, Bracale U, Ciardiello F, Troiani T. Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models. J Exp Clin Cancer Res 2019;38:236. [PMID: 31164152 DOI: 10.1186/s13046-019-1230-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
557 Peeters M, Forget F, Karthaus M, Valladares-Ayerbes M, Zaniboni A, Demonty G, Guan X, Rivera F. Exploratory pooled analysis evaluating the effect of sequence of biological therapies on overall survival in patients with RAS wild-type metastatic colorectal carcinoma. ESMO Open 2018;3:e000297. [PMID: 29531837 DOI: 10.1136/esmoopen-2017-000297] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
558 Merkel S, Schellerer VS, Wein A, Semrau S, Geppert C, Göhl J, Hohenberger W, Weber K, Grützmann R. The influence of tumour site on prognosis in metastatic colorectal carcinomas with primary tumour resection. Int J Colorectal Dis 2018;33:1215-23. [PMID: 29915904 DOI: 10.1007/s00384-018-3098-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
559 Morikawa T, Inada R, Nagasaka T, Mori Y, Kishimoto H, Kawai T, Umeda Y, Mishima H, Goel A, Fujiwara T. BRAF V600E mutation is a predictive indicator of upfront chemotherapy for stage IV colorectal cancer. Oncol Lett 2018;15:2195-201. [PMID: 29434925 DOI: 10.3892/ol.2017.7553] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
560 Epistolio S, Cefalì M, Spina P, Molinari F, Movilia A, Cergnul M, Mazzucchelli L, De Dosso S, Frattini M, Saletti P. Occurence of RAS reversion in metastatic colorectal cancer patients treated with bevacizumab. Oncotarget 2021;12:1046-56. [PMID: 34084279 DOI: 10.18632/oncotarget.27965] [Reference Citation Analysis]
561 Ryan ÉJ, Creavin B, Sheahan K. Delivery of Personalized Care for Locally Advanced Rectal Cancer: Incorporating Pathological, Molecular Genetic, and Immunological Biomarkers Into the Multimodal Paradigm. Front Oncol 2020;10:1369. [PMID: 32923389 DOI: 10.3389/fonc.2020.01369] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
562 da Silva WC, Godman B, de Assis Acúrcio F, Cherchiglia ML, Martin A, Maruszczyk K, Izidoro JB, Portella MA, Lana AP, Campos Neto OH, Andrade EIG. The Budget Impact of Monoclonal Antibodies Used to Treat Metastatic Colorectal Cancer in Minas Gerais, Brazil. Appl Health Econ Health Policy 2021;19:557-77. [PMID: 33506317 DOI: 10.1007/s40258-020-00626-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
563 Moorcraft SY, Jones T, Walker BA, Ladas G, Kalaitzaki E, Yuan L, Begum R, Eltahir Z, Wotherspoon A, Montero-Fernandez A, Teixeira Mendes LS, Gonzalez de Castro D, Wilson SH, Proszek P, To YM, Hawkes E, Roy A, Cunningham D, Rao S, Watkins D, Starling N, Bowcock AM, Chau I. Molecular profiling of colorectal pulmonary metastases and primary tumours: implications for targeted treatment. Oncotarget 2017;8:64999-5008. [PMID: 29029407 DOI: 10.18632/oncotarget.17048] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
564 Tsukui Y, Yamaguchi T, Maekawa S, Takano S, Sato T, Enomoto N. Dickkopf-4 gene expression is associated with differentiation and lymph node metastasis in colorectal cancer. JGH Open 2019;3:409-16. [PMID: 31633047 DOI: 10.1002/jgh3.12177] [Reference Citation Analysis]
565 Creutzfeldt A, Suling A, Oechsle K, Mehnert A, Atanackovic D, Kripp M, Arnold D, Stein A, Quidde J. Integrating patient reported measures as predictive parameters into decisionmaking about palliative chemotherapy: a pilot study. BMC Palliat Care 2016;15:25. [PMID: 26928745 DOI: 10.1186/s12904-016-0101-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
566 De Nicola F, Goeman F, Pallocca M, Sperati F, Pizzuti L, Melucci E, Casini B, Amoreo CA, Gallo E, Diodoro MG, Buglioni S, Mazzotta M, Vici P, Sergi D, Di Lauro L, Barba M, Pescarmona E, Ciliberto G, De Maria R, Fanciulli M, Maugeri-Saccà M. Deep sequencing and pathway-focused analysis revealed multigene oncodriver signatures predicting survival outcomes in advanced colorectal cancer. Oncogenesis 2018;7:55. [PMID: 30032163 DOI: 10.1038/s41389-018-0066-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
567 Kratz JD, LoConte NK. Defining Early Multidisciplinary Goals: NEXTO Trial in High-Risk Colorectal Cancer with Liver Metastases. Ann Surg Oncol 2020;27:4075-8. [PMID: 32444912 DOI: 10.1245/s10434-020-08629-w] [Reference Citation Analysis]
568 Junior Gde L. Controversies in colorectal cancer: First line treatment with epidermal growth factor inhibitors and RAS in 2014. Indian J Med Paediatr Oncol 2014;35:140-2. [PMID: 25197175 DOI: 10.4103/0971-5851.138960] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
569 Rodríguez-Casanova A, Bao-Caamano A, Lago-Lestón RM, Brozos-Vázquez E, Costa-Fraga N, Ferreirós-Vidal I, Abdulkader I, Vidal-Insua Y, Rivera FV, Candamio Folgar S, López-López R, Muinelo-Romay L, Diaz-Lagares A. Evaluation of a Targeted Next-Generation Sequencing Panel for the Non-Invasive Detection of Variants in Circulating DNA of Colorectal Cancer. J Clin Med 2021;10:4487. [PMID: 34640513 DOI: 10.3390/jcm10194487] [Reference Citation Analysis]
570 Rachiglio AM, Sacco A, Forgione L, Esposito C, Chicchinelli N, Normanno N. Colorectal cancer genomic biomarkers in the clinical management of patients with metastatic colorectal carcinoma. Exploration of Targeted Anti-tumor Therapy 2020;1:53-70. [DOI: 10.37349/etat.2020.00004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
571 Aranda E, Aparicio J, Alonso V, Garcia-Albeniz X, Garcia-Alfonso P, Salazar R, Valladares M, Vera R, Vieitez JM, Garcia-Carbonero R. SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015. Clin Transl Oncol 2015;17:972-81. [PMID: 26669312 DOI: 10.1007/s12094-015-1434-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
572 Konieczkowski DJ, Johannessen CM, Garraway LA. A Convergence-Based Framework for Cancer Drug Resistance. Cancer Cell 2018;33:801-15. [PMID: 29763622 DOI: 10.1016/j.ccell.2018.03.025] [Cited by in Crossref: 93] [Cited by in F6Publishing: 80] [Article Influence: 31.0] [Reference Citation Analysis]
573 Fiorentini G, Sarti D, Aliberti C, Carandina R, Mambrini A, Guadagni S. Multidisciplinary approach of colorectal cancer liver metastases. World J Clin Oncol 2017; 8(3): 190-202 [PMID: 28638789 DOI: 10.5306/wjco.v8.i3.190] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 24] [Article Influence: 5.6] [Reference Citation Analysis]
574 García-Foncillas J, Alba E, Aranda E, Díaz-Rubio E, López-López R, Tabernero J, Vivancos A. Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review. Ann Oncol 2017;28:2943-9. [PMID: 28945877 DOI: 10.1093/annonc/mdx501] [Cited by in Crossref: 39] [Cited by in F6Publishing: 43] [Article Influence: 9.8] [Reference Citation Analysis]
575 Lizarbe MA, Calle-Espinosa J, Fernández-Lizarbe E, Fernández-Lizarbe S, Robles MÁ, Olmo N, Turnay J. Colorectal Cancer: From the Genetic Model to Posttranscriptional Regulation by Noncoding RNAs. Biomed Res Int 2017;2017:7354260. [PMID: 28573140 DOI: 10.1155/2017/7354260] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
576 Ali SM, Pal SK, Wang K, Palma NA, Sanford E, Bailey M, He J, Elvin JA, Chmielecki J, Squillace R, Dow E, Morosini D, Buell J, Yelensky R, Lipson D, Frampton GM, Howley P, Ross JS, Stephens PJ, Miller VA. Comprehensive Genomic Profiling of Advanced Penile Carcinoma Suggests a High Frequency of Clinically Relevant Genomic Alterations. Oncologist 2016;21:33-9. [PMID: 26670666 DOI: 10.1634/theoncologist.2015-0241] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 5.6] [Reference Citation Analysis]
577 Tsvetkova E, Sud S, Aucoin N, Biagi J, Burkes R, Samson B, Brule S, Cripps C, Colwell B, Falkson C, Dorreen M, Goel R, Halwani F, Maroun J, Michaud N, Tehfe M, Thirlwell M, Vickers M, Asmis T. Eastern Canadian Gastrointestinal Cancer Consensus Conference 2014. Curr Oncol 2015;22:e305-15. [PMID: 26300681 DOI: 10.3747/co.22.2603] [Reference Citation Analysis]
578 Krens LL, Simkens LH, Baas JM, Koomen ER, Gelderblom H, Punt CJ, Guchelaar HJ. Statin use is not associated with improved progression free survival in cetuximab treated KRAS mutant metastatic colorectal cancer patients: results from the CAIRO2 study. PLoS One. 2014;9:e112201. [PMID: 25375154 DOI: 10.1371/journal.pone.0112201] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
579 Marin JJG, Macias RIR, Monte MJ, Herraez E, Peleteiro-Vigil A, Blas BS, Sanchon-Sanchez P, Temprano AG, Espinosa-Escudero RA, Lozano E, Briz O, Romero MR. Cellular Mechanisms Accounting for the Refractoriness of Colorectal Carcinoma to Pharmacological Treatment. Cancers (Basel) 2020;12:E2605. [PMID: 32933095 DOI: 10.3390/cancers12092605] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
580 Blank A, Roberts DE 2nd, Dawson H, Zlobec I, Lugli A. Tumor Heterogeneity in Primary Colorectal Cancer and Corresponding Metastases. Does the Apple Fall Far From the Tree? Front Med (Lausanne) 2018;5:234. [PMID: 30234115 DOI: 10.3389/fmed.2018.00234] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
581 Ouchi K, Takahashi S, Yamada Y, Tsuji S, Tatsuno K, Takahashi H, Takahashi N, Takahashi M, Shimodaira H, Aburatani H, Ishioka C. DNA methylation status as a biomarker of anti-epidermal growth factor receptor treatment for metastatic colorectal cancer. Cancer Sci 2015;106:1722-9. [PMID: 26426205 DOI: 10.1111/cas.12827] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
582 Maughan TS, Meade AM, Adams RA, Richman SD, Butler R, Fisher D, Wilson RH, Jasani B, Taylor GR, Williams GT. A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine? Br J Cancer. 2014;110:2178-2186. [PMID: 24743706 DOI: 10.1038/bjc.2014.182] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
583 Martin SZ, Wagner DC, Hörner N, Horst D, Lang H, Tagscherer KE, Roth W. Ex vivo tissue slice culture system to measure drug-response rates of hepatic metastatic colorectal cancer. BMC Cancer 2019;19:1030. [PMID: 31675944 DOI: 10.1186/s12885-019-6270-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
584 Nakajima H, Fukuoka S, Masuishi T, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Negoro Y, Komoda M, Makiyama A, Denda T, Hatachi Y, Suto T, Sugimoto N, Enomoto M, Ishikawa T, Kashiwada T, Ando K, Yuki S, Okuyama H, Kusaba H, Sakai D, Okamoto K, Tamura T, Yamashita K, Gosho M, Moriwaki T. Clinical Impact of Primary Tumor Location in Metastatic Colorectal Cancer Patients Under Later-Line Regorafenib or Trifluridine/Tipiracil Treatment. Front Oncol 2021;11:688709. [PMID: 34211856 DOI: 10.3389/fonc.2021.688709] [Reference Citation Analysis]
585 Okita A, Takahashi S, Ouchi K, Inoue M, Watanabe M, Endo M, Honda H, Yamada Y, Ishioka C. Consensus molecular subtypes classification of colorectal cancer as a predictive factor for chemotherapeutic efficacy against metastatic colorectal cancer. Oncotarget. 2018;9:18698-18711. [PMID: 29721154 DOI: 10.18632/oncotarget.24617] [Cited by in Crossref: 60] [Cited by in F6Publishing: 65] [Article Influence: 15.0] [Reference Citation Analysis]
586 Domenico C, Antonella I, Benedetto C, Luigi S, Antonio C, Lidia C, Giuseppe S, Gallelli L. Panitumumab Induced Forearm Panniculitis in Two Women With Metastatic Colon Cancer. Curr Drug Saf 2019;14:233-7. [PMID: 31113346 DOI: 10.2174/1574886314666190522094713] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
587 Chiadini E, Scarpi E, Passardi A, Calistri D, Valgiusti M, Saragoni L, Zoli W, Amadori D, Ulivi P. EGFR methylation and outcome of patients with advanced colorectal cancer treated with cetuximab. Oncol Lett 2015;9:1432-8. [PMID: 25663927 DOI: 10.3892/ol.2015.2876] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
588 Kim ST, Hong JY, Lee J, Park JO, Lim HY, Kang WK, Park YS. Pemetrexed/Erlotinib as a Salvage Treatment in Patients with High EGFR-Expressing Metastatic Colorectal Cancer Following Failure of Standard Chemotherapy: A Phase II Single-Arm Prospective Study. Target Oncol 2020;15:67-73. [PMID: 31820199 DOI: 10.1007/s11523-019-00691-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
589 Liu J, Cheng Y, Wang X, Zhang L, Liu H. An Optimal Mean Based Block Robust Feature Extraction Method to Identify Colorectal Cancer Genes with Integrated Data. Sci Rep 2017;7:8584. [PMID: 28819308 DOI: 10.1038/s41598-017-08881-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
590 Kircher SM, Mohindra N, Nimeiri H. Cost estimates and economic implications of expanded RAS testing in metastatic colorectal cancer. Oncologist 2015;20:14-8. [PMID: 25410095 DOI: 10.1634/theoncologist.2014-0252] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
591 Brijwani N, Jain M, Dhandapani M, Zahed F, Mukhopadhyay P, Biswas M, Khatri D, Radhakrishna VD, Majumder B, Radhakrishnan P, Thiyagarajan S. Rationally co-targeting divergent pathways in KRAS wild-type colorectal cancers by CANscript technology reveals tumor dependence on Notch and Erbb2. Sci Rep 2017;7:1502. [PMID: 28473715 DOI: 10.1038/s41598-017-01566-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
592 Isella C, Brundu F, Bellomo SE, Galimi F, Zanella E, Porporato R, Petti C, Fiori A, Orzan F, Senetta R, Boccaccio C, Ficarra E, Marchionni L, Trusolino L, Medico E, Bertotti A. Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer. Nat Commun. 2017;8:15107. [PMID: 28561063 DOI: 10.1038/ncomms15107] [Cited by in Crossref: 118] [Cited by in F6Publishing: 99] [Article Influence: 23.6] [Reference Citation Analysis]
593 Punt CJ, Koopman M, Vermeulen L. From tumour heterogeneity to advances in precision treatment of colorectal cancer. Nat Rev Clin Oncol. 2017;14:235-246. [PMID: 27922044 DOI: 10.1038/nrclinonc.2016.171] [Cited by in Crossref: 239] [Cited by in F6Publishing: 236] [Article Influence: 39.8] [Reference Citation Analysis]
594 Shitara K, Yonesaka K, Denda T, Yamazaki K, Moriwaki T, Tsuda M, Takano T, Okuda H, Nishina T, Sakai K, Nishio K, Tokunaga S, Yamanaka T, Boku N, Hyodo I, Muro K. Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G. Cancer Sci. 2016;107:1843-1850. [PMID: 27712015 DOI: 10.1111/cas.13098] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 6.2] [Reference Citation Analysis]
595 Zhong L, Wang R, Wang Y, Peng S, Ma Y, Ding S, Yang H, Chen S, Luo X, Wang W. Dual inhibition of VEGF and PARP suppresses KRAS-mutant colorectal cancer. Neoplasia 2020;22:365-75. [PMID: 32629177 DOI: 10.1016/j.neo.2020.06.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
596 Fritz J, Lefebvre O, Fernandez A, Schmidt J, Bagnard D. Prediction of Drug Efficacy in Colon Cancer Preclinical Models Using a Novel Ranking Method of Gene Expression. Cancers (Basel) 2020;12:E149. [PMID: 31936310 DOI: 10.3390/cancers12010149] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
597 Nakayama I, Shinozaki E, Matsushima T, Wakatsuki T, Ogura M, Ichimura T, Ozaka M, Takahari D, Suenaga M, Chin K, Mizunuma N, Yamaguchi K. Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients. BMC Cancer 2017;17:38. [PMID: 28068936 DOI: 10.1186/s12885-016-2994-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
598 Sepulveda AR, Hamilton SR, Allegra CJ, Grody W, Cushman-Vokoun AM, Funkhouser WK, Kopetz SE, Lieu C, Lindor NM, Minsky BD, Monzon FA, Sargent DJ, Singh VM, Willis J, Clark J, Colasacco C, Rumble RB, Temple-Smolkin R, Ventura CB, Nowak JA. Molecular Biomarkers for the Evaluation of Colorectal Cancer. Am J Clin Pathol 2017;147:221-60. [PMID: 28165529 DOI: 10.1093/ajcp/aqw209] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
599 Taniguchi F, Nyuya A, Toshima T, Yasui K, Mori Y, Okawaki M, Kishimoto H, Umeda Y, Fujiwara T, Tanioka H, Yamaguchi Y, Goel A, Nagasaka T. Concordance of acquired mutations between metastatic lesions and liquid biopsy in metastatic colorectal cancer. Future Sci OA 2021;7:FSO757. [PMID: 34840814 DOI: 10.2144/fsoa-2021-0059] [Reference Citation Analysis]
600 Lou E, Xiu J, Baca Y, Nelson AC, Weinberg BA, Beg MS, Salem ME, Lenz HJ, Philip P, El-Deiry WS, Korn WM. Expression of Immuno-Oncologic Biomarkers Is Enriched in Colorectal Cancers and Other Solid Tumors Harboring the A59T Variant of KRAS. Cells 2021;10:1275. [PMID: 34063999 DOI: 10.3390/cells10061275] [Reference Citation Analysis]
601 Osumi H, Shinozaki E, Yamaguchi K. Circulating Tumor DNA as a Novel Biomarker Optimizing Chemotherapy for Colorectal Cancer. Cancers (Basel) 2020;12:E1566. [PMID: 32545750 DOI: 10.3390/cancers12061566] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
602 Padder RA, Bhat ZI, Ahmad Z, Singh N, Husain M. DRP1 Promotes BRAFV600E-Driven Tumor Progression and Metabolic Reprogramming in Colorectal Cancer. Front Oncol 2020;10:592130. [PMID: 33738242 DOI: 10.3389/fonc.2020.592130] [Reference Citation Analysis]
603 Lanman RB, Mortimer SA, Zill OA, Sebisanovic D, Lopez R, Blau S, Collisson EA, Divers SG, Hoon DS, Kopetz ES, Lee J, Nikolinakos PG, Baca AM, Kermani BG, Eltoukhy H, Talasaz A. Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA. PLoS One 2015;10:e0140712. [PMID: 26474073 DOI: 10.1371/journal.pone.0140712] [Cited by in Crossref: 399] [Cited by in F6Publishing: 347] [Article Influence: 57.0] [Reference Citation Analysis]
604 Kim SY, Kim TW. Current challenges in the implementation of precision oncology for the management of metastatic colorectal cancer. ESMO Open 2020;5:e000634. [PMID: 32188714 DOI: 10.1136/esmoopen-2019-000634] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
605 Bayle A, Basile D, Garinet S, Rance B, Laurent-Puig P, Blons H, Taieb J, Perkins G. Next-Generation Sequencing Targeted Panel in Routine Care for Metastatic Colon Cancers. Cancers (Basel) 2021;13:5750. [PMID: 34830904 DOI: 10.3390/cancers13225750] [Reference Citation Analysis]
606 Garde Noguera J, Jantus-Lewintre E, Gil-Raga M, Evgenyeva E, Maciá Escalante S, Llombart-Cussac A, Camps Herrero C. Role of RAS mutation status as a prognostic factor for patients with advanced colorectal cancer treated with first-line chemotherapy based on fluoropyrimidines and oxaliplatin, with or without bevavizumab: A retrospective analysis. Mol Clin Oncol 2017;6:403-8. [PMID: 28451421 DOI: 10.3892/mco.2017.1149] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
607 Sakai K, Yoneshige A, Ito A, Ueda Y, Kondo S, Nobumasa H, Fujita Y, Togashi Y, Terashima M, De Velasco MA, Tomida S, Nishio K. Performance of a novel KRAS mutation assay for formalin-fixed paraffin embedded tissues of colorectal cancer. Springerplus 2015;4:7. [PMID: 25674493 DOI: 10.1186/2193-1801-4-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
608 Byun JH, Ahn JB, Kim SY, Kang JH, Zang DY, Kang SY, Kang MJ, Shim BY, Baek SK, Kim BS, Lee KH, Lee SI, Cho SH, Sohn BS, Kim S, Hwang IG, Nam EM, Seo BG, Oh SC, Lee MA, Lee SC, Hong JH, Park YS. The impact of primary tumor location in patients with metastatic colorectal cancer: a Korean Cancer Study Group CO12-04 study. Korean J Intern Med 2019;34:165-77. [PMID: 29172407 DOI: 10.3904/kjim.2016.348] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
609 Aung KL, Stockley TL, Serra S, Kamel-Reid S, Bedard PL, Siu LL. Testing ERBB2 p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer. Cold Spring Harb Mol Case Stud 2016;2:a001016. [PMID: 27626067 DOI: 10.1101/mcs.a001016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
610 Segelov E, Chan D, Shapiro J, Price TJ, Karapetis CS, Tebbutt NC, Pavlakis N. The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials. Br J Cancer. 2014;111:1122-1131. [PMID: 25072258 DOI: 10.1038/bjc.2014.404] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
611 Gibson TJ, Smyth P, Mcdaid WJ, Lavery D, Thom J, Cotton G, Scott CJ, Themistou E. Single-Domain Antibody-Functionalized pH-Responsive Amphiphilic Block Copolymer Nanoparticles for Epidermal Growth Factor Receptor Targeted Cancer Therapy. ACS Macro Lett 2018;7:1010-5. [DOI: 10.1021/acsmacrolett.8b00461] [Cited by in Crossref: 9] [Article Influence: 2.3] [Reference Citation Analysis]
612 Wasan H, Meade AM, Adams R, Wilson R, Pugh C, Fisher D, Sydes B, Madi A, Sizer B, Lowdell C, Middleton G, Butler R, Kaplan R, Maughan T; COIN-B investigators. Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial. Lancet Oncol 2014;15:631-9. [PMID: 24703531 DOI: 10.1016/S1470-2045(14)70106-8] [Cited by in Crossref: 72] [Cited by in F6Publishing: 27] [Article Influence: 9.0] [Reference Citation Analysis]
613 Parisi A, Cortellini A, Cannita K, Venditti O, Camarda F, Calegari MA, Salvatore L, Tortora G, Rossini D, Germani MM, Boccaccino A, Dell'Aquila E, Fulgenzi C, Santini D, Tursi M, Tinari N, Marino PD, Lombardi P, Keränen SR, Álvaro MH, Zurlo IV, Corsi DC, Emiliani A, Zanaletti N, Troiani T, Vitale P, Giampieri R, Merloni F, Occhipinti MA, Marchetti P, Roberto M, Mazzuca F, Ghidini M, Indini A, Garajova I, Zoratto F, Monache SD, Porzio G, Ficorella C. Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study. Cancers (Basel) 2020;12:E1259. [PMID: 32429380 DOI: 10.3390/cancers12051259] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
614 Borie F, Dubray V, Tretarre B. Impact of recommendations and new therapies on the prognosis of colon cancer with synchronous liver metastasis. Clin Res Hepatol Gastroenterol 2021;:101856. [PMID: 34963650 DOI: 10.1016/j.clinre.2021.101856] [Reference Citation Analysis]
615 Erdem ZN, Schwarz S, Drev D, Heinzle C, Reti A, Heffeter P, Hudec X, Holzmann K, Grasl-Kraupp B, Berger W, Grusch M, Marian B. Irinotecan Upregulates Fibroblast Growth Factor Receptor 3 Expression in Colorectal Cancer Cells, Which Mitigates Irinotecan-Induced Apoptosis. Transl Oncol 2017;10:332-9. [PMID: 28340475 DOI: 10.1016/j.tranon.2017.02.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
616 Blagoev KB, Wilkerson J, Burotto M, Kim C, Espinal-Domínguez E, García-Alfonso P, Alimchandani M, Miettinen M, Blanco-Codesido M, Fojo T. Neutral evolution of drug resistant colorectal cancer cell populations is independent of their KRAS status. PLoS One 2017;12:e0175484. [PMID: 28981524 DOI: 10.1371/journal.pone.0175484] [Reference Citation Analysis]
617 Hutchinson RA, Adams RA, McArt DG, Salto-Tellez M, Jasani B, Hamilton PW. Epidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancer. J Transl Med 2015;13:217. [PMID: 26149458 DOI: 10.1186/s12967-015-0531-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
618 Baek SK, Lee KT, Bae SB, Lee SC. Evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer. Korean J Intern Med 2019;34:1188-96. [PMID: 31346151 DOI: 10.3904/kjim.2019.071] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
619 Smyth E, Khan K, Valeri N. Translational research and application of basic biology to clinical trial development in GI cancers. Ann Transl Med 2018;6:164. [PMID: 29911112 DOI: 10.21037/atm.2018.05.05] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
620 Dubbink HJ, Deans ZC, Tops BB, van Kemenade FJ, Koljenović S, van Krieken HJ, Blokx WA, Dinjens WN, Groenen PJ. Next generation diagnostic molecular pathology: critical appraisal of quality assurance in Europe. Mol Oncol 2014;8:830-9. [PMID: 24704265 DOI: 10.1016/j.molonc.2014.03.004] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 4.3] [Reference Citation Analysis]
621 Nakamura Y, Yoshino T. Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer. Oncologist 2018;23:1310-8. [PMID: 29700206 DOI: 10.1634/theoncologist.2017-0621] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
622 Ye P, Cai P, Xie J, Wei Y. The diagnostic accuracy of digital PCR, ARMS and NGS for detecting KRAS mutation in cell-free DNA of patients with colorectal cancer: A systematic review and meta-analysis. PLoS One 2021;16:e0248775. [PMID: 33770081 DOI: 10.1371/journal.pone.0248775] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
623 Maitra R, Augustine T, Dayan Y, Chandy C, Coffey M, Goel S. Toll like receptor 3 as an immunotherapeutic target for KRAS mutated colorectal cancer. Oncotarget 2017;8:35138-53. [PMID: 28422714 DOI: 10.18632/oncotarget.16812] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
624 Imyanitov E, Kuligina E. Molecular testing for colorectal cancer: Clinical applications. World J Gastrointest Oncol 2021; 13(10): 1288-1301 [PMID: 34721767 DOI: 10.4251/wjgo.v13.i10.1288] [Reference Citation Analysis]
625 Matsumoto A, Shimada Y, Nakano M, Oyanagi H, Tajima Y, Nakano M, Kameyama H, Hirose Y, Ichikawa H, Nagahashi M, Nogami H, Maruyama S, Takii Y, Ling Y, Okuda S, Wakai T. RNF43 mutation is associated with aggressive tumor biology along with BRAF V600E mutation in right-sided colorectal cancer. Oncol Rep 2020;43:1853-62. [PMID: 32236609 DOI: 10.3892/or.2020.7561] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
626 Patel SB, Gill D, Garrido-Laguna I. Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer. Onco Targets Ther 2016;9:75-86. [PMID: 26770060 DOI: 10.2147/OTT.S68558] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
627 Ou SI, Nagasaka M, Zhu VW. Liquid Biopsy to Identify Actionable Genomic Alterations. Am Soc Clin Oncol Educ Book 2018;38:978-97. [PMID: 30231331 DOI: 10.1200/EDBK_199765] [Cited by in Crossref: 32] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
628 Thierry AR, Pastor B, Jiang ZQ, Katsiampoura AD, Parseghian C, Loree JM, Overman MJ, Sanchez C, Messaoudi SE, Ychou M, Kopetz S. Circulating DNA Demonstrates Convergent Evolution and Common Resistance Mechanisms during Treatment of Colorectal Cancer. Clin Cancer Res. 2017;23:4578-4591. [PMID: 28400427 DOI: 10.1158/1078-0432.ccr-17-0232] [Cited by in Crossref: 48] [Cited by in F6Publishing: 29] [Article Influence: 9.6] [Reference Citation Analysis]
629 Jones JC, Renfro LA, Al-Shamsi HO, Schrock AB, Rankin A, Zhang BY, Kasi PM, Voss JS, Leal AD, Sun J, Ross J, Ali SM, Hubbard JM, Kipp BR, McWilliams RR, Kopetz S, Wolff RA, Grothey A. Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer. J Clin Oncol. 2017;35:2624-2630. [PMID: 28486044 DOI: 10.1200/jco.2016.71.4394] [Cited by in Crossref: 142] [Cited by in F6Publishing: 90] [Article Influence: 28.4] [Reference Citation Analysis]
630 Chen J, Guo F, Shi X, Zhang L, Zhang A, Jin H, He Y. BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients. BMC Cancer. 2014;14:802. [PMID: 25367198 DOI: 10.1186/1471-2407-14-802] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
631 Sumransub N, Vantanasiri K, Prakash A, Lou E. Advances and new frontiers for immunotherapy in colorectal cancer: Setting the stage for neoadjuvant success? Mol Ther Oncolytics 2021;22:1-12. [PMID: 34307839 DOI: 10.1016/j.omto.2021.05.001] [Reference Citation Analysis]
632 Hummel M, Hegewisch-Becker S, Neumann JHL, Vogel A. BRAF testing in metastatic colorectal carcinoma and novel, chemotherapy-free therapeutic options. Pathologe 2021. [PMID: 34259881 DOI: 10.1007/s00292-021-00946-5] [Reference Citation Analysis]
633 Leichsenring J, Koppelle A, Reinacher-Schick A. Colorectal Cancer: Personalized Therapy. Gastrointest Tumors 2014;1:209-20. [PMID: 26676107 DOI: 10.1159/000380790] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
634 Napolitano S, Martini G, Martinelli E, Della Corte CM, Morgillo F, Belli V, Cardone C, Matrone N, Ciardiello F, Troiani T. Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFR-dependent and in cetuximab-resistant human colorectal cancer cells. Oncotarget 2017;8:82773-83. [PMID: 29137301 DOI: 10.18632/oncotarget.19797] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
635 Lee WS, Lee JN, Baek JH, Park YH. RAS status in Korean patients with stage III and IV colorectal cancer. Clin Transl Oncol 2015;17:751-6. [PMID: 25997687 DOI: 10.1007/s12094-015-1301-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
636 Geißler AL, Geißler M, Kottmann D, Lutz L, Fichter CD, Fritsch R, Weddeling B, Makowiec F, Werner M, Lassmann S. ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer. Oncotarget 2017;8:17164-90. [PMID: 28199979 DOI: 10.18632/oncotarget.15211] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
637 Rosati G, Fé A. Prolonged clinical response with regorafenib administered as second-line therapy in an elderly patient suffering from peritoneal carcinomatosis of colon cancer. J Chemother 2021;33:187-92. [PMID: 33372585 DOI: 10.1080/1120009X.2020.1866823] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
638 Poloznikov A, Nikulin S, Bolotina L, Kachmazov A, Raigorodskaya M, Kudryavtseva A, Bakhtogarimov I, Rodin S, Gaisina I, Topchiy M, Asachenko A, Novosad V, Tonevitsky A, Alekseev B. 9-ING-41, a Small Molecule Inhibitor of GSK-3β, Potentiates the Effects of Chemotherapy on Colorectal Cancer Cells. Front Pharmacol 2021;12:777114. [PMID: 34955846 DOI: 10.3389/fphar.2021.777114] [Reference Citation Analysis]
639 Jin M, Long ZW, Yang J, Lin X. Correlations of IGF-1R and COX-2 Expressions with Ras and BRAF Genetic Mutations, Clinicopathological Features and Prognosis of Colorectal Cancer Patients. Pathol Oncol Res 2018;24:45-57. [PMID: 28188432 DOI: 10.1007/s12253-017-0195-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
640 Fang L, Yang Z, Zhou J, Tung JY, Hsiao CD, Wang L, Deng Y, Wang P, Wang J, Lee MH. Circadian Clock Gene CRY2 Degradation Is Involved in Chemoresistance of Colorectal Cancer. Mol Cancer Ther 2015;14:1476-87. [PMID: 25855785 DOI: 10.1158/1535-7163.MCT-15-0030] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 4.6] [Reference Citation Analysis]
641 Zhang F, Cheong JK. The renewed battle against RAS-mutant cancers. Cell Mol Life Sci 2016;73:1845-58. [PMID: 26892781 DOI: 10.1007/s00018-016-2155-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
642 Ohhara Y, Fukuda N, Takeuchi S, Honma R, Shimizu Y, Kinoshita I, Dosaka-Akita H. Role of targeted therapy in metastatic colorectal cancer. World J Gastrointest Oncol 2016; 8(9): 642-655 [PMID: 27672422 DOI: 10.4251/wjgo.v8.i9.642] [Cited by in CrossRef: 58] [Cited by in F6Publishing: 54] [Article Influence: 9.7] [Reference Citation Analysis]
643 DeStefanis RA, Kratz JD, Emmerich PB, Deming DA. Targeted Therapy in Metastatic Colorectal Cancer: Current Standards and Novel Agents in Review. Curr Colorectal Cancer Rep 2019;15:61-9. [PMID: 31130830 DOI: 10.1007/s11888-019-00430-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
644 Tay RY, Wong R, Hawkes EA. Treatment of metastatic colorectal cancer: focus on panitumumab. Cancer Manag Res 2015;7:189-98. [PMID: 26150735 DOI: 10.2147/CMAR.S71821] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
645 Semrad TJ, Fahrni AR, Gong IY, Khatri VP. Integrating Chemotherapy into the Management of Oligometastatic Colorectal Cancer: Evidence-Based Approach Using Clinical Trial Findings. Ann Surg Oncol 2015;22 Suppl 3:S855-62. [PMID: 26100816 DOI: 10.1245/s10434-015-4610-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
646 le Rolle AF, Chiu TK, Fara M, Shia J, Zeng Z, Weiser MR, Paty PB, Chiu VK. The prognostic significance of CXCL1 hypersecretion by human colorectal cancer epithelia and myofibroblasts. J Transl Med 2015;13:199. [PMID: 26104296 DOI: 10.1186/s12967-015-0555-4] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.7] [Reference Citation Analysis]
647 Lakatos G, Köhne CH, Bodoky G. Current therapy of advanced colorectal cancer according to RAS/RAF mutational status.Cancer Metastasis Rev. 2020;39:1143-1157. [PMID: 32648137 DOI: 10.1007/s10555-020-09913-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
648 Ren Z, Che J, Wu XW, Xia J. Analysis of KRAS Mutation Status Prediction Model for Colorectal Cancer Based on Medical Imaging. Comput Math Methods Med 2021;2021:3953442. [PMID: 34976107 DOI: 10.1155/2021/3953442] [Reference Citation Analysis]
649 Tsujii Y, Hayashi Y, Maekawa A, Fujinaga T, Nagai K, Yoshii S, Sakatani A, Hiyama S, Shinzaki S, Iijima H, Takehara T. Cardiac metastasis from colon cancer effectively treated with 5-fluorouracil, leucovorin, and oxaliplatin (modified FOLFOX6) plus panitumumab: a case report. BMC Cancer. 2017;17:152. [PMID: 28228152 DOI: 10.1186/s12885-017-3147-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
650 Kurreck A, Geissler M, Martens UM, Riera-Knorrenschild J, Greeve J, Florschütz A, Wessendorf S, Ettrich T, Kanzler S, Nörenberg D, Seidensticker M, Held S, Buechner-Steudel P, Atzpodien J, Heinemann V, Stintzing S, Seufferlein T, Tannapfel A, Reinacher-Schick AC, Modest DP. Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109). J Cancer Res Clin Oncol 2020;146:2681-91. [PMID: 32449003 DOI: 10.1007/s00432-020-03257-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
651 Brandi G, De Lorenzo S, Nannini M, Curti S, Ottone M, Dall’Olio FG, Barbera MA, Pantaleo MA, Biasco G. Adjuvant chemotherapy for resected colorectal cancer metastases: Literature review and meta-analysis. World J Gastroenterol 2016; 22(2): 519-533 [PMID: 26811604 DOI: 10.3748/wjg.v22.i2.519] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 40] [Article Influence: 6.0] [Reference Citation Analysis]
652 Goldstein DA, Ahmad BB, Chen Q, Ayer T, Howard DH, Lipscomb J, El-Rayes BF, Flowers CR. Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer. J Clin Oncol 2015;33:3727-32. [PMID: 26304904 DOI: 10.1200/JCO.2015.61.9569] [Cited by in Crossref: 61] [Cited by in F6Publishing: 35] [Article Influence: 8.7] [Reference Citation Analysis]
653 Bibeau F, Sabourin J. Médecine de précision, médecine de décision. Annales de Pathologie 2014;34:347-8. [DOI: 10.1016/j.annpat.2014.09.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
654 Yamamoto I, Nosho K, Kanno S, Igarashi H, Kurihara H, Ishigami K, Ishiguro K, Mitsuhashi K, Maruyama R, Koide H, Okuda H, Hasegawa T, Sukawa Y, Okita K, Takemasa I, Yamamoto H, Shinomura Y, Nakase H. EZH2 expression is a prognostic biomarker in patients with colorectal cancer treated with anti-EGFR therapeutics. Oncotarget 2017;8:17810-8. [PMID: 28147317 DOI: 10.18632/oncotarget.14863] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
655 Troiani T, Napolitano S, Della Corte CM, Martini G, Martinelli E, Morgillo F, Ciardiello F. Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. ESMO Open 2016;1:e000088. [PMID: 27843640 DOI: 10.1136/esmoopen-2016-000088] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 9.3] [Reference Citation Analysis]
656 Yousef AI, El-Masry OS, Yassin EH. The anti-oncogenic influence of ellagic acid on colon cancer cells in leptin-enriched microenvironment. Tumour Biol 2016;37:13345-53. [PMID: 27460082 DOI: 10.1007/s13277-016-5284-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
657 Nöpel-Dünnebacke S, Conradi LC, Reinacher-Schick A, Ghadimi M. [Influence of molecular markers on oncological surgery of colorectal cancer]. Chirurg 2021;92:986-95. [PMID: 34448902 DOI: 10.1007/s00104-021-01486-7] [Reference Citation Analysis]
658 Shiovitz S, Grady WM. Molecular markers predictive of chemotherapy response in colorectal cancer. Curr Gastroenterol Rep 2015;17:431. [PMID: 25663616 DOI: 10.1007/s11894-015-0431-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
659 Ros J, Baraibar I, Sardo E, Mulet N, Salvà F, Argilés G, Martini G, Ciardiello D, Cuadra JL, Tabernero J, Élez E. BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer. Ther Adv Med Oncol 2021;13:1758835921992974. [PMID: 33747149 DOI: 10.1177/1758835921992974] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
660 Broes S, Lacombe D, Verlinden M, Huys I. Toward a Tiered Model to Share Clinical Trial Data and Samples in Precision Oncology. Front Med (Lausanne) 2018;5:6. [PMID: 29435448 DOI: 10.3389/fmed.2018.00006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
661 Loupakis F, Stein A, Ychou M, Hermann F, Salud A, Österlund P. A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer. Target Oncol 2016;11:293-308. [PMID: 26687849 DOI: 10.1007/s11523-015-0400-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
662 Dang Y, Gao H, Huang S, Qi T. Clinical complete regression after local radiotherapy combined with chemotherapy for stage IV rectal cancer: A case report. Mol Clin Oncol 2020;13:186-90. [PMID: 32714544 DOI: 10.3892/mco.2020.2049] [Reference Citation Analysis]
663 Shimada Y, Kameyama H, Nagahashi M, Ichikawa H, Muneoka Y, Yagi R, Tajima Y, Okamura T, Nakano M, Sakata J, Kobayashi T, Nogami H, Maruyama S, Takii Y, Hayashida T, Takaishi H, Kitagawa Y, Oki E, Konishi T, Ishida F, Kudo SE, Ring JE, Protopopov A, Lyle S, Ling Y, Okuda S, Ishikawa T, Akazawa K, Takabe K, Wakai T. Comprehensive genomic sequencing detects important genetic differences between right-sided and left-sided colorectal cancer. Oncotarget 2017;8:93567-79. [PMID: 29212173 DOI: 10.18632/oncotarget.20510] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
664 Chiu KWH, Lam KO, An H, Cheung GTC, Lau JKS, Choy TS, Lee VHF. Long-term outcomes and recurrence pattern of 18F-FDG PET-CT complete metabolic response in the first-line treatment of metastatic colorectal cancer: a lesion-based and patient-based analysis. BMC Cancer 2018;18:776. [PMID: 30064385 DOI: 10.1186/s12885-018-4687-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
665 Thomsen CB, Hansen TF, Andersen RF, Lindebjerg J, Jensen LH, Jakobsen A. Monitoring the effect of first line treatment in RAS/RAF mutated metastatic colorectal cancer by serial analysis of tumor specific DNA in plasma. J Exp Clin Cancer Res 2018;37:55. [PMID: 29530101 DOI: 10.1186/s13046-018-0723-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16]